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ABSTRACT
The AS/AGU rat is a spontaneous recessive mutation which arose in a closed colony o f Albino 
Swiss (AS) rats. It is characterised by disordered locomotion including a wide gait, whole body 
tremor and frequent falling over in continuous locomotion. It has been demonstrated that there is 
a substantial dysfunction o f the nigro-striatal dopaminergic system which begins with a marked 
reduction in dopamine release in the striatum, followed by a reduction in whole tissue dopamine 
levels and, finally, a loss o f dopaminergic cells.
The mutation has recently been shown to be a stop codon in the gene responsible for the activity 
o f protein kinase C (PKC) -y. Although few specific functions are known for this particular 
isoform (and those that are appear to cover widely disparate types of CNS activity), the PKC 
family in general has a role in transmitter packaging and release, as well as in ion channel 
modulation and receptor sensitivity. It is very likely, therefore, that the mutation will affect other 
transmitter systems in addition to the dopaminergic system already investigated. Furthermore, all 
human neurodegenerative conditions which combine disordered locomotion with basal ganglia 
and aminergic dysfunction have shown evidence o f effects on several transmitter sysems.
This study was undertaken, therefore, to look at the integrity and functioning o f the raphe-striatal 
serotonergic system in the mutant, using the parent strain as a control. This is an exciting model, 
since any differences found must stem directly or indirectly from a single point mutation.
Initial experiments were carried out to verify a) the nature of the mutation and b) the connectivity 
of the dorsal and median raphe nuclei to the striatum in these strains. Immunocytochemical 
investigations o f the AS wild-type showed positive staining for PKC-y in many parts o f the brain, 
including cerebral and cerebellar cortices, striatum, substantia nigra and raphe regions; no 
staining could be found in the AS/AGU mutant. This confirms the identification o f the gene 
mutation.
Injections o f the tracer cholera toxin-B were made into the dorsal caudate-putamen (a region o f 
the basal ganglia found to be particularly affected in previous work on the dopaminergic system). 
Cells of the dorsal raphe nucleus (but not the median raphe nucleus) were found to be 
retrogradely labelled. Labelling ocurred throughout the dorsal raphe nucleus, with peak cell 
numbers occurring in the centre o f the rostral-caudal distribution o f the nucleus. Approximately a 
third o f the cell bodies were positively stained for CB-T. This confirms that the dorsal caudate-
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pLitamen receives a strong afferent input from the dorsal raphe nucleus, but that the median raphe 
does not project to the striatum.
Three complimentary experiments were carried out to examine the integrity o f the raphe nuclei 
and their serotonergic innervation o f the striatum.
Firstly, the AS/AGU mutants were found (by conventional and stereological counting methods) 
to have reduced numbers o f 5-HT-ir cells in the dorsal raphe nucleus compared to the wild-type. 
The reduction was some 20-25%. No such loss was found in the median raphe nucleus.
Secondly, experiments were carried out to assay serotonin, dopamine and their metabolites in 
post mortem micropunches o f several brain regions using HPLC-ECD methods. Serotonin and 
dopamine were both significantly reduced in several parts o f the caudate-putamen, as well as 
(respectively) the dorsal raphe nucleus and substantia nigra. By contrast, metabolite levels such as 
5-HIAA and DOPAC were elevated. This suggests that both transmitter systems are affected as a 
result o f the mutation, but that the deficit is in transmitter release rather than synthesis.
To test the effects o f the mutation on release, microdialysis experiments were carried out with 
indwelling cannulae in the dorsal caudate-putamen which sampled the extracellular fluid. HPLC- 
ECD with a highly sensitive Intro detector showed that extracellular levels o f both 5-HT and DA 
were extremely reduced in mutants compared to the parent strain but, again, metabolite levels 
were higher. Previous studies on dopamine have interpreted this as the result o f dopamine being 
free within the terminal cytoplasm and a similar phenomenon could account for the present 
findings on serotonin.
Micropunch studies also revealed that administration of 5-HTP led to increased 5-HT and 5- 
HIAA levels in both striatum and raphe nuclei. Similarly, L-DOPA administration led to 
increased DA and DOPAC levels. A further finding, namely that administration o f L-DOPA 
could reduce 5-HT levels, while administration o f 5-HTP could elevate DA levels, points to 
important interactions between the two systems.
Since both AS and AS/AGU rats showed expected changes in 5-HT levels with 5-HTP 
administration, it was decided to use a simple behavioural test - total locomotion per unit time as 
recorded with an automated infra-red system - to see if  5-HT manipulation could affect 
locomotion in the two strains. In both strains, 5-HT depletion by pCPA reduced locomotion, 
while augmentation by 5-HTP increased it; saline administration was neutral. The percentage
Xchanges were largely similar between the two strains, although mutants responded more 
positively to 5-HTP administration than controls.
The results demonstrate that the raphe-striatal serotonergic system o f the AS/AGU rat is 
compromised in the same way as the nigro-striatal dopaminergic system. Because the two 
systems are inter-linked morphologically and physiologically, it is unclear whether the mutation 
exerts a direct affect on each system separately or whether one system (or each system) affects 
the other. The results continue to demonstrate that the symptoms of the AS/AGU rat and its 
neural deficiencies make it a useful animal to study human conditions involving cell loss, 
movement and the basal ganglia.
1 General Introduction
1.1 Introduction
The AS/AGU rat is a spontaneous recessive mutation with a stop codon in the gene 
for protein kinase C (PKC)-gamma and which exhibits locomotor dysfunction. The 
dopaminergic nigrostriatal system has already been shown to be affected by this 
mutation. Because the PKC family of enzymes may be involved in the packaging or 
release of neurotransmitters in vesicles, and because other aminergic neurons may 
also be involved in the basal ganglia and their disorders, I have investigated the 
raphe-striatal serotonergic system in these mutants and the parent AS strain.
So I intend to wiite in my introduction about the basal ganglia, movement disorders, 
aminergic input to the basal ganglia, models of neurodegenerative disorders such as 
Parkinson’s disease and finally about the AS/AGU rat as a valuable model of 
neurodegenerative disease.
1.2 Basal ganglia
The basal ganglia are among the most complex and least understood structures in the 
mammalian forebrain (for major reviews see Alexander et ah,1986; Parent, 1990; 
Parent and Hazrati, 1995; Crossman, 2000; Pollack, 2001; Baev et al., 2002; Jose et 
al., 2002; Lehericy and Geradin, 2002; Yelnik, 2002; Wichmann and DeLong, 2003) 
The definition of ‘basal ganglia’ is subject to some variation, but key structures 
include the corpus striatum (caudate nucleus, putamen and globus pallidus), 
subthalamic nucleus and the substantia nigra. These subcortical nuclei interconnect 
and their afferent and efferent comiections extend tluougliout the telencephalon, 
diencephalon and midbrain. Together with motor cortical areas and the cerebellum, 
the basal ganglia have an important role in motor integration whereby sensory 
information modulates the timing and trajectory of movement to produce both
accurately aimed and smoothly executed actions. These ideas came initially from 
observation in Parkinsonian patients where damage to the basal ganglia not only 
caused a slowing of voluntary movement but also frequently resulted in 
uncontrollable involuntary movements.
The neostriatum consists of the caudate nucleus and putamen; these are separate 
components in the primate brain, but united in rodents. They form the input nuclei of 
the basal ganglia, receiving almost all of the afferent information from the cerebral 
cortex. The globus pallidus has two segments, internal and external (sometimes 
called medial and lateral segments respectively). The subtantia nigra is located 
within the midbrain and has two cytologically distinct zones. The first, known as the 
pai's reticulata, is located ventrally and is distinctly pale in nature and the second is a 
more dorsally-sited pigmented zone known as the pars compacta. It is this region 
which in humans gives the substantia nigra its characteristic dark appearance in post 
mortem specimens and is made up of neuromelanin-containing dopaminergic 
neurons. The internal segment of the globus pallidus and the substantia nigra pars 
reticulata are sometimes considered to be a single structure due to the similarities 
they share in cytology, connectivity and function. In fact these structures form the 
major output for the entire basal ganglia, directing information tlirough the thalamus 
and on to the premotor, motor and prefrontal cortices. One of the major differences 
between the basal ganglia and other motor systems is that they don’t make any direct 
connections with the spinal cord. In contrast, the basal ganglia contain several 
structurally and functionally distinct closed circuits (loops) connecting the cerebral 
cortex, basal ganglia, thalamus and cortex again. At least five circuits are thought to 
exist, all of which are organised in parallel and segregated from each other in that 
they engage different regions of the basal ganglia and thalamus and their output is 
centred on different areas of the frontal lobe.
1.2.1 The basal ganglia- circuity and parallel processing
The basic basal ganglia circuitry with inhibitory and excitatory connections is shown 
in figure 1. Different regions of cerebral cortex reach the striatum by excitatory 
glutamatergic projections (Young et ah, 1981). Early studies using autoradiography 
showed that cortical afferents arising from the somatomotor cortex preferentially 
innervate the putamen (Kunzle, 1977), while association cortex afferents innervate 
the caudate nucleus (Goldman and Nauta, 1977). This helped form the theory that 
input from different cortical areas is segregated and remains so throughout the 
neostriatum. The premotor and motor cortices also send excitatory afferents to the 
subthalamic nucleus which is the only other structure within the basal ganglia 
receiving a direct cortical input (Afsharpour, 1985; Stanton et ah, 1988). The 
striatum also receive afferents from the substantia nigra pars compacta which are 
mainly dopaminergic fibres (Moore et ah, 1971) and there is a possibility that the 
centromedian-parafascicular nuclei of the thalamus give an indirect cortical input 
(Beckstead, 1984).
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Figure 1.1 An updated version of the basal ganglia circuitry originally 
represented by Alexander and Crutcher (1986), showing the connectivity of the 
direct and indirect pathways of the basal ganglia. Inhibitory projections are 
shown as filled arrows, excitatory projections as open arrows. Gpe = external 
segment of the globus pallidus; SNc = substantia nigra pars compacta; SNr = 
substantia nigra pars reticulata; STN = subthalamic nucleus; Thai = thalamus; 
PPN = pedunculopontine tegmental nucleus; HBN = lateral habenular nucleus; 
SC = superior colliculus; and RF = reticular formation.
The basic circuit contains a ‘direct pathway’ to the output nuclei (the internal 
segment of the globus pallidus and the substantia nigra pars reticulata) and an 
‘indirect pathway’ (via the external segment of the globus pallidus and the 
subthalamic nucleus). The direct pathway from the striatum consists of GABAergic 
and substance P-containing neurons and is an inhibitory efferent pathway whereas 
the indirect pathway reaches the output nuclei via GABAergic and enkephalin- 
containing striatal projection neurons. These form the first part of the pathway 
innervating the external segment of the globus pallidus which in turn projects to the 
subthalamic nucleus via purely GABAergic neurons (Albin et al., 1989; Jose et al., 
2002).
The final part of the indirect pathway which connects the subthalamic nucleus to the 
output nuclei is an excitatory glutamatergic projection (Nakanishi et al., 1987; Smith 
and Parent, 1988). These two striatal efferent systems have opposing effects on the
basal ganglia output nuclei and subsequently upon the thalamic nuclei each of the 
circuits iimervate. The striatum has another efferent pathway this time innervating 
the substantia nigra pars compacta. This is thought to consist of GABA and 
substance P neurons as in the case of the direct pathway. The output nuclei project 
via an inhibitory GABAergic pathway to the thalamic nuclei (Penney and Young, 
1981; Chevalier et ah, 1985).
Both output nuclei have a high level of spontaneous basal activity which exerts an 
inhibitory effect on the thalamic nuclei and is modified by the opposing effects of the 
direct and indirect pathways. There are two possibilities as to how this paiallel 
processing affects movement. Firstly, the direct and indirect pathways may both 
innervate the same set of output neurons. This could cause a ‘smoothing’ of the 
cortically-initiated motor pattern which is reinforced by the direct pathway. A second 
possibility is that the two pathways are directed to different output nuclei neurons, 
resulting in reinforcement of a selected motor pattern via the direct pathway while 
the indirect pathway filters out the conflicting patterns (Alexander and Crutcher. 
1990c).
1,2.2 The compartmental organisation of the striatum
Regular Nissl staining of the striatum shows a largely homogeneous mass. With the 
benefit of techniques such as retrograde tracing, histochemistry, 
immunohistochemistry and histopharmacology, two levels of compartmental 
organisation emerged in the striatum: patch-matrix compartments, and the 
organisation of separate striatopallidal and striatonigral systems.
Striatal patch-matrix systems are demonstrated and determined by specific 
neurochemical markers and also by underlying neuronal connections. The patch 
compartment is defined by p-opiate binding (Herkenham and Pert, 1981), and by low 
expression of acetylcholinesterase (Butcher and Hodge, 1976). The term striosome
(“striatal body”) was first used by Graybiel and Ragsdale (1978), to describe these 
areas of low cholinesterase activity. Five-nucleotidase (Schoen and Graybiel, 1992) 
was also found to be an excellent marker for striosomes in the rat.
The matrix compartment can be defined by staining for the calcium binding protein 
calbindin, and by the immunoreactivity of somatostatin positive fibres (Gerfen et al., 
1985). Patch-matrix organisation is predominantly found in the caudate-putamen, 
extending into the dorsolateral and ventromedial areas.
In the rat, it was observed that compartmental organisation of cortico-striatal 
afferents was related to their laminar origin rather than to their cortical areas of 
origin (Gerfen, 1989), with different cortical laminae innervating patch and matrix 
compartments. Thus corticostriatal neurons in infragranular layers project principally 
to patches, with the matrix being the main recipient of axons from supragranular 
layers. A similar pattern exists in primates but is complicated by the fact that 
allocortical areas have a higher concentration of corticostriatal neurons arising from 
infragranular layers, whereas in neocortical areas, supragranulai* corticostriatal 
neurons are more numerous (Arikuni and Kubota, 1986). These corticostriatal 
projections terminate principally on the dendrites of medium spiny projection 
neurons where they have an excitatory effect due to glutamate. These findings are 
consistent with studies that show the developmental relationship between medium 
spiny neurons of the patches and matrix, and neurons of deep and superficial cortical 
laminae respectively (Fishell and Van der Kooy, 1987).
If striatal medium spiny neurons can be divided into two populations (patch and 
matrix) that have a relationship with the laminar (Gerfen, 1989) and regional 
(Donoghue and Herkenham, 1986) organisation of the cortex, they can also be 
characterised by their respective projections to globus pallidus, entopenduncular 
nucleus (EPN) and substantia nigra, with striatopallidal neurons arborizing within the
GP, and striatonigral neurons extending to the EPN and SN (Parent et ah, 1984). 
Gerfen (1992) hypothesised that striatopallidal projections to many cholinergic and 
substance P-expressing areas of the ventr al pallidum originate largely in the patch 
striatal area, whereas matrix neurons tend to project to the predominantly 
GABAergic enkephalin-containing neurons.
Tracing techniques in rats have shown that although both types of neurons project to 
the substantia nigra, patch neurons project to the dopaminergic cell groups in the 
SNpc, and cell islands in the SNpr, whereas matrix neurons project to areas in the 
SNpr containing GABAergic neurons (Gerfen, 1984; 1985).
1,2.3 The basal ganglia-motor circuit
The cortico-striato-thalamo-cortical loop described above is not unitary. Indeed, 
there appear to be several loops eg. motor, oculomotor, associative, limbic and 
orbitofrontal.
One of the most interesting circuits is the motor circuit which has received a lot of 
attention. In this circuit the putamen receives the majority of the information entering 
the basal ganglia from the cerebral cortex, particularly from the primary motor and 
sensory cortices, the arcuate premotor area and the supplementary motor area 
(Kunzle, 1977; Selemon and Goldman-Rakic, 1985). This information is 
somototopically organised into distinct zones i.e. there are sepai’ate zones for the arm 
and leg etc. (Kimzle, 1975; Crutcher and De Long, 1984; Alexander and De Long, 
1985). Topographic projections from the putamen reach specific areas of the internal 
and external segment of the globus pallidus and the substantia nigra pars reticulata 
(Johnson and Rosvold, 1971; Parent et al., 1984). The degree of specificity amongst 
these projections is still maintained at the level of the thalamic nuclei where 
connections are made with the nucleus ventralis lateralis pars oralis, lateral nucleus
ventralis anterior pars parvocellularis, lateral nucleus ventralis anterior pars 
magnocellularis and centromedian nucleus (De Vito and Anderson, 1982; Kinsky et 
al., 1985). These nuclei in turn close the circuit with thalamocortical projections to 
the supplementary motor area, the premotor cortex and the motor cortex 
(Wiesendanger et ah, 1985; Matelli et ah, 1989).
The role of the basal ganglia in normal movement in primates remains unclear. A 
large proportion (30-50%) of neuronal activity within the supplementary motor area, 
motor cortex, putamen and both segments of the globus pallidus appears to code for 
the direction of limb movement (Mitchell et ah, 1987; Crucher and De Long 1984; 
Alexander and Cratcher, 1990a) and there are individual cells which are direction- 
dependent. However, there are also cells which are range-dependent and ones which 
respond to complex variables such as movement linked to reward. Many studies have 
shown that the motor circuit is involved in movement planning with neuronal 
discharge when an instructional or anticipatory stimulus was presented to the animal 
(Alexander and Crutcher, 1990a; Wise et ah, 1983; Tanji and Kurata, 1985; 
Georgopoulos et ah, 1989). Movement preparation is thought to be mediated through 
a separate subchannel from movement execution and is believed to occur in each of 
the somatotopic motor circuit channels. Other experiments have demonstrated 
additional organisation within the somatotopic channels where further subchannels 
are thought to be specific for target location, limb trajectory/kinematics and muscle 
activity pattern. These processes are all thought to occur in parallel (Alexander and 
Crutcher, 1990a).
1.3 Movement disorders
Although there is uncertainty regarding the normal function of the basal ganglia, 
there is better understanding of dysfunction in the basal ganglia which can result in
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many movement disorders. These disorders can be classified into two categories; 
hypokinetic and hyperkinetic. Many of them involve the aminergic systems.
1.3.1 Multiple system atrophy
Multiple system atrophy (MSA) is a term introduced by Graham and Oppenheimer 
(1969). MSA is sporadic degenerative disease characterised by a combination of 
Parkinsonism, autonomic and cerebellar dysfunction and pyramidal signs (see major 
reviews by Wenning et al., 1995; Kaufmann, 1998).
Pathologically there are varying degrees of cell loss and gliosis principally affecting 
the substantia nigra and putamen (striatonigral degeneration), pontine nuclei, 
cerebellar Purkinje cells and inferior olives (olivopontocerebellar atrophy), 
intermediolateral cell columns of the thoracic spinal cord, and Onuf s nucleus in the 
sacral cord. Symptoms include ataxia, rigidity and general autonomic failure as well 
as problems with balance, coordination and speech.
In striatonigral degeneration, treatment with levodopa was found to be effective. 
Data from PD brain banks showed that up to 10% of those brains from patients 
diagnosed with PD turn out to have MSA (Kaufmann, 1998).
1.3.2 Progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a hypokinetic disease which predominantly 
occurs in men, with an onset of disease in middle to late life. The duration of the 
condition until death is relatively short (5.3 years).
The main symptoms of the disease are pronounced imbalance with frequent falls, 
bradykinesia, rigidity, ‘pure akinesia’ (Mastsuo et al., 1991; ïmai et al,, 1986),
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vertical gaze palsy and dementia. Treatment with L-dopa has no or minimal effect 
(Collins et al., 1995).
Nigrostriatal dysfunction is the main cause of PSP with an 80-90% decrease in 
dopamine, tyrosine hydroxylase and D2 receptors in the striatum (Russell, 2001).
1.3.3 Corticobasal degeneration
There are similarities between corticobasal degeneration, idiopathic Parkinson’s 
disease and PSP (Bergen et al, 1996).
Clinically, corticobasal degeneration is characterised by an asymmetrical akinetic- 
rigid syndrome, cognitive loss (apraxia and aphasia) and extrapyramidal motor 
dysfunction (rigidity and dystonia). This disease is very rare and dementia can be 
seen in late stages of the disease.
Neuropathologically, this disease is characterised by severe neuronal loss and gliosis 
in the cerebral cortex with the presence of swollen, achromatic, tan positive staining 
Pick cells, atrophy in frontoparietal cerebral cortex, loss of dopaminergic cells and 
gliosis in the substantia nigra. Like PSP, it is poorly responsive to L-dopa treatment 
(see review Watts et al, 1995).
1.3.4 Parkinson’disease
One of the most documented hypokinetic disorders is Parkinson’s disease. This 
disease is more common with advancing age and affects approximately 1 per cent of 
the population over 65. The average duration from diagnosis of Parkinson’s disease 
to death is thirteen years.
The main symptoms include akinesia, which is difficulty initiating movement, 
bradykinesia, which is a slowing of movement, muscular rigidity (commonly
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referred to as cog-wheel rigidity), flexed posture and a postural tremor that is usually 
worse at rest. These features were found to be due to a selective striatal dopamine 
deficiency in the early 1960’s though this has been more accurately described as 
degeneration of the nigrostriatal dopaminergic neurons (Homykiewicz, 1966; 
Bernheimer et al., 1973). An important association occurs between Parkinson’s 
disease and elderly dementia with the frequency being 6.6 times higher compared to 
non-Parkinsonian-patients (Mayeux et al., 1990). Many of the clinical, pathological 
and biochemical features of human Parkinson’s disease have been demonstrated in 
animals treated with 1 -Methyl-4-Phenyl-1,2,3,6 tetrahydropyridine, more commonly 
referred as MPTP (Bankiewicz et al., 1986; Burns et al., 1983). Therefore, the 
majority of the work done in this area is on MPTP-treated animals.
It has been demonstrated that a loss of striatal dopamine promotes increased 
transmission via the indirect pathway (Filion et al., 1988). The initial part of the 
indirect pathway is inhibitory, with GAB A/enkephalin striatal neurons projecting to 
the external segment of globus pallidus. Therefore, decreased activity of the external 
segment of the globus pallidus will release the subthalamic nucleus from the 
inhibitory constraint produced by its GABA-mediated pathway. This in turn will 
result in increased firing by the subthalamic nucleus neurons causing excitation of 
the basal ganglia output nuclei (internal segment of the globus pallidus and the 
substantia nigra pars reticulata) via the excitatory gluatmatergic pathway that 
connects both of them. Reduced firing of the G ABA/substance P neurons of the 
direct pathway will result in decreased inhibition of the basal ganglia output nuclei, 
again causing their excitation, A combination of the opposing effects on the direct 
and indirect striatal projections results in an overt increase in output nuclei firing 
causing inhibition of thalamocortical neurons via GABAergic projection. This in turn 
will reduce firing in the glutamatergic neurons projecting to the motor areas of the
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cerebral cortex and may decrease the responsiveness of the precentral motor field 
engaged by the motor circuit thus producing the symptoms of Parkinson’s disease 
(Filion et al., 1988). These features of increased activity in striatal neurons 
projecting to the external segment of the globus pallidus and reduced activity in the 
striatal neurons projecting to the internal segment of the globus pallidus were also 
reported in 6-hydroxydopamine lesioned animals frequently used as models of 
Parkinson’s disease.
Further studies in support of this mechanism revealed that the concentration of 
substance P in the output nuclei of the basal ganglia was reduced in Parkinson’s 
disease patents (Waters et al., 1988; Agid et al., 1987). However enkephalin levels in 
the external segment of the globus pallidus often remained unchanged (Agid et al., 
1987). Surgery performed on the subthalamic nucleus was found to alleviate the 
symptoms of Parkinson’s disease which supports the proposal that excessive 
subthalamic nucleus activity is a key step in this process (Bergman et al., 1990; Aziz 
et al., 1991 ; Limousin et al., 1995). More recently a paper by Chesslet and Delfs 
(1996) suggests that the model may need correcting following evidence that activity 
in the external segment of the globus pallidus is increased after nigrostriatal 
dopamine depletion by MPTP. This is thought to be due to the excitatory 
glutamatergic projection from the subthalamic nucleus which has an increased 
neuronal discharge rate (Tremblay et al., 1989; Pan and Walters, 1988). A similar 
finding was noted in 6-hydroxydopamine lesioned animals (Porter et al., 1994).
Olanow and Tatton (1999) have described the involvement of genetic factors in PD, 
since about 5-10% patients have a familial form of Parkinsonism with an autosomal 
dominant pattern of inheritance. The incidence of PD is greater in family members 
than in age-matched controls. There ar e large numbers of different genes involved in
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PD and these may relate to protein misfolding (McNaught et al., 2002; Ryu et al.,
2002) for reviews see (Soto, 2003)
Also, Olanow and Tatton (1999) have outlined many factors, which may cause
neurodegeneration in PD:
1- Oxidative stress, where damaging levels of hydrogen peroxide and then reactive 
oxygen species are increased as result of:
a- Increased dopamine turnover,
b- A deficiency in glutathione,
c- A build up of reactive iron which can lead to hydroxyl radical formation.
2- Mitochondrial dysfunction, where an approximately 40% decrease in complex I 
activity of the mitochondrial respiratory chain has been found in the SNc of PD 
patients while other brain regions are unaffected.
3- Excitotoxicity, which results from increased glutamate formation.
Normal Parkinson's Disease Huntington s D isease
CORTEXCORTEX
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Figure 1.2 Basal ganglia thalamocortical circuitry A) under normal conditions. B) with 
Parkinson's disease C) with Huntington's disease. Inhibitory projections are shown as filled 
arrows, excitatory projections as open arrows. Changes in arrow thickness refiect differential 
changes beteen disease states. Gpi = internal segment of the globus pallidus; Gpe = external 
segment of the globus pallidus; SNc = substantia nigra pars compacta; SNr = substantia nigra 
pars reticulata; STN = subthalamic nucleus; VL = ventrolateral thalamus; PPN 
=pendunculopontine tegmental nucleus; CM/PF = centromedian/ farafasicular nucleus of 
thalamus. From Wichmann and DeLong (1998).
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1.3.5 Huntington’s disease
This is named after George Huntington, who first described this disorder in 1872. 
Huuntington’s disease (HD) typically begins in mid-life between the age of 30 and 
45, though onset may occur as early as the age of 2. Children who develop the 
juvenile form of the disease rarely live to adulthood. HD affects males and females 
equally and can be seen in a variety of ethnic and racial groups.
HD is a hyperkinetic disorder characterised by progressive chorea, rigidity, dementia, 
dystonia, cognitive deficit and psychological disturbance. It is an autosomal 
dominant hereditaiy neurodegenerative disease. The mutation which is responsible 
for HD is an expanded poly glutamine repeat (CAG) within exon 1 of the gene that 
codes for the protein Huntingtin (Reddy et al., 1999; Hedreen and Folstein, 1995). 
The choreoathetosis of Huntington’s disease is found to be the result of a selective 
loss of the striatal GAB A/enkephalin neurons that project to the external segment of 
the globus pallidus (Albin et al., 1989). Reiner et al., (1988) also revealed that there 
was a selective loss of enkephalin-immunoreactive striatal terminals in the external 
segment of the globus pallidus in the early stages of Hrmtington’s disease. This 
would cause excess GABAergic inhibition of the subthalamic nucleus which in turn 
produces a reduced excitatory input to the output nuclei of the basal ganglia. The 
output nuclei will thereafter project a reduced inhibitory outflow causing excessive 
disinhibition of the thalamus resulting in excessive positive feedback to the 
precentral motor fields in the supplementary motor area, premotor cortex and motor 
cortex. The end result of this mechanism is likely to be the choreiform movements 
that are seen in Huntington’s disease. The substance P striatal terminals are well 
preserved until the later stages of the disease when they too are selectively lost.
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1.4 Aminergic inputs to the basal ganglia
Although the core circuitry of the basal ganglia takes the form of cortico-striato- 
thalamo-cortical loops (see above) it is clear that there ai'C aminergic inputs from 
midbrain cell groups, which exert a considerable effect on the activity of the loops. 
Most attention has focused on dopaminergic inputs.
1.4.1 Dopamine
Dopamine was found in the brain in 1959, since when a massive and varied body of 
work has been carried out.
The existence of a dopaminergic innervation of the brain was suggested by 
biochemical studies (Thierry et al., 1973a,b) and subsequently confirmed by 
anatomical work utilising glyoxylic acid-induced histofluorescence (Lindvall et al., 
1974; Lindvall and Bjorklund, 1974), histofluorescence in combination with tract- 
tracing (Tork and Turner, 1981), autoradiography (Descarries et al., 1987), 
immunohistochemistry against the synthesising enzyme tyrosine hydroxylase (TH) in 
combination with destruction of the NA system (Berger et al., 1985) and, finally, 
immunohistochemistry with antibodies against dopamine (DA) itself, ending the 
problems of distinuishing between DA and NA that hampered earlier work 
(Papadopoulos et al., 1989b).
Dopamine is synthesised from the amino acid tyrosine, which is first conveited into 
dihydroxyphenylalanine (dopa) by tyrosine hydroxylase, the rate-limiting enzyme in 
the biosynthetic pathway; dopa is, in turn, decarboxylated to dopamine. Dopamine 
synthesis is modulated by the end product inhibition of tyrosine hydroxylase (TH) 
through negative feedback; in addition, depolarization of dopaminergic cells results 
in TH activation, thus maintaining the balance between DA synthesis and release
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(Joh et a l, 1978). Like the other monoamines, DA is catabolised by monoamine 
oxidase (MAO).
In studies using iontophoretic application, DA has been demonstrated to inliibit 
cortical neurons in the cat (Reader, 1978) and rat (Bunney and Aghajanian, 1976; 
Reader et al., 1979a) but, like 5-HT, it has also been shown to have excitatory action 
on some neurons.
The action of DA is terminated by reuptake into the presynaptic terminals by a DA- 
specific reuptake earner (Coyle et al., 1969), which involves the dopamine 
transporter (Hitri et al., 1994; Zhou et al., 2003).
Dopamine receptors were originally divided into type D1 and D2 in the 1970’s, since 
when more have emerged with the cloning of types D3, D4, D5 and their isoforms; 
they belong to G-protein coupled types (for review see Wolfarth and Ossowska,
1995).
Nearly 80% of all the brain’s DA is located in the putamen of the corpus striatum, 
which is densely innervated by the pai s compacta of the substantia nigra via the 
nigrostriatal pathway. The substantia nigra is not the only source of striatal 
dopamine. Other midbrain dopaminergic cell groups which project to the striatum 
include the retrorubral region (A8) and the medially situated ventral tegmental area 
(A 10) which is the main source of dopamine for the ventral striatum, prefiontal 
cortex and limbic targets, although these regions also receive some connection from 
the medial SNc (Fallon and Loughlin, 1995).
Homykiewicz (1966) and Bernheimer et al., (1973) revealed that the nigrostriatal 
dopaminergic projection is degenerated m Parkinson’s disease and thereafter a great 
deal of research was devoted to devising pharmacological and surgical mechanisms 
to reverse the symptoms of this disease.
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L-dihydroxyphenylalanine (L-dopa) is one of the earliest drugs used in the treatment 
of Parkinson’s disease. It is converted by the enzyme aromatic L-amino acid 
decarboxylase to dopamine, the neurotransmitter deficient in the disease (Lloyd et 
al., 1975; Melamed et a l, 1985). The dopamine that is formed is thought to substitute 
for the loss of dopaminergic input to the striatum that underlies the pathology of the 
condition. Not only dopamine agonists such as L-dopa and bromocriptine, but also 
muscarinic antagonists such as benzhexol and benztropine have been found to be 
beneficial in the treatment of the disease and this gave rise to the hypothesis that 
symptoms might be due to a striatal dopamine-acetylcholine imbalance. It was 
thought that degeneration of the nigrostriatal dopaminergic system lead to an 
overactivity of the striatal cholinergic system thus producing the symptoms of 
Parkinson’s disease, which are reversed through the adminstration of L-dopa.
Recent experiments with 6 -hydroxydopamine lesioned rats using microdialysis 
where L-dopa was inserted into both the striatum and the substantia nigra 
demonstrated that the substantia nigra pars reticulata released a high concentration of 
dopamine. Experiments performed by Orosz and Bennett (1992) indicated that 
following L-dopa adminstration there was a far greater increase in the concentration 
of dopamine in the extracellular fluid of the substantia nigra pars reticulata than in 
the striatum. This indicates that the SN could be a major site of dopamine production 
in the hemiparkinsonian rat. Therefore, it may be assumed that the effects of L-dopa 
on basal ganglia function extend beyond the restoration of dopamine concentration 
within the striatum.
1.4.1.1 Dopamine interactions
Many investigations have centred on the interaction of dopamine with other 
transmitters in the basal ganglia circuitry. Particular attention has been paid to the
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interaction of dopamine with glutamate, an excitatory amino acid within the 
neostriatum. This is because glutamatergic and dopaminergic afferents have been 
found to converge upon the same striatal GAB A neuron (Bouyer et al., 1984) and 
recent work indicates the possibility of direct interaction (Shimizu et al., 1990; 
Garcia-Munoz et al., 1991). Garcia-Munoz et al, (1991) propose that dopamine 
released from nigral afferents diffuses and stimulates the glutamatergic terminals via 
a process of non-synaptic volumetric transmission. On the other hand it is thought 
that there may be a striato-pallido-thalamo-cortico-striatal neural loop that releases 
glutamate and aspartate following dopamine release in the neostriatum (Barbito et 
al., 1989; Carlsson and Carlsson, 1990). Many of the experiments perfomaed on the 
conscious rat involved acute injections of amphetamine and apomoiphine which are 
dopamine receptor (both D1 and D2) agonists and thus release dopamine into the 
neostriatum on administration. These drugs were found to cause an increase in the 
extracellular concentration of both glutamate and aspartate as well as the inhibitory 
amino acid G ABA, taurine and glycine. It has been proposed that these effects could 
be part of a protective alarm system for neurotoxic injury, since hypoxia and 
ischaemia have been found to produce an increase in both the concentration of 
dopamine and the excitatory amino acid glutamate and aspartate in the neostriatum 
(Golbus et al., 1988; Damsma et al., 1990; Akiyama et al., 1991). Moreover, 
dopamine depletion and glutamatergic receptor blockade have been shown to 
attenuate neuronal death following hypoxic/ischaemic injury (Weinberger et al., 
1985; Gill et al., 1987; Clemens and Phebus, 1988). Therefore, increased dopamine 
concentration leading to the release of glutamate and aspartate may mediate the toxic 
effects that are produced. Both taurine and GABA are thought to exert a protective 
role during a hypoxic/ischaemic insult (Stemau et al., 1989).
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Dopamine is known to interact with many other substances within the central 
nervous system, including opiods in the basal ganglia and forebrain, serotonin and 
GABA in the midbrain, norepinephrine and cholecystokinin elsewhere within the 
CNS.
1,4.2 Serotonin
The central or midline (raphe) location of the large neurons of the brain stem has 
attracted the attention of anatomists since the time of Ramon y Cajal, who described 
these cells as large multipolar neurons with imcertain projections. No one suspected 
that they contained the same chemical substance distributed throughout the body. For 
many years, investigators had known of a blood-bome chemical that produced 
vasconstriction (a 'Serum' factor that affected blood vessel ‘tonus’ hence the name 
Serotonin) and of a substance present in the gut that increased intestinal motility 
(enteramine). In the mid-twentieth century, serotonin or 5-hydroxy tryptamine (5- 
HT), the single compound producing both these effects, was isolated and 
synthesised, and its molecular structure was elucidated (Hamlin and Fisher, 1951). 
Shortly thereafter, 5-HT was found to be present in the mammalian CNS in 
significant quantities and to be concentrated in varying amount in different regions of 
the brain. This led to the proposal of 5-HT as a CNS neurotransmitter.
Localisation of the cell bodies and axon terminals was initially visualised in the 
1960’s with the Falck-Hillarp method of formaldehyde-induced histofluorescence 
(Dahlstorm and Fuxe, 1964). However, the instability of the fluorophore produced 
meant that this method could not provide information on the serotonergic innervation 
of the brain at the same level of sensitivity as it did for the catecholaminergic 
innervation. Alternative methods were subsequently used to localise 5-HT in the 
brain: autoradiogiaphy either at the light microscope (Conral et al., 1974; Bobillier et
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al, 1976, 1979; Azmitia and Segal, 1978; Moore et al., 1978) or at the election 
microscope level (Aghajanian and Bloom, 1967; Descarries et al., 1975); lesion 
studies combined with biochemistry (Geyer et al., 1976) or histochemistry 
(Ungerstedt, 1971). More recently, the preferred method of immunohistochemistry 
with antibodies against 5-HT has demonstrated the full extent of serotonergic 
innervation (Steinbush et al., 1978; Lidov et al., 1980; Lidov and Moliver, 1982a,b) 
The serotonergic cell bodies are restricted to clusters in the brain stem, but their 
fibres, using most of the known longitudinal pathways, innervate nearly every area of 
the brain (Steinbusch, 1981; Steinbusch and Verhofstad, 1981; Tork, 1990). The 
neurons in the entire mammalian CNS number in billions, whereas serotonergic cells 
number in the thousands and they constitute -1/1,000,000 of all CNS neurons. 
However, their influence on their target sites appears to go far beyond these numbers. 
In the rat brain it is estimated that there are -6x10^ serotonergic varicosities/mm 
cortical tissue. By extrapolation, this means that each serotonergic neurons projecting 
to the cortex may be responsible for 5x10^ serotonergic varicosities, that each of their 
cortical target neurons receives -  2 0 0  varicosities, and that serotonergic terminals 
may account for as many as 1/500 of all axon terminals in rat cortex (Audet et al., 
1989).
The 5-HT cell bodies in the brain are located in the brain stem (Chojnacka-Woj cik, 
1995; Jacobs and Azmitia, 1992; Morgan et al., 1987), in raphe nuclei groups which 
extend from the midbrain to the medulla oblongata. These areas are classified into 
nine regions (B1-B9) (Dahlstrom and Fuxe, 1964; Steinbusch, 1981; Tork, 1990; 
Weissmann et al., 1987) rostral 5-HT neurons have ascending projections that 
innervate virtually all areas of the brain, whereas the caudal cell groups project to the 
spinal cord (Goridis and Rohrer, 2002)
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Serotonergic neurons synthesize 5-HT from dietary tryptophan, which is converted to 
5 -hydroxy-tryptophan by the rate limiting enzyme tryptophan 5 -hydroxylase. 5- 
hydroxy-tryptophan is, in turn, converted to 5-HT by aromatic-L-amino acid 
decarboxylase. The production rate is believed to be adjusted by impulse-coupled 
regulation of tryptophan hydroxylase activity (for review see Cooper et al, 1986), 
Serotonin itself is metabolised initially into 5-hydroxy-indole-acetaldehyde by 
monoamine oxidase (MAO), the enzyme that oxidatively deaminates all monoamines 
to their corresponding aldehydes; further oxidation by aldehyde dehydrogenase leads 
to the formation of 5-hydroxy-indole acetic acid (see Osborne, 1982).
Serotonin is released by stimulation of the serotonergic cell bodies in the raphe 
nuclei. These cells possess 5-HT autoreceptors, suggesting that 5-HT regulates its 
own release. However, other neuiotransmitters and modulators (dopamine, 
noradrenaline, acetylcholine) have also been implicated in this regulation. Drugs and 
experimental compounds like reserpine, Tc-chloroamphetamine (PCA), and 
methlyene-dioxy-methamphetamine (MDMA/ ‘Ecstasy’) can also cause release of 5- 
HT (for review, see Green et a l, 1995). The action of 5-HT upon postsynaptic 
receptors, as studied by iontophoretic application, is chiefly inhibitory (Reader, 
1978), although it can also have (or facilitate) excitatory activity (Nedegaardt et a l,
1987). This action is terminated by reuptake into the presynaptic terminal; the uptake 
system has a high specificity and does not interact with other monoamines.
Serotonin receptors were originally classified as D and M types in the 1950’s and 
later as 5-HTl, 5-HT2, 5-HT3 and more recently, 5-HT4. The advent of molecular 
cloning techniques brought about an explosive increase in the number of distinct 5- 
HT receptors subtypes that can be identified reaching the cuirent number of 14. 5- 
HT3 is a ligand-gated ion channel, while the rest belong to G-protein coupled types 
(Teitler and Herrick-Davis, 1994, Leonard, 1996).
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Serotonergic cell bodies appear very early (E l2) in the embryonic development of 
the rat, when they form a cluster on either side of the floor plate of the 
rhombencephalon, accompanied by short, non-varicose fibers (Aitken and Tork,
1988). This cluster gives rise to the ascending fibres, while a second one, appearing 
caudally at E l4, gives rise to the descending ones. The dorsal and the median raphe 
nuclei, which will be examined in this thesis, arise hom the first cluster.
1.5 Animals models of Parkinson’s disease
For the last 40 years, one research goal has been to find an animal model which can 
mimic Parkinson’s disease. One of the first models was introduced by Ungersted 
(1968) who developed the 6 -hydroxydopamine (6 -OHDA) treated rat. The drug, 
injected into the substantia nigra or into the striatum, accumulates in dopaminergic 
neurons and kills them owing to toxicity that is thought to involve the generation of 
free radicals. 6 -OHDA is frequently injected in one side of the striatum to produce a 
unilateral lesion, leaving the contralateral side as the control. Marmosets with a 6 - 
OHDA lesion showed 98% depletion of DA in the neostriatum, 90% depletion in the 
preffontal cortex, as well as a loss of noradrenaline and 5-HT compared to controls 
receiving saline (Annett et al., 1992). The model is complex because contralateral 
effects can complicate data inteipretation (Jenner et al., 1992). Moreover, the motor 
deficits examined are usually apomorphine- or amphetamine-induced rotations which 
are not characteristic of PD patients.
1 -methyl-4-phenyl-1,2,3,6 -tetrahydropyridine (MPTP) treatment also induces 
Parkinsonism (Alexander et al., 1992; Jenner et al., 1992), particularly in primates 
where it causes a loss of DA neurons in the pars compacta of the SN, together with a 
loss of DA and DA uptake sites in the striatum (Alexander et al., 1992). It was first 
noticed when heroin addicts developed severe PD after using a ‘designer drug’
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contaminated with MPTP. MPTP is a lipophilic which can cross the blood brain 
barrier, where it is metabolised to 1 -methyl-4-phenylpyridinium (MPP+) by 
monoamine oxidase B, an enzyme involved in catecholamine degradation (fig 1.3).
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Figure 1.3 Pathogenesis of neuronal dysfunction produced by neurotoxins that affect 
dopamine neurons. The mechanisms by which neurotoxins kill dopamine neurons involve 
mitochondrial dysfunction and oxidative damage. 6-hydroxydopamine (6-OHDA) is taken up by 
the dopamine transporter and it then generates free radicals. l-methyl-4-phenyl-l,2,3,6- 
tetrahydropyridine (MPTP) is converted by monoamine oxidase B (MAOB) to l-methyl-4- 
phenylpyridinium (MPP+) MPP+ is taken up by the dopamine transporter and can then be 
accumulated by mitochondria, leading to complex I inhibition and the generation of free 
radicals, or by the vesicular monoamine transporter, thus reducing toxicity. Rotenone is a direct 
inhibitor of complex 1, which also leads to free-radical generation. MPTP and rotenone 
treatment increase the expression of a-synuclein and, in the latter case, this leads to the 
formation of Lewy bodies. From Flint Beal, (2001).
In primates, MPTP-treated animals were found to have most of the signs of PD. In 
monkeys, the drug was able to produce the typical behavioural features, including the 
tremor which does not occur in most primate species following MPTP intervention 
(Elsworth et al., 1992). The main difficulty with MPTP toxicity as a model of PD is 
that it is an acute or subacute process, whereas PD is a slowly progressive illness.
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Others experimental models of Parkinson’s disease have been produced by infusing 
rats intravenously with rotenone - a lipophilic pesticide. This leads to dopaminergic 
nigrostriatal degeneration which produces hypokinesia and rigidity and, more 
interestingly, the animals accumulate fibrillai' cytoplasmic inclusions that contain 
ubiquitin and a-synuclein as found in Lewy bodies (Betarbet et al., 2000). However, 
only half of the rats treated with rotenone developed lesions (Flint Beal, 2001). 
Alpha-synuclein models in Drosophila and mouse have been introducing as models 
of Parkinson’s disease but they lack several of characteristic features of PD (for 
review see Flint Beal, 2001).
Mutant strains of laboratory rodents (especially mice) with locomotor disorders have 
arisen spontaneously. In general, they are poor breeders with low life expectancies, 
and are complicated in that they may have cerebellar deficiencies including a 
micro cerebellum or loss of Purkinje or granule cells. These mice include weaver, 
staggerer and totterer strains (Gupta et al., 1986; Triahou et al., 1987; 1988). 
Knockouts of DA receptor by types gene deletion have been used to produce other 
models. For example, Drago et al., (1996) reported D ia knockouts to show no gross 
neurological deficit. On assessing phenotype in terms of accumulation of visually 
observed rearing events and line-crossing in an open field over a 15 min period, Dia 
mutants were characterised by a reduced level of rearing but no significant reduction 
in locomotion. By contrast, Xu et al., (1994a,b) using a photo beam analysis reported 
that there were increases in activity with reduction only in visually observed 
grooming, but not in rearing or sniffing, over a Ih period. Such finding showed that 
Dia knockouts can not be characterised simplistically as either hypoactivity or 
hyperactivity but, rather, by complex, topographical shifts between individual 
elements of behaviour in the natural mouse repertoire that cannot be encapsulated by 
either term (for review see Waddington et al., 2001).
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Dib/5 knockouts showed increases in both horizontal and vertical activity in terms of 
photocell beam breaks; there was also enhanced performance on the rotarod (Sibley, 
1999).
Baik et ah, (1995) showed that D2 knockout mice had an abnormal posture, with fore 
and hind paws flattened to the ground; impaired gait, with sprawled hind legs; 
impaired rotarod performance, with a shorter latency to fall.
D3 knockout features include increased line-crossing, as an index of locomotor 
activity, and in rearing but not in grooming events (Steiner et al., 1997).
Knocking out D4 led to reduced horizontal and vertical movements in terms of 
photocell beam intennptions over repeated testing (Rubinstein et al., 1997).
1.6 The AS/AGU rat
In the Laboratory of Human Anatomy at the University of Glasgow, the AS/AGU rat 
has arisen as a spontaneous mutation within a closed inbred colony of Albino Swiss 
(AS) rats. The mutation is recessive (Campbell et a l, 1996), and AS/AGU rats have 
been isolated as a tme breeding substrain. Phenotypic differences are therefore, the 
result of single point mutation. The mutant animals show serious movement 
impairments including rigidity, a staggering gait and a tendency to fall over every 
few steps, a slight whole body tremor and difficulty in initiating movement (Clarke 
and Payne, 1994; Payne et al, 1998).
Several studies including histological, neurochemical, immunocytochemical and 
locomotor analysis revealed that in the AS/AGU mutants there are:
A- No gross morphological difference between the mutant and the parent brains.
Neocortical and cerebellar areas looks normal.
B- Immunocytochemical studies showed a reduction (c.60%) in TH-immunoreactive 
cell bodies in the SNc of the mutant strain at 1^  years of age (Clarke and Payne,
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1994). Another preliminary study showed a reduction in noradrenergic cells in 
the locus coemleus (Scott et al, 1994).
C- At 6  months, there is a reduction (20-30%) in whole tissue dopamine levels 
measured in striatal micropunches using High performance liquid 
chromatography with electrochemical detection (HPLC-ECD) (Campbell et al.,
1996).
D- At 3 months, microdialytic studies showed a massive reduction (-80%) in 
extracellular dopamine in the dorsal caudate putamen, compared with AS 
controls when measured with HPLC-ECD.
E- Behavioural studies showed that AS/AGU rats have a marked difficulty in 
initiating movement, and are generally unable to perform simple non-invasive 
locomotor tests such as rotating in mid-air and walking down a variety of 
inclined ramps of various widths.The deficits are significant at 6 and 12 months. 
L-dopa was found to restore striatal dopamine levels and ameliorate many 
locomotor deficiencies in AS/AGU rats (Campbell et al., 1998).
F- There is a marked reduction in utilisation of 2-deoxy-glucose in several brain 
areas including substantia nigra pars compacta (SNc), subthalamic nucleus and 
ventrolateral thalamus (Lam et al., 1998).
1.6.1 The AS/AGU mutation
Genetic mapping, involving multiple backcross studies, has revealed the agu 
mutation to possess very tight linkage to a marker in the 3’ untranslated region of the 
protein kinase c y isoform encoding gene. Subsequently, sequencing of this gene 
revealed as far as we know, it is a single point mutation a substitution resulting in a 
stop codon between the regulatory and catalytic domains (Craig et al., 2001).
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Truncation of the PKC y coding region before the catalytic domain may lead to the 
expression of the regulatory domain only, or the inactivation of the messenger RNA. 
In any case PKC y activity is complelety abolished in AS/AGU rats.
PKC y has been labelled a CNS restricted isoform (Kano et al., 1995). But recent 
finding suggest expression ouside of the CNS.
Expression patterns of PKC y within the CNS are largly unclear but it is known that 
levels aie high in Purkinje cells, medium sized neurons of the striatum and globus 
pallidus, which project to the substantia nigra pars reticulata, and spinal cord (Chen 
et al., 1995). In addition, activition of PKC in nerve cells found to have affect in 
modulation of ion channels (Shearman et al., 1989), the desensitisation of receptors 
(Huganir and Greenyard, 1990), and the enhancement of neurotransmitter release.
The aim of this project is to examine a second aminergic neuronal system the raphe- 
striatal serotonergic system to establish whether it is degenerate or dysfuntional in 
the mutant AS/AGU rat compared to the parent AS strain. This will be carried out by 
a series of experiments.
Firstly, it is essential to determine if the genetic defect had been identified correctly, 
so different regions in the brain will be investigated by means of anti PKC 
y immunocytochemistry in the mutant (AS/AGU) and parent AS rat.
Secondly it is important to confirm that rostal projections from the raphe do 
innervate the caudate-putamen as previous literature suggests and this will be done 
by a retrograde tracing study.
Experiments three onwards then examine the integrity of the serotonergic raphe 
striatal system in three ways
i) an evaluation of the numbers of 5-HT-ir cells in the dorsal and median raphe 
nuclei (Experiment 3)
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ii) measurement of the levels of indole- and catecholamines in several striatal 
and medbrain regions by micropunch and HPLC-ECD (Experiment 4)
iii) measurement of extracellular levels of indole-and catecholamines within the 
caudate-putamen using in vivo microdialysis followed by HPLC-ECD 
(Experiment 5)
Experiment 4 will also include the effects of simple pharmacological 
manipulations on indole- and catecholamine levels in the mutant and parent 
strain. The final experiment (Experiment 6) will determine whether similar 
manipulations can affect behaivour in the two strains using a simple study of 
spontanous locomotion.
It is hoped by these means to establish whether similar dificits occur within 
the midbrain serotonergic system of the AS/AGU mutant as have already 
been demonstrated in the midbrain dopaminergic system? The expectation is 
that deficit are likely to occur since
a) natur ally occurring syndromes in the humans which involve the basal 
ganglia and locomotion often lead to dysfunction of several transmitters 
systems, and
b) it is unlikely that a basic enzyme such as protein kinase C (whose - 
isoform is defective in the AS/AGU mutant) would be restricted in its 
action to one tranamitter system only.
Finally, it is hoped that the results obtained in these experiments will give 
insight into the potential use of the AS/AGU rat as a model for important 
human neurodegenerative conditions.
2 Experiment 1. PKCy expression in AS and 
AS/AGU mutant rats
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2.1 Introduction
Protein kinase C (PKC) is an enzyme which is located in a wide variety of tissues. Within 
the nervous system, PKC is involved in widely diverse functions. Thus, activation of PKC 
in nerve cells is found to be linked to modulation of ion channels (Shearman et al., 1989; 
Baraban et al., 1985; Madison et al., 1986), the desensitisation of receptors (Huganir and 
Greenyard, 1990), modification of neuronal plasticity (Routtenberg et al., 1985; Akers et 
al., 1986) and, most interestingly, the enhancement of neurotransmitter release (Malenka et 
al., 1986,1987). The role of PKC in cell surface signal transduction is now also widely 
accepted and well documented (for review, see Nishizuka, 1984 a,b; 1986).
There ai e at least 14 isoforms of PKC that have been identified in mammalian tissue, each 
of which has a specific expression pattern. One of them is PKC y which is said to be 
restricted to the CNS, being expressed in Purkinje cells and medium sized neurons of the 
striatum and globus pallidus (Chen et al., 1995). Experiments on PKC y knockout mice 
have shown a link with synaptic plasticity, control of long term potentiation and 
elimination of surplus climbing fibres in the developing cerebellum (Kano et al., 1995; 
Chen et al., 1995). PKC y deficient mice exhibit ataxia (Kano et al., 1995) and impaired 
motor coordination, but are capable of discrete motor learning (Chen et al., 1995). In the 
basal ganglia there is dense localisation of PKC y in the cytoplasm of medium sized 
neurons projecting to the substantia nigm; in perikarya and neuropil in the striatum; and 
neuropil in the substantia nigra (Yoshihara et al., 1991).
The aim of this chapter is to confiim the PKC y mutation in the AS/AGU rat by 
immunocytochemistry (ICC).
Different neuronal regions were chosen because of the expected high expression of this 
enzyme in striatum, substantia nigra, dorsal raphe and cerebellum in normal animals. It
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was expected that PKC y would be absent in the mutant rat (AS/AGU) all in areas chosen 
if the genetic defect had been identified correctly (Craig et ah, 2001). The same regions 
were analysed in the AS rat in order to assess the presence of PKC y and to verify that the 
technique was appropriate to the study.
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2.2 Material and Methods
2.2.1 Animals
One year old AS and AS/AGU male rats (3 in each group) were used in this experiment.
2.2.2 Immunocytochemistry (ICC)
An ICC technique was used in this experiment according to the protocol which was first 
employed by Hsu and colleagues (1981).
The rats were deeply anaesthetized with an overdose of Sodium pentobarbitone BP (Vet) 
(Rhone-Merieux, Spire Greencentre, Harlow, Essex, 60mg/ml). They were then perfused 
through the left ventricle with 100ml Ringer’s solution containing the vasodilator 
Lignocaine followed by 500ml 4% paraformaldehyde (2944744 BDH) in 0.1 M phosphate 
buffer. The brains were dissected out and post-fixed in formalin overnight. Pieces of brain 
containing areas of interest were dehydrated through an ascending ethanol series using a 
Histokinette automatic tissue processor, then processed for paraffin at 57 ”C, serially 
sectioned at 6 pm and mounted on APES (3-aminopropyltriethoxysilane) coated slides.
The sections were deparaffinized and rehydrated before undergoing a high temperature 
antigen unmasking technique. Slides were immersed in boiling 0.0 IM sodium citrate 
buffer (pH 6.0) in a Prestige stainless steel pressure cooker. The temperature was then 
raised to 121 *^C for 1 minute,
2.2.3 Immunocytochemistry on wax sections
Sections were incubated in 0.5% hydrogen peroxide (H2O2) for 10 minutes to eliminate 
endogenous peroxidase activity. After rinsing in O.OIM phosphate buffered saline (PBS, 
3x5 mins), sections were treated with 1% normal goat serum (NGS) in PBS with 3% triton- 
xlOO for 1 hour to clear background staining. They were then incubated in a humidity 
chamber overnight at 4°C with the primary antibody (anti-PKC-y ; RDI) (1:1000) diluted in
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PBS containing 3% triton-xlOO. The rest of procedure was carried out at room 
temperature. After rinsing in PBS (3x5 mins), a biotinylated anti-rabbit secondary antibody 
raised in goat (1:500 dilution) Jackson ImmunoReaearch Laboratories, INC, West Grove, 
PA, U.S.A) and then an Avidin-biotin complex (1:50; Vector Laboratories, INC, 
Burlingame, CA, U.S.A) were used to label the bound primary antibody. The location of 
the antigen-antibody complex was visualised by incubating sections in a medium 
containing 0.05% 3,3- diaminobenzidine, 0.01% H2O2 and 0.02% nickel chloride in O.OIM 
phosphate buffer (2-5 mins).
After dehydration sections were mounted in Histomount (Hughes & Hughes, LTD., 
Willington, Somerset, UK).
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2.3 Results
2.3.1 PKC-y immunostaining in cerebellum
PKC Y antibodies stained the cell bodies and dendrites of Purkinje cells in control (AS) 
rats. There was also obvious staining of the axon of these cells. Furthermore, there was no 
obvious staining of basket or stellate cells in the molecular layer or other cell types in the 
granule layer when PKC y antibody was used.
In the mutant rat (AS/AGU) there was no specific staining in any layers of the cerebellum 
either in cell bodies or terminals.
Figure 2-1 A cross section of cerebellum from an Albino Swiss (AS) male rat aged 12 
months. The section has been immunostained for protein kinase C (PKC)- y and 
Purkinje cells are readily visualised. (xlOO).
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Figure 2-2 A cross section of cerebellum from mutant (AS/AGU) male rat aged 12 
months. The section has been immunostained for protein kinase C (PKC)-y but no 
specific staining in any layers of the cerebellum was found. (x20)
2.3.2 PKC-y immunostaining in the Hippocampus
PKC Y immunoreactivity was distributed throughout the hippocampal formation.
Large numbers of immunoreactive pyramidal cells were present in the CA1-CA3 layers. 
Intense immunoreactivity was found in the perikarya and there was moderate 
immunoreactivity in the nuclei of the pyramidal cells. The neuropil of the hippocampus 
was moderately stained and the most intense immunoreactivity was found in the proximal 
portion of the stratum radiatum of the CA3 region.
In the mutant rat (AS/AGU) there was no specific staining in any regions of the 
hippocampus.
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Figure 2-3 A cross section of hippocampus from an AS maie rat aged 12 months. The 
section has been immunostained for protein kinase C (PKC)-y and dense 
immunoreactivity occurred in the fiber bundle-like structure in CA3. (xlOO)
Figure 2-4 AS hippocampus (xlOO)
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Figure 2-5 A cross section of hippocampus from mutant (AS/AGU) male rat aged 12 
monthes. The section has been immunostained for protein kinase C (PKC)-y but no 
specific staining was found in any region of the hippocampus. (x20)
2.3.3 PKC-y immunostaining in the cerebral cortex
Staining occurred throughout the neocortex, although with varying intensities of 
immunoreactivity. PKC y immunoreactivity showed positive staining in neurons 
resembling pyramidal cells and their apical dendrites in layers II to VI, while layer I was 
nearly devoid of staining. PKC y immunopositive neuropil of AS (control) rats was seen in 
layers I, II, V, and VI.
In the mutant rat (AS/AGU) there was no staining in any layers of the cerebral cortex.
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Figure 2-6 A cross section of cerebral cortex from an AS maie rat aged 12 months. 
The section has been immunostained for protein kinase C (PKC)-y. (x40)
Figure 2-7 Higher magnification of 2.6 showing PKC)-y immunoreactivity. 
Immunopositive cells are seen in layer II. (xlOO)
Lack of staining for PKC-y in cerebral cortex of mutant rat is shown in Fig 2.9
2.3.4 PKC-y immunostaining in the striatum
PKC y immunoreactivity was abundant in the perikarya, neuropil and fibre bundles of the 
striatum of AS (control) rats. Staining was found in numerous medium sized neurons 
scattered throughout the CP but was less intense in the globus pallidus.
In the mutant rat (AS/AGU) there was no specific staining in any areas of the striatum.
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Figure 2-8 A cross section of striatum from an Albino Swiss (AS) male rat aged 12 
months. The section has been immunostained for protein kinase C (PKC)-y. (x20)
M S-
Figure 2-9 A cross section of striatum from mutant (AS/AGU) male rat aged 12 
months. The section has been immunostained for protein kinase C (PKC)-y and no 
staining was detected in any areas of the mutant rat. (x20)
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2.3.5 PKC-y immunostaining in the substantia nigra
PKC y immunoreactivity was abundantly present in the neuropil of AS (control) rats which 
showed more intense immunoreactivity in the medial than in the lateral part of the pars 
reticulata, whereas the neuronal perikarya were not labelled.
In the mutant rat (AS/AGU) there was no specific staining in any layers of the substantia 
nigra.
Figure 2-10 A cross section of substantia nigra from an Albino Swiss (AS) male rat 
aged 12 months. The section has been immunostained for protein kinase C (PKC)- 
y and labelled neuropil throughout SN. (x30)
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Figure 2.11 A cross section of substantia nigra from mutant (AS/AGU) male rat aged 
12 months. The section has been immunostained for protein kinase C (PKC)-y and 
there no staining was found. (x30)
2.3.6 PKC-y immunostaining in DRN & MRN
PKCy immunoreactivity was less abundant in the neuropil of the DRN where no labelled 
cells were seen in the control animals (AS). In contrast, there were a few labelled cells 
been in the MRN of control AS rats.
In the mutant rat (AS/AGU) there was no specific staining in any area of the DRN and 
MRN.
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Figure 2-12 A cross section of DRN & MRN from an Albino Swiss (AS) male rat aged 
12 months. The section has been immunostained for protein kinase C-y and labelled 
neuropil of DRN can be seen. (x40)
Figure 2-13 Higher magnification of fig 2.14 showing the labelled neuropil of DRN 
from an Albino Swiss (AS) rat. (xlOO)
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Figure 2-14 A cross section of DRN and MRN from a mutant (AS/AGU) male rat 
aged 12 months. The section has immunostained for protein kinase C-y and there no 
staining in both neuclei. (x25)
Figure 2-15 Cross section of MRN of an Albino Swiss (AS) rat showing a few labelled 
cells. (xlOO)
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2.4 Discussion
In this discussion I will briefly review the following points:
A) Do my immuno cytochemical studies support the identification of the defective gene as 
that for PKC-y (Craig et al., 2001)?
B) In normal animals, does the pattern of PKC-y reactivity reflect the previous literature?
C) What effects might a PKC-y deficiency have?
ICC shows positive labelling of PKC y in AS animals while AS/AGU rats show no 
labelling at all in any of the brain areas studied. This confirms the identification of the gene 
by Craig et al (2001).
In the case of the cerebellum, the labelling was within cerebellar Purkinje cell bodies and 
dendrites which agrees well with previously published data (Huang et al., 1988; Kano et 
al., 1995). Other immunoreactive areas in the present study also confirm previous reports 
of staining e.g. in the hippocampus (Huang et al., 1988; Saito et al., 1994), cerebral cortex 
(Huang et al., 1988; Tsujino et al., 1990), the caudate- putamen and substantia nigra 
(Yoshihara et al., 1991).
Electron microscopic studies on the hippocampus showed PKC-y immunoreactivity in the 
presynaptic neiwe terminals and also in postsynaptic dendrites. The PKC-y was present 
homogeneously in presynaptic terminals of the shaft synapse and appeared to be associated 
with synaptic vesicles (Saito et al., 1994).
Studies comparing expression of the 3 types of isoforms, a,|3,y in cerebellum found that 
Pui*kinje cells were stained for all 3, but only y was present in their dendritic trees which 
indicate that if both kinases are involved in release, y may play a large role proximal to the 
cell body (Huang et al., 1988).
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The specification of the antibody (anti-PKC-y ; RDI) for the active site at the carboxyl 
terminus (the region which has been shown to be missing in the agu mutation Craig et al, 
2001) leads to selective labelling of PKC-y and shows no cross reactivity for other PKC 
isoforms. Mutant rats should not therefore show staining in any of the areas examined and 
this indeed was the case in this study,
Loss of activity of PKC-y must be related to the neurochemical, neurodegenerative and 
locomotor disorders exhibited by these rats.
Hashimoto (1988) reported that PKC-y was only expressed postnatally so there was no 
chance of a deficit producing substantial developmental errors. In contrast, other 
investigators have found the expression of PKC-y in the embryonic chick brain (McIntyre 
et al, 1999). In addition more recent work on Xenopus has confirmed a role for PKC-y in 
early brain development (Kramer et al, 2002).
Much available litertaure deals with the PKC family in general, rather than specific 
isoforms. However, both PKC and other subsets (alpha and beta) are known to be intrically 
involved in the packaging and release of neurotransmitters (Ben-Shlomo et a l, 1991). The 
role of PKC-y in synaptic mechanisms is unclear and made more complicated in that the 
absence of PKC-y can lead to upregulated activity of other isoforms (e.g. alpha and beta) 
by cellular compensatory mechanisms (Chen. 1995).
Activation of PKC by phorbol esters causes phosphorylation and redistribution of 
dopamine and serotonin transporters in transfected LLC-PKl and HEK293 cells 
respectively (Apparsundaram et a l, 1998) and treatment with PKC activator induces 
movement of GAB A transporter proteins between cytoplasmic membrane vesicles and the 
surface membrane m Xenopus laevis oocytes (Apparsundaram et a l, 1998).
Even at low concentrations, glutamate release can be enhanced by PKC activators such as 
PMA and antagonised by PKC inhibitors (Nakamura et a l, 2003). Also studies on o 1 
agonist-mediated inhibition of NMDA-stimulated f  H] dopamine release is transduced by
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a PKC signalling system. Regulation is abolished by pre-treatment with PMA inhibitors 
(Nuwayhid and Werling, 2003).
5-HT:A receptor is enriched in many brain areas including the striatum (Pazos et al., 1985, 
1987). Furthermore, experiments performed with PKC inhibitors confirmed that PKC was 
involved in the regulation of 5-HT:A receptor mRNA by agonists and implicate the 
conventional subgroup of PKC isoforms.
Upon treatment of C6 glioma cells with 5-HT, levels of PKC-y increased in the nuclear 
fraction suggesting that PKC-y may be involved in the regulation of 5-HT:A receptor 
expression in response to agonist treatment (Anji et al., 2001). Indeed, the post-synaptic 
regulation of G ABA and 5-HT receptors by PKC-y has been linked to anxiety (Bowers et 
al., 2000).
Downregulation of PKC by chronic exposur e to PMA induced 5-HT secretion. PKC 
isoforms mediate secretion of 5-HT by Parafollicular cells (Pf cells) Liu et al., 2000). More 
recent work has confirmed the role of PKC-y in 5-HT secretion (Liu et al., 2003). The 
findings on Pf cells ar e likely to be very relevant to other neuronal mechanisms induced by 
Ca"^  ^entry, including synaptic transmission.
It is with the knowledge that PKC can influence 5-HT release (and the knowledge that this 
PKC-y deficient mutant exhibits reduced DA release and subsequent loss of DA cells) that 
I have undertaken three experiments. These will respectively answer the questions
1- Are 5-HT-containg neurons reduced in the AS/AGU rat ?
2- Are 5-HT levels reduced in a vai iety of brain regions of the AS/AGU mutant rat and 
how does the mutant respond to simple manipulation of 5-HT by pharmacological 
means compared to the parent (AS) strain ?
3- Is 5-HT release in the striatum reduced in the AS/AGU mutant ?
As a prelude to experiments 2 & 3 it is necessary to confirm the projections fiom DRN to 
striatum and this is the next experiment I shall report.
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3 Experiment 2. Investigation of the rostral projections 
from the raphe nuclei using the retrograde tracer
cholera toxin
5 0
3.1 Introduction
The dorsal and median raphe nuclei in the midbrain are amongst the major nuclei 
composed of serotonergic cells (Azmitia and Segal, 1978; Chojnacka-Wojcik, 1995; Dray, 
1981; Jacobs and Azmitia, 1992; Van der Kooy and Hattori, 1980).
The mapping of aminergic neurons started with the formaldehyde-induced fluorescence 
(FIT) technique, which allows microscopic visualization of monoamines in freeze-dried 
tissues (Falck et al., 1962). Subsequent modifications of the FIF techniques allowed a 
variety of authors (Dahlstrom and Fuxe, 1964; Fuxe and Jonsson, 1967; Bjorklund et al., 
1971; Fuxe and Jonsson, 1974; Jonsson et al., 1975; Azmitia and Flenriksen, 1976; 
Bjorklund et al., 1976; Loren et al., 1976; Smialowska, 1979) to demonstrate that the 
midbrain raphe nuclei contain numerous serotonin-synthesizing cells which give rise to 
both ascending and descending fibers.
In the midbrain, six ascending fibre tracts were identified, the dorsal raphe nucleus being 
the sole source of four tracts with one arising from the median raphe nucleus and one 
shaied (Azmitia, 1978). The tracts can be classified as those lying within the medial 
forebrain bundle (MFB) a collection of ascending and descending connections between the 
forebrain and midbrain (for review Guillery, 1957). The dorsal raphe forebrain tracts lie in 
the ventrolateral aspect of the medial forebrain bundle and project mainly to lateral 
forebrain structures (e.g. basal ganglia, amygdala, and the pyriform cortex). The median 
raphe forebrain tracts lie in the ventromedial aspect of the MFB and project to medial 
forebrain areas (e.g., cingulate cortex, medial septum and hippocampus). The importance 
of the MFB as the ascending route for 5-HT projections in the rodent brain has been 
stressed by workers using electrolytic (Heller et al., 1962) and neuiotoxic (Jacobs et al., 
1977) lesioning techniques as well as by autoradio graphic comiection tracing (Azmitia and 
Segal, 1974; Conrad et al., 1974; Moore and Halaris, 1975). The latter technique has 
provided anatomical evidence for divergent projections from the midbrain nuclei (DRN 
and MRN) (Bobillier et al., 1975; Pierce et al., 1976). The descending fibers of the DRN
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are distributed to the cerebellum, the lower brain stem and the spinal cord (Steinbusch et 
a l, 1981).
A subsequent experimental tool involves the identification of neuronal cell bodies 
following injections into their tai'get field. One possible mechanism is by the uptake of 
material by the axon terminal, and its transport in a centripetal or retrograde direction to 
the cell body. This technique started about thirty years ago when horseradish peroxidase 
was used to retrogradely label motoneurons supplying the gastrocnemius muscle and 
retinal ganglion cells innervating the optic tectum (Kristensson and Olsson, 1971; LaVail 
and LaVail, 1972).
Since then, retrograde tracing has become the main tool for studying neuronal connectivity 
in both the central and peripheral nervous system (Schwab et a l, 1979; Stockel et a l,
1977; Trojanowsky et a l, 1982; Wan et al, 1982). Varieties of these tracers (often 
involving horseradish peroxidase conjugates with increased sensitivity) make it possible to 
suit almost any experimental design (Wan et a l, 1982). They include retrogradely- 
transported molecules that fluoresce or can be detected immunocytochemically (Horikawa 
and Powell, 1986; Luppi et a l, 1987), tracers linked to colloid gold particles (Basbaum and 
Menetrey, 1987; Llewellyn-Smith et a l, 1990), fluorescent latex microspheres (Katz et a l,
1984) and, most recently, viruses which reveal chains of neui’ons that innervate the target 
at which the virus was injected (Aston-Jones and Card, 2000) have been widely used.
A particularly efficient retrograde tracer is cholera toxin (CT), which is transported in both 
the peripheral and central nervous systems (Stockel et a l, 1977; Luppi et al, 1987); it was 
introduced as a retrogradely transported marker in 1977 (Sawchenko and Gerfen, 1985).
It is known that gangliosides represent a relatively large proportion of neui'onal membrane 
lipids and cholera toxin is bound with high affinity to gangliosides (Stoeckel et a l, 1977). 
The aim of this study is to investigate the localization of possible serotonergic (5-HT) 
projections fiom the dorsal and median raphe nuclei within the neostriatum of AS and 
AS/AGU rats.
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In order to determine the connectivity between the raphe and the caudate-putamen, the 
retrograde tracer cholera toxin b (CTb) was injected into 1- the anterior caudate-putamen 
(ACPU) and 2- the dorsal caudate-putamen (DCPU). ICC was carried out for CTb and 5- 
HT within the midbrain and cell counts were carried out.
These two regions were chosen as previous experimental work on dopamine depletion 
suggested that the DCPU was badly affected in the AS/AGU mutant whereas the ACPU 
was not (Campbell et al., 1996). Projections from the substantia nigra pars compacta (SNc) 
were also examined in CTb-treated animals, using tyrosine hydroxylase (TH) 
immunoreactivity to confirm that the cells were dopaminergic.
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3.2 Material and Methods
Adult male rats aged 12 months were used, 4 AS and 5 AS/AGU in each case. Two pi of 
solution of choleragenoid (Cholera toxin B subunit) (Sigma) was injected stereotaxically 
by means of 10 pi Hamilton syringe into either the anterior (ACPU) or dorsal caudate- 
putamen (DCPU).
Rats were anaesthetized using Xylazine (Rompun; Bayer pic.. Bury St. Edmund, UK., 37 
mg/kg) and Ketamine (Vetalar; Park & Davies, Pontypool, UK., 73 mg/kg) in a ratio of 
1:2. The injections were given at 1.1 ml/kg. In order to confirm deep anaesthesia, the “pad 
pinching” technique was used (where no reflexual withdrawing of the foot was observed 
when full anaesthesia was reached). It was very important to keep the eye moist until the 
end of the procedure.
A small area on the head was shaved and then wiped with alcohol. The rats were then 
placed into a Kopf stereotaxic frame (Munich, Germany) with ear bars, nose clips and teeth 
clips.
An incision was made using a scalpel and the skin retracted using curved Spencer Wells 
forceps. The skull was scraped using a scalpel blade to remove the periosteum and the area 
dried using a cotton bud. Bregma (the intersection of the coronal and sagittal sutures) was 
identified and marked using a pencil, and confirmed independently prior to taking the 
bregma co-ordinates.
Lateral, antero-posterior and dorso-ventral co-ordinates (+ 0.35mm, -0.1mm and -0.4mm 
respectively) were taken using the x,y, and z scales on the stereotaxic fiame. From these 
co-ordinates, new co-ordinates were calculated depending on the area of interest using the 
Paxinos and Watson (1982) stereotaxic brain atlas.
A micro syringe was placed directly over the brain area corresponding to these new co­
ordinates and again this was maiked using a pencil and confirmed independently. A hole 
was drilled into the skull over the pencil mark and the area dried with a cotton bud. The 
micro syringe was then placed over the hole and lowered into the brain very slowly to reach
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the appropriate ventral co-ordinate then allowed to rest for at least two minutes; 1 pi of 
cholera toxin b was then injected and after, another minute, another 1 pi of toxin was 
injected. The needle was then left in for a further two minutes to prevent leakage of the 
toxin and then withdrawn very slowly.
The hole was sealed with Redifast powder (Wright Health Group Ltd., Dundee, U.K.) and 
Redifast solution (Wright Health Group Ltd., Dundee, U.K.), the rat removed from the 
stereotaxic frame and the skin incision sutured. The rats were then given 0.1 ml 
atipamezole hydrochloride (antisedan 5mg/ml; Pfizer Ltd, Kent) in order to reverse the 
effects of the anaesthetic and allowed to recover before being replaced into clean cages. 
One week following brain micro-injection of CTb the animals were sacrificed and their 
brains removed. The rats were deeply anaesthetised with phenobarbitone sodium BP 
(Rhone-Merieux, Spire Greencentre, Harlow, Essex, 60mg/lml) and perfused with 
Ringer’s solution via intracardiac cannulation, and fixed with 4% paraformaldehyde. The 
rats were decapitated using scissors and their brains removed carefully using ronguers 
(Merck Ltd., Leicester), before being post-fixed overnight in the same fixative.
Before any ICC procedures were canied out it was established whether or not the injection 
had gone into the correct area. This was checked via a light microscope. Signs of the 
injection site were a noticeable crack due to the shiinkage of the surrounding tissue and red 
blood cells along with a large deposit of cholera toxin itself due to leakage, if any. If the 
injection was not in the target area then that particular animal was not used.
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Figure 3-1 Injection site in the DCPU. (x40 )
3.2.1 Immunocytochemistry
3.2.1.1 5-HT staining
ICC for 5-HT (see experiment 3).
3.2.1.2 Cholera Toxin b staining
No blocking serum was required as the primary antibody was goat anti-cholera toxin B. 
The sections were incubated overnight in 1:40,000 primary antibody at 4 C^ then incubated 
for sixty minutes in biotinylated secondary antibody (1:500 biotinylated antigoat) before 
continuing as above.
3.2.1.3 Double labelling
After three PBS rinses, the sections were incubated overnight in mixture o f primary 
antisera (Rabbit anti-serotonin and Goat anti cholera toxin b) the dilutions were (1/2,000 
and 1/20,000 respectively). The sections were then incubated for two hours in fluorescent 
secondary antibodies (fluorescein (FITC)-conjugated Donkey anti-Rabbit IgG and Texas 
red (TR)-conjugated Donkey anti-Goat IgG), the dilution was 1/100 for both. After two 
rinses with PBS the sections were mounted with Vectashield.
5 6
3.3 Results
3.3.1 Retrograde staining using cholera-b-toxin
3.3.1.1 Staining of the dorsal raphe nucleus from the dorsal caudate-putamen
Serotonin- and cholera toxin- immunoreactive staining was easily seen within the 
dorsal raphe nucleus. When 5-HT-ir cell numbers in the DRN were plotted along a rostral- 
caudal axis (Fig. 3.2), the numbers followed a slightly skewed normal distribution with 
peak cell numbers marginally rostral of the mid-point of the range (approximately Bregma 
- 7.8mm). Although the numbers of CTb cells were less than those staining for 5-HT, the 
distributions mirrored one another (Fig. 3.2).
When total cell numbers were considered, it was found that CTb cells represented 
40-50% of 5-HT-ir numbers in both AS and AS/AGU rats (Fig. 3.3). Allowing for the 
uncertainty of reaching all cells in the dorsal caudate-putamen by this method, this implies 
that at least half the serotonergic cells in the dorsal raphe nucleus have some connection 
with the DCPU in the area of the injection.
It is also possible to compare cell counts from AS and AS/AGU rats. This shows 
that AS/AGU rats have fewer 5-HT-ir cells than AS rats (t = 12.89, df = 5 p < 0.0001 T- 
TEST).
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Distribution of 5-HT and CTb +ve cells in 
the DCPU injected with CTb
2 3 4 5
number of section
Figure 3.2 Distribution of 5-HT and CTb +ve cells in the DCPU injected with CTb 
from rostral (1) to caudal (6).
Average of 5-HT cells projecting to DCPU per 
section in DRN
120
a  100
4* ^
a  5-HT
■  CTb
□
□  5-KT
■  CTb
AS AS/AGU
Figure 3-3 The numbers of 5-HT-ir and CTb-ir cells per 30pm section in the dorsal 
raphe nucleus of AS and AS/AGU rats aged 12 months after CTb injection into the 
dorsal caudate-putamen (DCPU). No 6 per group. All figures are means
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3.3.1.2 staining of the median raphe nucleus from the dorsal caudate-putamen
No staining with cholera-b-toxin was found.
3.3.1.3 Staining of the dorsal raphe nucleus from the anterior caudate-putamen
Although not an objective o f this experiment, I helped to supervise an Honours 
student who, as part o f her work, examined a single AS rat with cholera-b-toxin injected 
into the anterior caudate-putamen. The data from this single animal is shown in Fig. 3.4 
from which it can be seen that the number o f cells staining positively for CTb were about a 
third o f those staining for 5-HT.
5-HT cells in DRN of AS rat projects to ACPU
OCTb
Figure 3-4 5-HT-ir cells project to the ACPU (taken from L4 student whom I 
supervised).
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3.3.2 Double labelling
In the studies reported above, different sections were used for 5-HT and CTb 
immuno-staining. There remains, therefore, a remote theoretical possibility that these are 
different cell populations. To control for this, a double labelling experiment was carried 
out in which the same sections were stained for both 5-HT and CTb using fluorescent 
antibodies.
Although no counting were carried out, double labelling with 5-HT and CTb 
showed that most of the cells stained with CTb are 5-HT positive. Also it was clear that 
there are cells stained with 5-HT but not stained with CTb (Fig. 3.5) By contrast few cells 
stained with CTb that were not 5-HT positive cells.
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Figure 3.5 Coronal section of DRN stained with both 5-HT (green) and CTb (red).
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3.4 Discussion
The main purpose of this study was to confirm that the dorsal raphe nucleus projected to 
the caudate-putamen and to see whether serotonergic cells projecting from this midbrain 
raphe nucleus to different parts of the caudate putamen are uniformly distributed within the 
raphe or occupy specific areas.
Mapping can be done with many techniques; one of them is lesioning but this has the 
disadvantage of potentially affecting fibre systems passing through or close to the area of 
the lesion (Conrad et al., 1974). Some other techniques like fluorescence appear less 
sensitive for serotonin than for catecholamines (Conrad et al., 1974).
The injection of a retrograde tracer like CTb will avoid such problems and has many 
additional advantages. The technique depends upon the non-toxic part of CTb binding 
specifically to monosialoganglioside receptors on the nerve terminal surface (Stockel et al., 
1977). The binding capacity of CTb also results in a restricted injection site. Indeed, CT 
injection sites are at least twice as restricted as those of un-conjugated wheat germ 
agglutinin (WGA) with the same concentration and volume.
Many studies have shown greates sensitivity of CTb than other retrograde tracers such as 
(Peyron et al., 1998) who observed afferents to the DRN either not reported or 
underestimated in other studies used HRP or WGA-HRP (Aghajanian and Wang, 1977; 
Kalen et al., 1985). The technique can be carried out on paraformaldehyde or 
glutaraldehyde-fixed material or both.
CTb can be combined with immunohistochemistiy of many neurotransmitter substances 
(Luppi et al., 1987). In contiast, some retrograde tracers like nerve growth factor are 
confined to sensory and adrenergic neurons (Stoeckel et al., 1977).
The more complete retrograde staining obtained with CTb cannot be attributed to an 
uptake of CTb by fibers of passage as suggested by Chen and Aston-Jones (1995).
Chen et al (1999) found that CTb did not appear to effect PRV transport or infectivity, also 
the dense deposit of CTb did not appear to change over time.
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When considering rats as experimental subjects, one week after injection is long enough to 
provide a nice staining quality of the injected tracers (Lanciego et al., 2000). In the present 
study, ICC was carried out according to Peyron et ah, (1998) with some minor 
modifications.
The cholera b toxin tracing experiments produced results that confirm the known inter­
relationship between the DRN and the caudate putamen in terms of 5-HT 
neurotransmission in the rat. Both ACFU and DCPU were confirmed to receive inputs 
from the dorsal but not the median raphe nucleus. In both ACPU and DCPU, the sub­
population of serotonergic cells reached by the cholera toxin injection was between 30% 
and 50% of the total number. In the case of the DCPU, this pattern is much the same in 
both AS controls and mutant animals, although total cell numbers are reduced in the 
mutant for both 5-HT (as will be shown in details in experiment 3) and cholera toxin. This 
finding suggests that although 5-HT cell numbers in the AS/AGU dorsal raphe nucleus are 
reduced by ai’ound 22%, the integrity of the projections to the DCPU by remaining cells 
seems to be relatively intact, and that a reduction in 5-HT in the striatum is probably more 
likely to be the result of a production/release problem than due to there being a deficit in 
the DRN-DCPU connections. It should be borne in mind, however, that the remaining cells 
may have survived due to their having more robust comiections with the striatum, and that 
this does not rule out poor DRN-DCPU connectivity at an earlier stage in cells that were 
lost. It would be interesting to extend this study in future to an age range of animals in 
order to determine whether cell loss/striatal connection ratios were consistent with age.
The double fluorescent staining experiment demonstrates that all cholera-toxin positive 
neurons in the DRN are actually serotonergic, thus showing a proportional deficit between 
5-HT-positive cells and 5-HT projections to the dorsal striatum in the AS/AGU rat.
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4 Experiment 3. Cell numbers in the dorsal and median 
raphe nuclei of AS and AS/AGU rats
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4.1 Introduction
The cell bodies of most serotonergic neurons are located within the brainstem (Chojnacka- 
Wojcik, 1995; Jacobs and Azmitia, 1992; Morgan et ah, 1987). Those in the hindbrain 
project down to the spinal cord whilst another group in the midbrain projects rostrally. It is 
the group in the midbrain which was looked at in this experiment.
The area of the midbrain called the raphe nucleus can be divided into dorsal raphe and 
median raphe nuclei (DRN and MRN, respectively) and it is within these that the 
serotonergic neurons are concentrated (Azmitia and Segal, 1978; Chojnacka-Wojcik, 1995; 
Dray, 1981; Jacobs and Azmitia, 1992; Van der Kooy and Hattori, 1980), being most 
abundant in the dorsal raphe nucleus.
The cells of the dorsal and median raphe nuclei provide the vast majority of axonal 
processes containing serotonin (5-hydroxy tryptamine, 5-HT) that innervate the forebrain 
of the rat (Azmitia and Segal, 1978; Imai et ah, 1986; Jacobs and Azmitia, 1992).
However, the pattern of termination of 5-HT fibres to the forebrain differs between the 
DRN and MRN. Thus, whereas 5-HT cells within the DRN mainly innervate brain 
structures related to motor activity such as the basal ganglia, those in the MRN project 
preferentially, though not exclusively, to limbic regions such as the medial septum and 
hippocampus (Bobillier et al., 1975; Azmitia and Segal, 1978; Kohler et al., 1982; Imai et 
al,, 1986; Jacobs and Azmitia, 1992; Mcquade and Sharp, 1997).
In addition, the axons of 5-HT cells of the MRN are thicker and have larger varicosities 
compared to serotonergic cells in the DRN (Kosofsky and Molliver, 1987; Mamounas et 
al., 1991). The two nuclei also show differences in their sensitivity to neurotoxins 
(Mamounas and Molliver, 1988; Blier et al., 1990), agonists at somatodendritic 5-HT 1A 
autoreceptors (Sinton and Fallon, 1988; Hillegaart et al, 1990; Invernizzi et al, 1991; 
Casanovas et al, 1997) and in their activation as a response to aversive stimuli (Dilts and 
Boadle-Biber, 1995; Adell et a l, 1997). However, conflicting studies exist which have
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found no difference in the response to neurotoxins (Hensler et al., 1994; Gartside et al., 
1996) or the sensitivity to 5-HTlA agonists or selective 5-HT reuptake inhibitors (Hajos et 
ah, 1995).
As described in the Introduction, Parkinson’s disease was initially defined as a loss of both 
dopaminergic and serotonergic neurons, with paiticular loss of lai'ge 5-HT cells in the 
dorsal raphe found post-mortem (Jellinger, 1992). Other related syndromes (e.g. MSA, 
PSNP) show cell loss in multiple aminergic systems (Hedera and Whitehouse, 1994).
The purpose of this experiment, therefore, was to see if AS/AGU mutants had reduced 5- 
HT neurons as well as redueed DA neurons (as previously reported).
Both midbrain raphe nuclei, the dorsal raphe nucleus and median raphe nucleus were 
examined. The reasons for choosing these two nuclei is to see:
A/ whether the serotonergic system is affected at all in the AS/AGU rat and 
B/ whether the damage is general or speeific to neurons projecting to the basal ganglia.
So numbers of serotonergic cells have been counted in both nuclei in AS and AS/AGU 
rats.
The numbers of cells in particular brain regions or nuclei is a fundamental piece of 
information and cell counts have been carried out in many brain areas in many different 
species and using many different methods. Serotonergic neurons in the brain and the raphe 
nuclei in particular have been counted in rat (Dahlstrom and Fuxe, 1964; Beaudet and 
Descarries, 1976; Nygren and Olson, 1977; lorez et al., 1978; Descanies et al., 1979; 
Jacobs and Azmitia, 1992), cat (Wiklund et ah, 1981), monkey (Hatzidimitriou et ah,
1999) and in human (Agid et ah, 1987; Jellinger, 1992).
Quantitive methods for analyzing the morphology of the brain have undergone a revolution 
in the past fifteen years. The unique elements of this revolution include systematic random 
sampling, measuring three-dimensional quantities such as total neuronal number and 
volume, and using unbiased methods to estimate these tluee-dimensional quantities (Sterio, 
1984; Gundersen, 1986; Swaab and Uylings, 1987; Gundersen et ah, 1988; Bolender et ah,
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1991; Oorschot et al., 1991; Mayhew, 1992; Oorschot, 1994). One of these unbiased 
methods is the Cavalier! principle, which enables the determination of the total volume of 
the brain structure of interest. Another is the optical disector method, which enables the 
determination of the number of neurons in a sub-volume of the brain structure. The product 
of the total volume and the number of neurons in a sub-volume (i.e., the neuronal density, 
or the Nv) by these methods yields an unbiased estimate of the total number of neurons. 
Such total number studies permit reliable comparisons to be made between species, 
between normal and diseased human conditions, and between control and experimentally 
injured animals (Pakkenberg et al., 1991; Bjugn, 1993; Oorschot, 1994; Raadsheer et al., 
1994). Total neuronal numbers are also important for theoretical approaches such as the 
computer modeling of brain function.
Data on total neuronal numbers within the rat raphe nuclei (e.g. by Dahlstrom and Fuxe, 
1964; BeauDet and Descarries, 1976; Nygren and olson, 1977; lorez et al., 1978;
Descarries et al., 1979; Jacobs and Azmitia, 1992; Wiklund et al., 1981; Hatzidimitriou et 
al., 1999; Agid et al., 1987) as well as counts involving human control and PD subjects 
(e.g. Jellinger, 1992) have not been made using unbiased stereological methods. Therefore, 
I have analysed the DRN and MRN of AS and AS/AGU rats
A/ using conventional cell counts in an interrupted series of sections in order to compare 
findings with previous authors.
B/ using unbiased Cavalier! and optical disector methods.
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4.2 Materials and Methods
4.2.1 Animals
Six male AS and six male AS/AGU rats were used, aged 12 months.
4.2.2 Immunocytochemistry (ICC)
In order to ensure that I was counting 5-HT cells, it was necessary to identify them by 
immunocytochemistry, a technique first employed by Hsu et ah, (1981).
The rats were deeply anaesthetized with an overdose of Sodium pentobarbitone BP (Vet) 
(Rhone-Merieux, Spire Greencentre, Harlow, Essex, 60mg/lml). They were then perfused 
thi-ough the left ventricle with 100ml Ringer’s solution containing the vasodilator 
Lignocaine, followed by 500ml 4% Paraformaldehyde (2944744 BDH) in 0.1 M phosphate 
buffer. The brains were removed and post-fixed in the perfusion fixative for 3 hour's. They 
were then washed three times for 10 minutes in PBS and immersed in 7% Sucrose (10274, 
BDH) and Sodium azide (S2002, SIGMA) in PBS before storage overnight at 4 ”C.
The brains were embedded in tissue-tek (4583, Miles) frozen in liquid-nitrogen and then 
cut at 30 pm thickness on a cryostat at -20 (Leica, Jung Frigocut 2800E). Coronal 
sections were taken in a rostral to caudal direction and collected serially in bottles 
containing O.IM phosphate buffer (PB). The sections were processed for 5-HT 
immunostaining.
4.2.2.1 Immunocytochemistry on cryostat sections
The sections were rinsed in PBS and incubated initially in Goat anti-serum in 0.3 Triton X- 
100 (30632, BDH) for one hour. This is used to bind charged proteins within the tissue and
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allow enhanced penetration of primary antibody. This was followed by incubation with the 
Primary antibody, at an optimal dilution in PBS containing 0.3% Triton X-100.
The primary antibody was Rabbit anti-Serotonin (Z02597, AFFINITI) at a dilution of 
1:10,000, which reliably labels serotonergic neurons in the midbrain. Initially, different 
dilutions of antiserum were tested under the same conditions in order to determine the 
optimum antibody concentrations.
PBS was used to dilute the antibodies and for all washes. Triton X-100 increased the 
penetration of antibodies (Grube, 1980). Incubation was performed in a humidified 
chamber at room temperature overnight.
The sites of polyclonal antibody-antigen reaction were visualized by the application of 
biotinylated donkey anti-rabbit immunoglobulin (IG) (RPN 1004, AMERSHAM) at a 
dilution of 1:250 for one hour at room temperature, followed by Avidin-Biotin-Peroxidase 
complex (20pl of solution A and 20 pi of solution B in 1ml of PBS Vector ABC elite kit) 
which binds to the secondary antibody as the Avidin portion of the complex contains 4 
binding sites specific to biotin. Finally, 5-HT-immunoreactivity was visualised using 3,3- 
diaminobenzidine (DAB). This reacts with the peroxidase portion of the ABC complex to 
form a brown reaction product after 3-5 minutes. As DAB is a carcinogen, care was taken 
to ensure that this part of the experimental protocol was carried out in a fume cupboard, 
using disposable laboratory equipment.
4.2.3 Cell Counting techniques
4.2.3.1 Conventional counts
The rostral-caudal length of the DRN/MRN is approximately 3mm (Paxinos and Watson, 
1982) thus yielding c. 100 x 30 pm thick coronal section. Every fifth section was 
collected, stained and counted using a microscope with a lOx eyepiece fitted with a
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graticule. All stained cells were counted throughout the dorsal and median raphe nuclei, 
yielding a value of the average number of 5-HT-ir cells per 30pm section.
4.2.3.2 Stereology
The optical disector technique (Wreford, 1995) was used to estimate 5-HT cell numbers in 
DRN & MRN. Total raphe nuclei volumes were estimated using the Cavalieri Principle 
(Mayhew, 1992). Slides used to estimate the number of cells were also used to estimate 
raphe nuclei volume to avoid any requirement for correction factors due to tissue 
shrinkage. A computer using AutoCADlt97 software (Autodesk Inc, San Rafael, CA) and a 
digitising tablet was used to estimate the surface area of selected sections (eveiy fifteenth 
section). The total surface area of these selected sections is designated SA. The thickness of 
each section is known (h), as is the distance between the sections (d), and total Raphe 
nuclei volume (tv) can be calculated by tv = SA x h x d. The numerical density was 
estimated using an Olympus BX50 microscope fitted with a motorized stage (Prior 
Scientific Instruments, Cambridge) and Stereologer software (Systems Planning Analysis, 
Alexandria, VA).
The absolute number of cells in each nucleus was then calculated by multiplying its 
volume by the cells numerical density.
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4.3 Results
To ensure optimal cell staining, it was first necessaiy to determine the appropriate 
concentration of primary antibody required. The concentration of primary antibody that 
resulted in clearly visible serotonergic cells was 1:10,000 and this was used tliroughout the 
successive ICC experiments. At this concentration, serotonergic cells within the dorsal and 
median raphe nuclei stained positively and could easily be identified (see fig 4.1). A clear 
distinction could readily be seen between the cells in the median raphe nucleus and those 
contained in the larger, dorsal raphe nucleus. Cells clusters were carefully examined at 
high magnification with repeated re-foucusing until the number of cells forming the eluster 
could be determined.
There was no difference in raphe nucleus size between two group of animals (AS and 
AS/AGU), nor any obvious difference in cell size or shape.
There appeared to be slight regional differences in cell morphology in the two raphe 
nuclei. Cells of the DRN were more densely stained, tended to have a triangular shape and 
their dendritic processes were highly visible (fig 4.2). In eontrast, cell bodies contained in 
the MRN were rounder, smaller and paler and the neuronal projections were less visible. 
Nevertheless, all serotonergic cells could be easily counted in both regions.
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Figure 4-1 Coronal section of the midbrain showing both dorsal (top) and median 
(bottom) raphe nuclei. This section is approximately -7.8mm relative to bregma. 
Magnification (x25)
Figure 4-2 Higher magnification of fig 4.1 shows the dorsal raphe nucleus after 
serotonin immunohistochemistry. (x65)
: V.
Figure 4-3 Higher magnification of fig 4.1 shows the median raphe nucleus after 
serotonin immunohistochemistry. (x65)
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4.3.1 Conventional Cell counts
The number of serotonergic cell bodies within the DRN and MRN of AS and AS/AGU rats 
can be seen in fig 4.4 and fig 4.5 respectively. A student t-test for independent samples was 
performed, using the Minitab statistics package. The results are summarized in table 4.1 
and shown pictorially in fig. 4.4. The data show a significant difference between the AS 
(control) and AS/AGU (mutant) rats, with mutants possessing c. 23% fewer 5-HT-ir cells 
in the dorsal raphe than controls (p<0.001).
By contrast, table 4.2 and fig. 4.5 show that there was no significant difference between 
AS and AS/AGU rats in the numbers of serotonergic cells in the median raphe.
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5-HT-ir cell numbers in DRN (conventional count)
as/agu
Figure 4.4 The average number of 5-HT immunoreactive cells per 30pm section in the 
dorsal raphe nucleus of control (AS) and mutant (AS/AGU) male rats aged 12 months 
(n = 6 per group). Counting was made by conventional means.
Animal AS AS/AGU
1 98 82
2 97.7 77.7
3 98.7 75.4
4 100 74
5 99.7 76
6 102 71
Average 99.35 76.02
SEM 0.65 1.50
t=  14.22 d f= 1 0  P< 0.001
Table 4.1 The average number o f 5-HT immunoreactive cells per 30pm section in the 
dorsal raphe nucleus o f control (AS) and mutant (AS/AGU) rats.
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5-HT-ir cell num bers In 
MRN(conventlonal counts)
IAS
I AS/AGU
Fig 4.5 the average number o f 5-HT-immunoreactive cells per 30pm section in the median 
raphe nucleus o f control (AS) and mutant (AS/AGU) male rats aged 12 months (n= 6 per 
group). Counting was made by conventional means
Animal AS AS/AGU
1 30 25
2 22 19.82
3 23 28.78
4 25 32
5 26 25
6 25 24
Average 25 25.9
SEM 1.23 1.9
T = 0.33 P> 0.75 DF= 8
Table 4.2. The average number o f 5-HT immunoreactive cells per 30pm section in the 
median raphe nucleus o f control (AS) and mutant (AS/AGU) rats.
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4.3.2 Cell count (using computerised stereology)
4.3.2.1 Estimation of the total volume of each raphe nucleus (Tv):
This was calculated according to the Cavalieri principle by multiplying three factors;
1- Surface area of selected sections (Sa)
2- The thickness of each section (H)
3- The distance between sections (D).
The surface area was measured by a computer with Auto CADlt97 software and digitising 
tablet.
So the total volume (Tv) of each raphe nucleus is calculated as:
Tv= Sa X H X D
4.3.2.2 Estimation of the numerical density (Nv) of 5-HT-ir cells:
Pilot studies were performed to determine appropriate measurement factors, which will 
reduce a coefficient of error (CE) to less than 0.10 (Gundersen and Jensen, 1987). Then the 
full study of calculating the Nv was achieved automatically using an Olympus BX50 
microscope fitted with a motorized stage and stereologer software.
4.3 2.3 Total neuronal number in dorsal and median raphe nuclei (Tn):
The absolute number of cells in each nucleus was calculated by multiplying the cell density 
by the volume Tn = Nv x Tv
The total number of serotonergic cells in the dorsal raphe nucleus of the two groups is 
shown in Table 4.3.
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Animal AS AS/AGU
1 8562 7196
2 8312 6850
3 8697 6611
4 8854 6484
5 9062 6991
6 8780 6749
Average 8711 6813
SEM 114.9 115.4
t=  12.77 d f= 1 0  P<0.001
Table 4.3. The total number o f 5-HT immunoreactive cells in the dorsal raphe nucleus of 
control (AS) and mutant (AS/AGU) rats, as measured by computerised stereological 
methods.
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Fig. 4.6. The total numbers o f 5-HT-immunoreactive cells per dorsal raphe nucleus in AS 
and AS/AGU male rats aged 12 months (n = 6 per group).
Counts were obtained by computerised stereological means.
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From table 4.3 and fig. 4.6, it is apparent that there is a very significant difference in the 
number of 5-HT-ir cells in the dorsal raphe nucleus of AS (control) and AS/AGU (mutant) 
rats. Mutants possess 22% fewer serotonergic cells than controls.
By contrast, we can see from table 4.4 and fig. 4.7 that there are no differences between 
AS (control) and AS/AGU (mutant) rats with respect to the numbers of 5-HT-ir cells in the 
median raphe nucleus.
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Animal AS AS/AGU
1 1022 1215
2 998 1017
3 1076 1002
4 1086 1042
5 1221 1053
6 985 1111
Average 1064 1073
SEM 38.8 35.3
t = 0.18 d f = 1 0  P<0.86
Table 4.4. The total number o f 5-HT immunoreactive cells in the median raphe nucleus of AS 
(control) and AS/AGU (mutant) rats as measured by computerised stereological methods.
5-HT-ir cell numbers in 
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Fig 4.7. The total number of 5-HT-immunoreactive cells per median raphe nucleus in control (AS) and 
mutant (AS/AGU) male rats aged 12 months (n = 6 per group).
Counts were obtained by computerised stereological means.
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4.4 Discussion
Two points require initial discussion. Firstly, are total cell numbers comparable to those 
found in previous studies and, secondly, are there differences in cell nimibers between 
control and mutant animals?
Cell numbers in the midbrain have been counted using conventional methods in different 
species. Descarries et al. (1979) reported that the total population of serotonergic cells in 
the DRN of adult rat was 11,428. In cat DRN the number was estimated to be 24,257 
(Wiklund et al., 1981). More recent work has indicated that there are 11,500 serotonergic 
neurons in the DRN of adult rat while there are 1100 serotonergic neurons in the MRN 
(Barry and Azmitia, 1992). Cell numbers in primates may be more equal in the two nuclei. 
Thus, 5-HT-ir cell counts in the DRN and MRN of squirrel monkeys showed that the 
numbers were 8,269 and 7,034 respectively (Hatzidimitriou et al., 1999).
In the present study the total numbers of serotonergic neurons were analysed using 
unbiased computerised sterological software and Cavalieri principle (Wreford, 1995; 
Mayhew, 1992 respectively). The data obtained by unbiased methods in the present study 
showed that serotonergic neuron numbers were 8,711 for the DRN and 1064 for the MRN 
of AS animals. These numbers are slightly lower than those reported with conventional 
methods (Descarries et al., 1979; Barry and Azmitia, 1992) but this may be accounted for 
by age and strain difference as well as the different methodology employed.
To answer the second question, this study shows that there are fewer 5-HT-ir cells in the 
DRN of the mutant rat compared to the AS control rats. The reduction is approximately 
23% when the total numbers were obtained using unbiased methods and 22% when 
counted by more conventional means. By contrast with the DRN, counts of the MRN 
serotonergic cells showed no difference between strains when measured either by 
conventional counts or by unbiased methods.
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The extent of 5-HT cell loss in the mutant rat is less than found previously for DAergic 
cells (C. 40%) in 1 year old animals (Payne and Clarke, 1994; Payne et ah, 2000), but is 
consistent with a general depletion of aminergic cells.
The reduction of 5-HT cells in DRN along with 40% loss in DA ergic cells in the mutant 
rat strongly suggests that the AS/AGU rat is a valuable model for studying 
neurodegenerative processes. Cell reductions of this magnitude have been reported in 
many human conditions related to movement disorders.
The change in cell numbers is likely to affect the target regions to which these cells 
project. The DRN is the principal source of striatal and cortical serotonin (Srebro and 
Lorens, 1975) and axons from the DRN project mainly to the caudate-putamen, amygdala 
and substantia nigra pars compacta (Azmitia and Segal, 1978; Imai et ah, 1986). There ar e 
also projections to the thalamus (Azmitia and Segal, 1978) and to the locus coeruleus 
(Imai et ah, 1986). In contrast, the MRN was found to send projections mainly to the 
hippocampus and the anterior hypothalamus (Azmitia and Segal, 1978; Van der Kar* and 
Lorens, 1979), and also the mammillary body (Bobiller et ah, 1979). Additionally, there 
was no evidence of axonal projection from the MRN to the striatum or amygdala (Bobiller 
et ah, 1979) or the substantia nigra (Imai et ah, 1986). Moreover, lesions of the DRN were 
found to cause much greater decreases of serotonin in the striatum than lesions of the MRN 
(Jacobs et ah, 1974; Van der Kar and Lorens, 1979).
The reduction in cell numbers in the mutant DRN leads to hypothesis that this will affect 
levels of 5-HT in the DRN and the striatum. To test this, I carried out the next experiment 
where levels of 5-HT were measured with HPLC-ECD using a micropunch extraction.
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5 Experiment 4. Levels of serotonin, dopamine and 
their metabolites in post mortem micropunch samples 
of the striatum and raphe nuclei of AS and AS/AGU
rats.
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5.1 Introduction
Movement disorders associated with the basal ganglia often involve dysftmction of 
multiple transmitter systems due to neuronal loss together with a reduced synthetic 
capacity in the remaining neurons. For example, PD is classically associated with 
degeneration of the dopaminergic nigrostriatal system and it is widely accepted that 
dopamine deficiency in this pathway plays a key role in the genesis of motor dysfunction 
(Jellinger, 1987). However, it is also clear that several other systems are involved, 
especially in the later stages of the disease (Jellinger, 1987). In patients with PD, 
noradrenaline concentration has been found to be depleted in the locus coeruleus (Mann et 
al, 1983; Agid et al., 1987) and in the limbic system (Agid et al., 1987). There is also 
cholinergic (Ach) depletion in the nucleus basalis of Meynert, pedunculopontine nucleus 
and Edinger-Westphal nucleus (Nakano and Hirano, 1983 Agid et al., 1987). Reductions in 
serotonin concentration have been reported in the substantia nigra, hippocampus and other 
known serotonin-rich regions of Parkinsonian brains (Agid, 1987; Rinne et a l, 1974; 
Scatton et a l, 1983). In addition to the 5-HT reduction, decreased 5-HIAA levels have 
been reported in the cerebrospinal fluid (CSF) of PD patients (Tohgi et al, 1993). Other 
neurodegenerative disorders related to Parkinson’s disease, such as supranuclear palsy and 
multiple system atrophy are also characterised by cell loss in a number of amine systems 
(Hedera and Wliitehouse, 1994).
Previous studies on the AS/AGU rat using HPLC-ECD have shown a decrease of 30-40% 
in the concentration of dopamine in the dorsal and lateral corpus striatum (Campbell et al, 
1995, 1997). The first part of this experiment was therefore undertaken to see if serotonin 
was depleted in the AS/AGU rat in the same way as dopamine, and to confiriu the latter. 
The second part of this experiment was undertaken to determine how the two strains 
responded to the administration of precinsors of serotonin and dopamine, either alone or in 
combination.
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In principle there are at least three possible ways to increase DA:
1- administration of DA e.g. by transplanting embryonic dopaminergic cells,
2- inhibition of enzymes responsible for DA breakdown,
3- increase of local synthesis through administration of the immediate DA precursor 
L-dopa (see fig 5.1)
L-Tyrosine
^  Tyrosine hydroxylase
3,4-Dihydroxyphenylalanine (DOPA)
DOPA decarboxylase 
3,4-Dihydroxyphenylethylamine (Dopamine)
I
Figure 5-1 Enzymatic pathway of dopamine synthesis.
Even a single injection of L-dopa leads to a rapid increase of DA in the animal brain 
(Carlsson et al., 1958; Langelier et al., 1973; Pletcher and Gey, 1962; Poirier et al., 
1967a,b) as well as in patients with Parkinson’s disease (Davidson et al., 1971; 
Horyniewick, 1966; Rinne et al., 1972). In animals, the increase is most conspicuous 
within the neostriatum (Poirier et a l, 1967b).
5-HT can be increased by systemic administration of the 5-HT precursor 5- 
hydroxytryptophan (5-HTP), which enters the brain and is decarboxylated by L-aromatic 
amino acid decarboxylase to form 5-HT (fig 5.2). In normal physiological conditions, this 
enzyme is not saturated with its substrate, so that administration of 5-HTP leads to 
increased synthesis of 5-HT (Moir and Eccleston, 1968) and an increase in levels of 5-HT 
(Moir and Eccleston, 1968; Okada et al, 1972) and its metabolite, 5-hydroxyindoleacetic 
acid (5-HIAA) in the brain (Moir and Eccleston, 1968; Okada et al, 1972; Cespuglio et ai, 
1981).
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Tryptophan
^  Trytophan hydroxylase
5-Hydroxytrytophan (5-HTP)
L-Aromatic amino acid decarboxylase 
5 -Hydroxytryptamine (serotonin)
Figure 5-2 Enzymatic pathway of 5-hydroxy tryptamine (5-HT) synthesis.
There are many procedures for the detennination of serotonin (5-HT) and its major 
metabolite 5-HIAA in the brain, including fluorometric (Bogdanski et al., 1956; Snyder et 
al., 1965; Curzon and Green, 1970; Miller and Maickel, 1970) and radio enzymatic assays 
to measure 5-HT synthesis within discrete micropunched brain nuclei (Saavedra et al., 
1973), as well as mass fragmentographic methods (Cattabeni et al., 1972). Usually the 
indoles are assayed separately and the preparation of the samples for analysis can be 
complicated and time consuming. Moreover, the reagents for radioenzymatic and mass 
fragmentographic methods are rather expensive. Furthermore, with radioenzymic assay, 
measurement of 5-HIAA- an indictor of 5-HT neuronal activity- camiot be achieved (Neff 
and Tozer, 1968). These methods have now been superceded by high perfoimance liquid 
clu'omatography (HPLC) with electrochemical detection (BCD). Methods for the 
measurement of 5-HT and 5-HIAA were introduced by Lackovic et al., (1981), Lyness et 
al., (1980) and Mefford and Barchas (1980) in macrodissected brain regions. This method 
is very sensitive and can measure less than nanogram quantities of 5-HT and 5-HIAA in 
the same chromatogram.
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5.2 Material and methods
5.2.1 Experiment 1, The basal levels of the serotonin and dopamine (and 
metabolites) in regions of the AS and AS/AGU rat brain.
Twelve AS and twelve AS/AGU male rats were used to measure the basal levels of 
serotonin and dopamine (and metabolites). All animals were killed by decapitation, the 
brains were removed and sectioned (see 5.2.2 below).
5.2.2 Experiment 2. Effect of serotonin and dopamine manipulation.
Ninety-six one year male rats were used:
12 AS and 12 AS/AGU received 5-HTP (50mg/kg) (i.p).
12 AS and 12 AS/AGU received L-DOPA (25mg/kg) (i.p).
12 AS and 12 AS/AGU received 5-HTP (50mg/kg) and L-DOPA (25mg/kg) in 
combination, (i.p).
12 AS and 12 AS/AGU received saline (control) (i.p).
All animals were killed either 30 or 60 minutes after injection. All received i.p injection of 
peripheral decarboxylase inliibitor (Carbidopa for 5-HTP 25mg/kg and Benserazide 
2.5mg/kg) half an hour before the drug being administrated.
The rats were killed by decapitation, using a guillotine. This method was used to prevent 
any possible effect of anaesthetics on amines levels and the brains were rapidly removed 
from the skull and placed on a block of dry ice. The decapitation procedures were in 
accordance with the Home Office Guidelines and were specifically licensed under the 
Animal (Scientific Procedures) Act 1986; the Home Office project licence was 60/2167. 
These brains were then sectioned coronally (20pm) using a Reichert-Jung Frigocut 2800 
cryostat. The Paxinos and Watson (1982) stereotaxic rat brain atlas was used as guide to 
determine specific landmar ks close to the area of interest and sectioning continued until a 
cut surface was obtained corresponding to Bregma + 2.2 (fig. 5.3). A bilateral sample was
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then taken from the anterior caudate putamen (ACPU) using a 1 mm outside diameter corer, 
to a depth o f 1 mm.
Figure 5-3 A coronal section of rat brain at Bregma + 2.2 mm showing the area of 
anterior caudate-putamen (A) removed by micropunch for HPLC-ECD analysis. 
Staining by toluidine blue, (x 25)
Sectioning continued until the fornix was seen to be above the decussation o f the anterior 
commissures. This corresponded to bregma -ft.8mm in the stereotaxic rat brain atlas. From 
here, bilateral samples were taken from the dorsal, lateral and ventral caudate putamen 
(DCPU, LCPU and VCPU) (fig.5.4). Finally bilateral samples were also taken from the 
dorsal and median raphe. This corresponded to bregma (-7.3mm).
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Figure 5-4 A coronal section of rat brain at Bregma -  0.8 mm showing the areas of dorsal, lateral and ventral caudate-putamen removed by micropunch for HPLC-ECD 
analysis. Staining by toluidine blue, (x 25)
All samples were placed into clean, clearly labelled Eppendorf tubes and then immediately 
frozen in liquid nitrogen.
Dihydroxy benzylamine hydrobromide (DHBA) was the internal standard used for this 
experiment as it is not present in the brain, and does not react with the neurotransmitters 
present in the samples. It is o f known concentration and is stable, therefore it can be used 
as a reference point to measure unknown concentrations. HCL is an acid which releases 
neurotransmitters from membranes and once released it stabilises them.
DHBA was added at a known concentration (50pl: lpg/20pl) to each sample along with 
hydrochloric acid (HCL) (O.IM; lOOpl).
The contents o f the tubes were mixed with a vortex mixer for 45 seconds each. Each 
sample was then centrifuged (3000 rpm/10 minutes at 4^C), and vortexed for 45 seconds to 
further homogenise the tissue; finally the samples were re-centrifuged for 10 min at 3500 
rpm at 4"C.
The supernatants were transferred into clean Eppendorf tubes using plastic micropipettes 
and the remaining protein pellets were kept for protein estimation (Lowry, 1951).
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All samples were kept at -8 0  until analysis by High performance liquid 
chromatography (HPLC) was carried out.
5.2.3 High performance liquid chromatography (HPLC):
HPLC is a form o f chromatography with two distinct phases, which uses high pressure to 
increase the speed o f separation and analysis o f different compounds in the sample.
It is a very valuable laboratory assay due to its speed, resolution and sensitivity o f analysis. 
Many compounds can be measured using this method including proteins, 
neurotransmitters, blood products etc (Jussoffe et al., 1993). Therefore, this method o f  
analysis was chosen for detection and evaluation o f neurotransmitters found in the 
samples.
An HPLC system consists o f 5 major components (see fig.5.5)
1- Pump (Gilson model 307)
2- Solvent reservoir
3- Analytical column
4- Data acquisition unit (Computer)
5- Detector (BCD) (Gilson model 141)
Figure 5-5 An Image of HPLC-ECD system showing the major components (Pump, 
Solvent reservoir. Analytical column. Detector and Data acquisition unit (Computer).
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The mobile phase is generally an aqueous medium, which differs according to the 
chemistry of the compounds being sepai ated and analysed. The pH also has an important 
influence on the separation procedure. The pump is responsible for delivering a 
reproducible and constant flow of mobile phase against pressure up to 3000 psi.
The analytical column is made from internally polished high-grade stainless steel and can 
vary from 10-25 cm long and 3-5mm internal diameter. The packing gel can be 5 or 10 
micron diameter. The packing gel that is most commonly used is consists of silica gel onto 
which organic chains (C l8) are chemically bonded providing a non-polar surface. This is 
known as the stationary phase.
The selection of a suitable detector depends on the chemical properties of compounds to be 
analysed and likely sources of interference. For the analysis of neurotransmitters an 
Electrochemical Detection (ECD) system must be used due to the redox chemistry of these 
compounds (Knox, 1978). ECD detectors can be up to 1000 times more sensitive than UV 
detectors towards electro-active species. In ECD, an electrochemical reaction occurs at the 
surface of a working electrode when an electro-active species is present. The resulting 
current is amplified and presented to the computer. The current produced by the 
electrochemical reaction if passed through the reference electrode would alter i f  s potential. 
An auxiliary electrode (made of glassy carbon) is used whose potential is electronically 
controlled so as to maintain the desired potential difference between the working and 
reference electrodes. As no current flows through the reference electrode, it becomes a 
stable and reliable half-cell which can be used as a reference point for measurements 
(Rocklin, 1993).
The computer monitors the output of the detector and allows both a qualitative and a 
quantitative evaluation of the cln omatographic separation. In terms of qualitative analysis, 
the computer produces a pictorial accoimt of the separation procedure within the analytical 
column i.e. a chromatogram (see fig. 5.6). As can be seen, clnomatograms give an 
indication of the retention times of compounds as a reference point to calculate response
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factors, peak areas and peak concentrations. An internal standard (DHBA) at a known 
concentration is injected with each sample in order to provide a reference peak from which 
other “unknown” peaks can be calculated.
The solutions used with HPLC are shown in Appendix 2.
The sample was injected via the injector port and forced at high pressure by the pump 
(Gilson 306) and mobile phase thr ough the column (Hichrom ODS) to the detector (Gilson 
141). The neurotransmitters present in the sample were separated according to their 
polarity and size. The silica packing gel inside the column consists of non-polar Cl 8 
bonded phase. Compounds with a high degree of polarity within the sample will therefore 
pass through to the electrochemical detector (ECD) at a more rapid rate. The ECD consists 
of three electrodes: a reference electrode which was set to +0.7V, the threshold required to 
initiate oxidization of the compounds, a working electrode where the redox potential of the 
compounds was measured, and an auxiliary electrode. The current produced at the surface 
of the working electrode was recorded by the data acquisition unit and displayed in the 
form of a peak. The computer stores information on peak concentration and retention time 
(time from injection to detection) in the form of a chromatogram.
Before analyzing the samples, 20 pi of composite standard was injected. This contains not 
only compounds which may be present in the sample tissue, but also the internal standard. 
From the composite standard chromatogram, the retention times and response factors of 
the compounds present were recorded and used for the calculation of neurotransmitter 
levels in the AS/AGU and control brain samples.
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Typical composite standard and sample chromatograms are shown in Figures 5.6a and b).
a)
I/ \
10
Time (minutes)
b)
1 0 0 0 -
0 -
10
Tune (minutes
Figure 5,6 Typical HPLC chromatograms from a) Composite standard, and b) 
sample. Peaks in order of elution are DHBA (internal standard), Dopamine, DOPAC, 
5-HIAA, 5-HT.
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5.2.4 Protein Estimation
Because the micropunch samples are very small, weight is a relatively unreliable variable 
and it has become customary to quantify transmitters and their metabolites according to the 
protein content of the sample. The Lowry assay (Lowry, 1951) was used for protein 
estimation. It is used to estimate the amount of protein present in a sample when the 
sample is too small to be weighed. It is based on the absorbance of a dye, Coomassie Blue, 
in the ultraviolet region of the spectrum at 595nm.
A standard protein Bovine Serum Albumin (BSA) was made up in distilled water. The 
concentrations used ranged from 10 to 200 pg. Coomassie Blue (0.9ml) was added to each 
solution, mixed and the absorbance recorded at 595mn. A standard curve was obtained 
using these values.
To each protein pellet 210pl of O.IM NaOH was added, the mixture vortexed for 45 
seconds and left overnight. The samples were stored at 4 °C.
Into a 2ml plastic cuvette, 1ml distilled water, 0.9ml of Coomassie Blue and 0.1ml of 
protein were added.
The contents were mixed up and the absorbance at 595mii was recorded using a 
spectrophotometer (LKB Biochrom Ultrospec 4050) to obtain the absorbance value. This 
was repeated twice to establish consistency between samples.
Using the equation of a straight line, y = mx + c, the unknown concentration of the protein 
was obtained from the standard curve by inserting the absorbance value of the protein (y) 
into the equation. The final concentration of each sample was in pg of protein.
All samples were injected freshly as 5-HT and 5-HIAA are said to be degraded quicker 
than other neurotransmitters.
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Each sample was injected twice. A composite standard was injected after every six 
“unknown” samples. Results were analysed and quantified using the following equations;
Area of unknown x Response factor 
Peak Concentration = ________ ______ _______________
Area of Standard
Peak Concentration x 60 (dilution factor)
Concentration of neurotransmitter =    .
(ng/wet weight) Tissue Weight (g)
5.2.5 Statistical Analysis
In Chapters 5 and 7, it has been necessary to carry out two-way analyses of variance 
where the numerical data can be assorted by variables such as strain (AS v. AS/AGU) and 
also treatment (control v. treatment Iv. treatment 2 ...etc). It was decided that the same 
tests should be used throughout the thesis to give consistency. However, some experiments 
used equal-sized groups whereas other experiments used gi'oups of different sizes. Written 
advice from Minitab Inc (State College, Pennsylvania, USA) suggested the use of the 
General Linear Model which allows both balanced and unbalanced designs. This procedure 
allows the initial identification of significant variance due to strain (but ignoring treatment) 
and treatment (but ignoring strain). It was therefore necessary to carry out a subsequent, 
second stage of analysis in which each individual group could be compared with each other 
using a one-way analysis of vaiiance (ANOVA). Tukey's test (set at 95%) was used as a 
post hoc test to generate Confidence Intervals for individual inter-gioup comparisons.
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5.3 Results
5.3.1 Comparison of serotonin and dopamine (and metabolites) levels in 
regions of the AS and AS/AGU rat brain
5.3.1.1 Serotonin (5-HT) levels.
These are generally lower in all parts of the caudate putamen in mutant AS/AGU rats 
compared to the parent AS strain. The differences are statistically significant in the dorsal 
(t = 6.69, df = 22, p < 0.001) and ventral (t =2.18, df = 22, p < 0.05) caudate-putamen, and 
approach significance in the lateral caudate-putamen (t = 2.03, df = 22, p < 0.06). 
Serotonin levels are much higher in the dorsal and median raphe nuclei than in the 
striatum. In the dorsal raphe, 5-HT levels are significantly higher in AS controls than in 
mutants (t = 16.95, df = 22, p < 0.001), but there are no strain differences in serotonin in 
the median raphe nucleus, (see Table 5.1)
5.3.1.2 5-hydroxyindole acetic acid (5-HIAA) levels.
By contrast with serotonin, levels of its metabolite 5-HIAA are not reduced in mutant rats 
within the caudate-putamen. Indeed, in one region, the dorsal caudate-putamen, levels are 
significantly higher (t = 8.25, df = 22, p< 0.001). Levels of 5-HIAA aie substantially 
higher in the dorsal and median raphe nuclei than in the striatum. In the dorsal raphe 
nucleus, 5-HIAA levels are significantly higher in the AS/AGU mutant than in the AS 
control (t = 11.71, df = 22, p< 0.001), but there are no strain differences in 5-HIAA levels 
in the median raphe nucleus, (see Table 5.1)
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5.3.1.3 Dopamine (DA) levels.
Previous studies (Campbell et al 1997) have shown lower DA levels in the AS/AGU 
mutant compared to the parent AS control in several regions of the caudate-putamen. 
These differences are confirmed in the present study. Thus, AS controls had higher levels 
of DA than mutants in the dorsal caudate-putamen (t = 17.88, df = 22, p < 0.001) and the 
lateral caudate-putamen (t = 11.22, df = 22, p < 0.001). There were no strain differences in 
the anterior or ventral caudate-putamen. Dopamine levels were non-detectable in the 
region of the dorsal and median raphe nuclei, (see Table 5.1)
5.3.1.4 Dihydroxyphenylacetic acid (DOPAC) levels.
By contrast with dopamine, levels of its metabolite DOPAC are generally not lower in the 
AS/AGU mutant compaied to the AS control. Indeed, levels of DOPAC were significantly 
higher in the mutant in the dorsal caudate-putamen (t = 6.48, df = 22, p < 0.001), lateral 
caudate-putamen (t = 5.20, df = 22, p < 0.001) and ventral caudate-putamen (t = 5.03, df = 
22, p < 0.001). Like dopamine itself, DOPAC levels were undetectable in the regions of 
the dorsal and median raphe nuclei, (see Table 5.1)
96
Brain
Region
5-HT 5-HIAA DA DOPAC
AS AS/AGU AS AS/AGU AS AS/AGU AS AS/AGU
ACPU 5.03
±0.45
4.86 
± 0.16
3.03
±0.17
3.01
±0.19
22.8
±0.4
23
±0.6
3.7
±0.32
2.9
±0.29
t 0.35 ns 0.06 ns -.25 ns 1.86 ns
DCPU 4.18
±0.11
2.67
±0.20
2.71
±0.13
4.18
±0.12
12.6
±0.3
7.3
±0.16
2.64
±0.14
3.8
±0.1
t 6.69, p <  0.001 -8.25 P<0.001 17.9 P<0.01 -6.5 P<0.01
LCPU 5.13
±0.37
3.77
±0.56
2.92
±0.23
3.13
±0.17
24.7
±0.4
19.1
±0.36
2.3
±0.1
2.93
±0.1
t 2.03 P<0.057 -0.73 ns 11.2 P<0.01 -5.2 P<0.01
VCPU 4.75
±0.41
3.62
±0.32
3.56
±0.25
3.45
±0.26
22.1
±0.7
21
±0.74
2.2
±0.1
4
±0.4
t 2.18 P<0.041 0.3 ns 1.2 ns -5.03 P<0.01
DRN 31.25
±0.46
22.17
±0.27
23
±0.43
30
±0.47
nd nd nd nd
t 16.95 P<0.001 -11.7 P<0.01
MRN 12
±0.49
12.3
±0.57
18.75 
± 0.65
17.75
±0.45
nd nd nd nd
t -0.33 ns 1.26 ns
Table 5.1. Levels of serotonin (5-HT), 5-hydroxyindoIe acetic acid (5-HlAA), dopamine (DA) and 
dihydroxyphenylacetic acid (DOPAC) in the anterior (ACPU), dorsal (DCPU), lateral (LCPU) and 
ventral (VCPU) caudate-putamen, dorsal (DRN) and median (MRN) raphe nuclei of the Albino Swiss 
(AS) rat and the AS/AGU mutant. All values are mean ng/wet weight ± SEM. nd = non-detectable For 
definitions and co-ordinates of the brain regions, see Material and Methods. All comparisons are 2- 
tailed t-tests.
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5.3.2 Comparison of the affect of the drugs on serotonin and dopamine 
(and metabolites) levels in regions of the AS and AS/AGU rat brain
Between pages 97-145 There are a numbers of pages showing analysis of variance for 
transmitters or metabolites for seneral brain regions. Groups are identified in tables by 
numbers, as identified below.
Key
i) for group analysis, 1 = AS control 2 = AS/AGU mutant
ii) for treatment (treat A)
1 = saline 30 mins, 2 = saline 60 mins.
3 = 5-HTP 30 mins, 4 = 5-HTP 60 mins.
5 = L-dopa 30 mins 6 = L-dopa 60 mins.
7 = both 30 mins 8 = both 60 mins. 
iv) for group x treatment (treatb)
11= AS, saline 30 mins, 12 = AS/AGU, saline 30 mins.
21 = AS, saline 60 mins, 22 = AS/AGU, saline 60 mins 
31 = AS, 5-HTP 30 mins, 32 = AS/AGU, 5-HTP 30 mins.
41 = AS, 5-HTP 60 mins, 42 = AS/AGU, 5-HTP 60 mins 
51 = AS, L-dopa 30 mins 52 = AS/AGU, L-dopa 30 mins.
61 = AS, L-dopa 60 mins 62 = AS/AGU, L-dopa 60 mins.
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71 = AS both 30 mins 72 = AS/AGU both 30 mins.
81 = AS both 60 mins 82 = AS/AGU both 60 mins.
5.3.2.1 Serotonin (5-HT)
1) Anterior caudate-putamen A two-way analysis of variance (ANOVA) showed no 
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 92.7, df = 7, p < 0.001) (see p 99). Serotonin levels were significantly elevated in 5- 
HTP-treated animals compared with saline-treated ones at both 30 and 60 minutes after 
treatment. Unexpectedly, treating rats with L-DOPA significantly reduced 5-HT below 
saline control levels, both at 30 and 60 minutes (p < 0.05). The inhibitory effect of L- 
DOPA continued when both L-DOPA and 5-HTP were given together as a combined 
treatment. Thus, thirty minutes after treatment, 5-HT levels remained significantly 
below saline-treated controls (p < 0.05) although levels had become comparable to 
controls by one hour after injection. Even though the analysis had shown no effect of 
group on variance, the ANOVA was extended to compare the response of AS and 
AS/AGU rats to these treatments; this confirmed that there were no significant 
differences between the two groups (p 99).
Two-way ANOVA: acp5-HT versus group, treata
99
Analysis of Variance for acp5-HT
Source DF SS MS F P
group 1 0.060 0.060 0.08 0.779
treata 7 492.796 70.399 92.70 0. 001
Interaction 7 9.977 1.425 1.88 0.084
Error 80 160.757 0.759
Total 95 563.590
Individual 95% Cl
group Mean ------ +-----------+---------- +■---------------+ ------------
1 5.15 (------------------*------------------------)
2 5.20 (-------------------*----
4.95 5.10 5.25 
Individual 95% Cl
-------------------- )
5.40
treata Mean ---------1------------H —
1 4.88 ( -* —  )
2 5.00
3 8.46 ( _*--)
4 9 . 2 3 ( - *--)
5 3.17
6 2 . 5 1  ^ ^
7 3. 77 ( — * ~ )
8 4 . 38
4.00 6 . 0 0 00 1 0 . 0 0
One-way ANOVA: acp5-HT versus treatb
Analysis of Variance for acp5-HT
Source DF SS MS F P
treatb
Error
Total
15
80
95
502.833
60.757
563.590
3 3 . 5 2 2
0.759
44.14 < 0.001
Individual 95% CIs For 
Based on Pooled StDev
Mean
Level N Mean StDev ------ 1------- ---- 1--------
11 6 4 . 950 1.793 Ç —  *—  j
12 6 4.817 0.449  ^— — Vr — )
21 6 5. 100 1.435 (_*__)
22 6 4 . 900 0. 681 (— *-)
31 6 8 . 950 1. 009 ( — * —  )
32 6 7 . 967 0.635 ( — — :*r ^ J
41 6 9. 600 1.115 {-*-*-)
42 6 8 . 8 5 0 0 . 2 8 8 (-*--)
51 6 2 . 8 6 7 0. 656 (_*__)
52 6 3. 467 0 .  656 (--* --)
61 6 2.000 0.303 {--* --)
62 6 3.017 0. 674 (----- j
71 6 3 . 5 3 3 0.857 ( - * - —_ J
72 6 4 . 000 0 . 4 0 0 ( — - J
81 6 4 .183 0.  662 ( -, -- — )
82 6 4 . 5 6 7 0.850 ( —- - ^ ^ )
Pooled StDev = 0.871 2.5 5.0 7.5 10.0
1 0 0
2) Dorsal caudatc-putameii A two-way analysis of variance (ANOVA) showed a highly 
significant effect of group (AS v AS/AGU F = 276, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 267, df = 7, p < 0.001) (see p 101). Serotonin levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). As found in the anterior 
caudate-putamen, treating rats with L-DOPA significantly reduced 5-HT below saline 
control levels, both at 30 and 60 minutes (p < 0.05). The inhibitory effect of L-DOPA 
continued when both L-DOPA and 5-HTP were given together as a combined 
treatment, although rats given the combined treatment had levels of 5-HT which were 
just comparable to controls at both thirty minutes and one hour after injection. When 
the analysis was extended to compare AS and AS/AGU rats (p 101) it is clear that AS 
rats have higher levels of 5-HT than AS/AGU mutants a) when both groups received 
saline, b) when both groups received 5-HTP and c) when both groups received a 
combination of L-DOPA and 5-HTP. When both groups received L-DOPA alone, 5- 
HT levels were extremely low and no differences were found between mutant and 
control strains.
Two-way ANOVA: dcp5-HT versus group, treata
1 0 1
Analysis of Variance for clcp5-HT
Source DF SS MS F P
group 1 53.551 53.551 276.36 0.001
treata 7 362.633 51.805 267.35 0 . 0 0 1
Interaction 7 22.092 3.156 16.29 0. 001
Error 80 15.502 0.194
Total 95 453.777
Individual 95% Cl
group Mean — 4— - ------- h----------- +—
1 4.558 (-*■
2 3.065 (-*--)
----- --------- --------j-----
3.000 3.500 4.000 
Individual 95% Cl
4.500
treata --------------------f.„_.
1 3.09 {-*)
2 3.75 (-*-)
3 6.47 ( -
4 7.48
5 2.12 (-*-)
6 1.69 { * - )
7 2.56 (-*-)
8 3.33 (*-)
----1------------------ --------------j------- ------ --------------- --{--- ------ — “ --------------j-------
1.50 3.00 4.50 6. 00 7.50
One-way ANOVA: dcpS-HT versus treatb
Analysis of Variance for dcp5-HT
Source DF S3 MS F P
treatb 15 438.276 29.218 150.79 < 0.001
Error 80 15.502 0.194
Total 95 453.777
Individual 95% CIs For Mean
Based on Pooled StDev
Level N Mean StDev ------ - --1------------1------------1------
11 6 4.0333 0 . 2 7 3 3 (*-)
12 6 2.1500 0.3391 (-*}21 6 4.3167 0.4167 (*-)
22 6 3.1833 0.5382 (-*)
31 6 7.9500 0.2881 {_+)
32 6 4 . 9 8 3 3 0.5845 (*)
41 6 8.9667 0.4590
42 6 6.0000 0.7127 (U51 6 2.4667 0.3882 (-*)
52 6 1.7667 0.2733 (*)
61 6 1.8000 0.3286 (*-)62 6 1.5833 0 . 3 1 8 9 (*-)
71 6 2.9833 0.3488 (*)
72 6 2.1333 0 . 1 6 3 3 (-*)
81 6 3.9500 0.7092 (-*)
82 6 2.7167 0 . 4 6 6 5 (-*)
Pooled StDev = 0.4402 2.5 5.0 7.5
{ - * )
1 0 . 0
1 0 2
3) Lateral caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
highly significant effect of group (AS v AS/AGU F = 19.09, df = 1, p < 0.001) as well 
as a very significant effect of treatment (F = 31.6, df = 7, p < 0.001) (see p 103). 
Serotonin levels were significantly elevated in 5-HTP-treated animals compared with 
saline-treated ones at both 30 and 60 minutes after treatment (p < 0.05). As found in 
both the anterior and dorsal caudate-putamen (see above), treating rats with L-DOPA 
significantly reduced 5-HT below saline control levels, both at 30 and 60 minutes (p < 
0.05). The inhibitory effect of L-DOPA was barely counteracted by 5-HTP when both 
were given together as a combined treatment; rats given the combined treatment had 
levels of 5-HT which were just comparable to controls at both thirty minutes and one 
hour after injection. When the analysis was extended to compare AS and AS/AGU rats 
(p 103) it is clear that AS rats have higher levels of 5-HT than AS/AGU mutants only 
when both groups received saline. When animals received 5-HTP, L-DOPA or a 
combination of the two, strain differences were not significant.
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Two-way ANOVA: Icp5-HT versus group, treata
Analysis of Variance for Icp5-HT
Source DF SS MS F P
group 1 24.81 24.81 19.09 0.001
treata 7 287.37 41.05 31. 60 0. 001
Interaction 7 3. 97 0.57 0.44 0 . 8 7 6
Error 80 1 0 3 . 9 3 1.30
Total 95 420.09
group
1
2
Mean
5.00
3.98
Individual 95% Cl
(  *  )
4.00 4.40 4.80 5.20
treata
1
2
3
4
5
6 
7
Mean 
4.22 
4. 67 
78 
49 
74 
08 
68 
22
Individual 95% Cl
1.60 3.20 4.80
( -------
6.40
One-way ANOVA: Icp5-HT versus treatb
Analysis of Variance for Icp5-HT
Source DF SS MS F P
treatb 15 316.15 21.08 16,22 < 0.001
Error
Total
80
95
103.93 
420.09
1. 30
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev ------------ j------------1------------1-----------
11 6 5.100 1.565 ( —  *---)
12 6 3.333 1.846
21 6 5.150 1. 089 -^-— ^ ^
22 6 4 .200 2 . 081
31 6 7.367 1. 164 ( — *---)
32 6 6.200 0. 660 (--- * --- )
41 6 8 . 050 0.742 (---*--- )
42 6 6. 933 0. 864 (---* —  )
51 6 3.033 0. 423
52 6 2.450 0.782
61 6 2.317 0.454  ^—  *---J
62 6 1.850 0.  675 ( —  *---)
71 6 4 . 033 0.855
72 6 3 . 3 3 3 1.846 Ç — — -— ^
81 6 4 . 917 0.736  ^— )
82 6 3.533 0.441
Pooled StDev = 1.140 2.5 5.0 7.5
1 0 4
4) Ventral caudate-putamen. A two-way analysis of variance (ANOVA) showed no 
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 56.98, df = 7, p < 0.001) (see p 105). Serotonin levels were significantly elevated in
5-HTP-treated animals compared with saline-treated ones at both 30 and 60 minutes 
after treatment. As with all the other regions of the striatum examined (see above), 
treating rats with L-DOPA significantly reduced 5-HT below saline control levels, both 
at 30 and 60 minutes (p < 0.05). A combined treatment of L-DOPA plus 5-HTP 
resulted in 5-HT levels which were comparable to saline-treated controls. Even though 
the analysis had shown no effect of group on variance, the ANOVA was extended to 
compar e the response of AS and AS/AGU rats to these treatments; this demonstrated 
only one significant difference, that mutants treated with saline for 60 minutes had 
lower levels of 5-HT than controls (p 105).
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Two-way ANOVA: vcp5-HT versus group, treata
Analysis of Variance for vcp5-HT
Source
group
treataInteraction
Error
Total
group
1
2
treata
1
2
3
4
5
6 
7
DF
1
7
7
80
95
SS 
0.570 
2 2 3 . 5 9 3  
2 9 . 1 3 5  
44.847 
298.145
Mean 
4 .34 
4 .19
Mean
3 . 8 9
4 .47
66 
58 
72 
27 
,27 
, 22
MS 
0.570 
31.942 
4.162 
0. 561
F
1 . 0 2  
56. 98 
7 .42
P
0.316
0 . 0 0 1
0 . 0 0 1
Individual 95% Cl
^  ( * )
4.05 4.20 4.35 4.50
Individual 95% Cl
( —  * —  )
( - *  —  )
( —  *— )
( —  * —  ) (— * - - )
( —  *--)
3.00 4 .50 6 . 0 0 7 . 50
One-way ANOVA; vcp5-HT v ersus treatb
Analysis
Source
treatb
Error
Total
Level
11
12
21
22
31
32
41
42
51
52 
61 
62
71
72 
81 
82
Pooled
of Variance for vcp5-HT
DF SS MS
15 253.298 16.887
80 44.847 0.561
95 298.145
N Mean StDev
6 3.7333 1 . 2 6 6 0
6 4.0500 1.3442
6 5.7667 0.6501
6 3.1833 0.6047
6 6.1167 0.4956
6 7.2000 1.2050
6 7.0667 0.6055
6 6 . 1 0 0 0 0.6229
6 2.4833 0 . 2 2 2 9
6 2.9667 0.8017
6 2.0167 0.2483
6 2.5167 0.4916
6 3.0333 0.3933
6 3.5167 0.6735
6 4.5000 0.6066
5 3.9500 0.5891
StDev = 0.7487
F
30.12
P
0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev
— + ----------------------H--------------------- + -  —
( —  * —  )( — *-- )
( ■
( ■ ■)
■ —  )
—  )
( —  * - ■
 ^ — —
 )
( —  * - -  )
( —  * —  )
(  —  *  —  ) 
( — *  
(  —  — ^  ^ 
---------------------------------------- t - -------------
2.0 4.0
 +  -
6 . 0
 + .
8 . 0
1 0 6
5) T>nr«al ranhe nucleus. A two-way analysis of variance (ANOVA) showed a highly 
significant effect of group (AS v AS/AGU F = 384, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 202. df = 7. p < 0.001) (see p 107). Serotonin levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). As found in the striatum 
(above), treating rats with L-DOPA significantly reduced 5-HT below saline control 
levels, both at 30 and 60 minutes (p < 0.05). The inhibitory effect of L-DOPA was only 
marginally counteracted by 5-HTP when both were given in combination, and rats 
given the combined treatment had levels of 5-HT which were still substantially and 
significantly lower than saline-treated controls at both thirty minutes and one hour after 
injection. When the analysis was extended to compare AS and AS/AGU rats (p 107) it 
is clear that AS rats have higher levels of 5-HT than AS/AGU mutants a) when both 
groups received saline, b) when both groups received 5-HTP, c) when both groups 
received L-DOPA and d) sixty minutes after both groups received a combination of L-
DOPA and 5-HTP.
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Two-way ANOVA: DrnS-HT versus group, treata
Analysis of Variance for Drn5-HT
Source DF SS MS F P
group 1 1504.96 1504.96 3 8 3 . 9 5 0.001
treata 7 5545.73 792.25 2 0 2 . 1 2 0.001
Interaction 7 793.23 1 1 3 . 3 2 28 . 91 0.001
Error 80 313.57 3 . 9 2
Total 95 8157.49
group12
Mean
29.56
21.64
Individual 95% Cl
{ - * - )
2 2 . 5 0 25.00 27.50
{-* — ) 
30. GO
treata12
3
4
56 
7
Individual 95% Cl
30.07 (-*-)
30.92 (-*)
33.75 (-*-)
34.50 (*-)
15.33 (-*)
13.83 (-*-)
20.67 (*-)
25.75 (-*")
18.00 24.00 30.00 36.00
One-way ANOVA: Drn5-HT versus treatb
Analysis of Variance for Drn5-HT
Source DF SS MS F P
treatb
Error
Total
15
80
95
7843.91
313.57
8157.49
522.93 
3. 92
133.41 < 0.001
Individual 95% CIs For 
Based on Pooled StDev
Mean
Level N Mean StDev ------------ 1--------- -— 1—
11 6 37.667 1. 633 (-*)
12 6 2 2 . 4 8 3 1.040 (*-)
21 6 39.833 1.835 (-*)
22 6 22.000 0.894 (-*-)
31 6 37.667 1. 633 (-*)
32 6 2 9 . 8 3 3 1.472 (-*)
41 6 3 9 . 8 3 3 1.835 (-*)
42 6 29.167 1.472 (*-)
51 6 17.000 1.414 (-*-)
52 6 13.667 0.816 ("*)
61 6 15.667 1.211 (-*)
62 6 12.000 1.414 (-*-)
71 6 21.000 4 . 336 (-*-)
72 6 20.333 2 . 3 3 8 (*")
81 6 27.833 3 . 4 8 8 (-*)
82 6 23.667 1.366 (-*)
Pooled StDev = 1. 980 20 30 40
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6) Median raphe nucleus A two-way analysis of variance (ANOVA) showed a highly 
significant effect of group (AS v AS/AGU F = 36.3, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 159.6, df = 7, p < 0.001) (see p 109). Serotonin 
levels were significantly elevated in 5-HTP-treated animals compared with saline- 
treated ones at both 30 and 60 minutes after treatment (p < 0.05). As found m the 
striatum and dorsal raphe (above), treating rats with L-DOPA significantly reduced 5- 
HT below saline control levels, both at 30 and 60 minutes (p < 0.05). Rats given a 
combined treatment of L-DOPA plus 5-HTP had levels of 5-HT which weie 
comparable to saline-treated controls. When the analysis was extended to compare AS 
and AS/AGU rats (p 109) AS rats have lower levels of 5-HT than AS/AGU mutants 
thiity minutes after L-DOPA administiation, and also after both groups received a 
combination of L-DOPA and 5-HTP.
Two-way ANOVA: Mrn5-HT versus group, treata
1 0 9
Analysis of Variance for Mrn5-HT
Source DF SS MS F P
group 1 3 6 . 2 6  3 6 . 2 6 16.47 0 . 0 0 1
treata 7 1117.05 159.58 72.47 0.001
Interaction 7 64.16 9.17 4.16 0.001
Error 80 176,17 2.20
Total 95 1393 . 64
Individual 95% Cl
group Mean --------+--------
1 11.59 (--------- *------ — )
2 12.81 (--------*-----------------+--------
11.50 12 . 00 12 .50 13.00
Individual 95% Cl
treata Mean — +---------- +— -------- + — --------+-----------
1 12.17 (—  * _ )
2 12. 08 (—  * — )
3 15.00 ( — *-)
4 19.08
5 9.00 (--*-)
6 7.27 (— *-)
7 10.41
8 12 .58 (-*-)— +---------- +—
7.00 10.50 14.00 17 .50
One-way ANOVA: Mrn5-HT versus treatb
Analysis of Variance for Mrn5-HT
Source DF SS MS F P
treatb 15 1217.47 81.16 36.86 < 0.001
Error 80 176.17 2 . 2 0
Total 95 1393.64
Individual 95% CIs For 
Based on Pooled StDev
Level N Mean StDev
11 6 11.333 1.633 )
12 6 13.000 2.098 ("*- )
21 6 1 2 . 667 1. 633
22 6 11.500 1 . 6 4 3 (-*-)
31 6 14.167 1.169 {-* —  )
32 6 15.833 1. 602 ( —  *.
41 6 19.667 1. 633
42 6 18.500 1 . 8 7 1
51 6 7 . 8 3 3 0.753 (-” *-)
52 6 10.167 1.229 (-* — }
61 6 7 . 033 0.816 (“*-)
62 6 7 .517 0 . 5 0 8 (-*-)
71 6 8 . 4 8 3 1 . 1 2 5 (-*-)
72 6 1 2 . 3 3 3 1 . 8 6 2 ( —  *- )
81 6 11.500 1.517
82 6 13 . 667 1. 633 ---------- +---------- +—
Pooled StDev = 1 . 4 8 4 1 0 . 0  15.0
 ^ ' 
*-)
2 0 . 0
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S.3.2.2 5-Hydoxyindole acetic acid (5-HIAA)
1) Anterior caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
significant effect of group (AS v AS/AGU F= 23.24, df=l, p <0.001) and a very 
significant effect of treatment (F =33.25, df = 7, p < 0.001) (see p 111). 5-HIAA levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). Treating rats with L-DOPA 
resulted in 5-HIAA levels intermediate between saline and 5-HTP treatment (and 
significantly different fi-om each for comparable times after administration, p < 0.05). 
When L-DOPA and 5-HTP were given together as a combined treatment, levels of 5- 
HIAA were comparable to giving 5-HTP alone. Wlien the analysis was extended to 
compare AS and AS/AGU rats (p 111) AS rats had higher levels of 5-HIAA than 
AS/AGU mutants at both thirty and sixty minutes after both groups received a 
combination of L-DOPA and 5-HTP.
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Two-way ANOVA; AcpHIAA versus Treat, Group
Analysis of Variance for AcpHIAA
Source DF SS MS F P
Treat 7 133.712 19.102 33 . 2 5 0.001
Group 1 1 3 . 3 5 0 13.350 23.24 0.001
Interaction 7 3 0 . 4 6 3 4.352 7 .58 0.001
Error 80 45.953 0.574
Total 95 223.478
Treat12
3
4
56 
7
Mean
3 . 0 2
3.02 
5.44 
6.15 
4 .14 
4 .74 
5 . 3 9  
6.13
Individual 95% Cl
( — * )
3.00
(■
4 . 00 5. 00 6 . 0 0
Group12
Mean 
5.13 
4 . 38
Individual 95% Cl
( * )
4 . 2 0  4.50 4.80
 +-
5. 10
One-way ANOVA: AcpHIAA versus Treatb
Analysis of Variance for AcpHIAA
Source DF SS MS F P
Treatb 15 176 . 2 1 8 11.748 18.04 < 0.001
Error
Total
80
95
52.107
2 2 8 . 3 2 5
0.651
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev -------- 1----------- 1------------1---------
11 6 3 . 1667 0 . 7062
12 6 2 . 8667 0 . 1 9 6 6 (---*--- }
21 6 2 . 8 8 3 3 0.4446 (---*--- )
22 6 3.1500 0 . 9 5 6 6 (---*--- )
31 6 5.9500 0. 8019
32 6 4.9333 0.5574
41 6 6 . 6333 0 . 7 6 0 7 ( — *---- )
42 6 5 . 6 6 6 7 1,0328 ( — *---- )
51 6 4.0833 0 . 4 7 0 8 (---- * —
52 6 5.1333 1. 2028
61 6 4.3500 0.4231
62 6 5.1333 1 . 2028
71 6 6.5000 1.0488
72 6 4.2833 0.5947 (---*--- )
81 6 7 . 4 5 0 0 1 . 1 3 0 9 ( *
)82 6 4 . 8167 0.3817
Pooled StDev = 0 . 80 7 1 3 . 2  4.8 6.4
1 1 2
2) Dorsal caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
significant effect of group (AS v AS/AGU F - 11.72, df=l, p <0.001) and a very 
significant effect of treatment (F =49.84, df = 7, p < 0.001) (see p 113). 5-HIAA levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05) especially at the latter time. 
Treating rats with L-DOPA, or L-DOPA in combination with 5-HTP, resulted in 5- 
HIAA levels intermediate between saline and 5-HTP treatment (p < 0.05). When the 
analysis was extended to compare AS and AS/AGU rats (p 113) AS/AGU rats had 
higher levels of 5-HIAA than AS/AGU mutants when treated with a) saline b) 5-HTP 
c) L-DOPA and d) L-DOPA in combination with 5-HTP.
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Two-way ANOVA: DcpHIAA versus Treat, Group
Analysis of Variance for DcpHIAA
Source DF SS MS F P
Treat 7 129.008 18.430 49.84 0.001
Group 1 4 . 3 3 5 4 . 335 11.72 0.001
Interaction 7 34.893 4 . 985 13 . 48 0.001
Error 80 2 9 . 5 8 3 0.370
Total 95 19 7 . 8 2 0
Treat12
3
4
56 
7
Mean
3.41
48
14
Individual 95% Cl
 ^ — "A; ^
{— * — )
7.05
98
34
4910
Group12
Mean 
4 .785 
5.210
(--*")( -* — )(--*"■)
3.60 4.80 6.00
Individual 95% Cl 
( * )
7 . 2 0
(-
4.800 5.000 5.200
 +-
5.400
One-way ANOVA: DcpuHIAA versus Treatb
Analysis of Variance for DcpuHIAA
Source DF SS MS F P
Treatb
Error
Total
15
80
95
168.236
2 9 . 5 8 3
197.820
11.216
0.370
3 0 . 3 3  < 0.001
Individual 95% CIs For 
Based on Pooled StDev
Mean
Level N Mean StDev -------- 1------------j----- ------ 1-----------
11 6 2 . 6667 0.2338 -^-"A" — —. J
12 6 4.1500 0.4593 ( —  * )
21 6 2.7500 0.6473 (-*--)
22 6 4.2000 0 . 3 7 9 5  ^ ^
31 6 6.2000 0.5550  ^ ^ —h j
32 6 6 . 0 8 3 3 0 . 5 6 3 6 (--^--)
41 6 7 . 2 8 3 3 0.6014  ^ - — “At .«  ^ j ;
42 6 6.8167 0.7333  ^ ■ j
51 6 4 . 13 3 3 0.5820  ^ ^
52 6 5 . 8 1 6 7 0.7333 (~"*— ) i61 6 4.4833 0 . 76 7 9 ( —  *—  ] }
62 6 6.2000 0.4427  ^ 'A' _ — J j'
71 6 5 . 0 8 3 3 0 . 89 7 6 {—  * — ) ]72 6 3 . 90 0 0 0.4472 ( —  *—  ) I
81 6 5 . 6 8 3 3 0 . 6 9 6 9 ( — j82 6 4.5167 0 . 64 0 1 ( —  *-- ) _____ ^___________ !
Pooled StDev = 0 . 60 8 1 3 . 2  4 . 8 6.4 I
1 1 4
3) Lateral caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
significant effect of group (AS v AS/AGU F= 8.83, df=l, p <0.01) and also a very 
significant effect of treatment (F = 21.57, df = 7, p < 0.001) (see p 115). 5-HIAA levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). Treating rats with L-DOPA 
resulted in 5-HIAA levels intermediate between saline and 5-HTP treatment - 
significantly different from saline at 60 minutes after administration (p < 0.05) and 
from 5-HTP at both 30 and 60 minutes (p < 0.05). When L-DOPA and 5-HTP were 
given together as a combined treatment, levels of 5-HIAA were comparable to giving 
5-HTP alone. When the analysis was extended to compare AS and AS/AGU rats (p 
115) AS rats had higher levels of 5-HIAA than AS/AGU mutants at sixty minutes after 
both groups received a combination of L-DOPA and 5-HTP (p < 0.05).
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Two-way ANOVA: LcpHIAA versus Treat, Group
Analysis of Variance for LcpHIAA
Source DF S3 MS F P
Treat 7 109.515 15.645 21.57 0.001
Group 1 6. 407 6.407 8 . 8 3 0.004
Interaction 7 2 3 . 3 4 5 3.335 4 . 60 0.001
Error 80 58.033 0.725
Total 95 197.300
Treat12
3
4
56 
7
Mean
2.97
07 
33 68 
81 
15 
, 63 
93
Individual 95% Cl
( * )( * ) (  )( * )
3.00
 +■
4.00
( * )
5.00 6.00
Individual 95% Cl
1 4.71 {-----------* — -
2 4.19 (----------- *----------)
4.00 4.25 4.50 4.75
One-way ANOVA: LcpHIAA versus Treatb
Analysis of Variance for LcpHIAA
Source DF SS MS
Treatb 15 139.266 9. 284
Error 80 58,033 0.725
Total 95 197.300
Level N Mean StDev
11 6 2 . 88 3 3 0 . 80 3 5
12 6 3.0667 0 . 5 5 7 4
21 6 2 . 9500 0 . 8894
22 6 3.1833 0 . 6 4 6 3
31 6 5.6500 0.8432
32 6 5.0167 0.7468
41 6 6.0000 1.1472
42 6 5.3667 0 . 6 8 6 1
51 6 3.6500 0 . 38 8 6
52 6 3 . 9 6 6 7 0.7339
61 6 4 . 0 6 6 7 0.9092
62 6 4 . 2 3 3 3 0.4131
71 6 5.1000 0 . 8 5 3 2
72 6 4.1667 0 . 6408
81 6 7.3500 1 . 6 0 4 7
82 6 4.5167 0.9928
Pooled StDev = 0 . 8517
F
1 2 . 8 0
P
< 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev
 )
(■
( — * )
3.2 4.8 6.4
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4) Ventral caudate-putamen. A two-way analysis of variance (ANOVA) showed no 
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 25.90, df = 7, p < 0.001) (see p 117). 5-HIAA levels were significantly elevated in 5- 
HTP-treated animals compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). Treating rats with L-DOPA resulted in 5-HIAA levels 
intermediate between saline and 5-HTP treatment (and significantly different ftom each 
for comparable times after administration, p < 0.05). Wlien L-DOPA and 5-HTP were 
given together as a combined treatment, levels of 5-HIAA were comparable to giving 
5-HTP alone. When the analysis was extended to compare AS and AS/AGU rats (p 
117) no differences between AS and AS/AGU rats were found.
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Two-way ANOVA: VcpHIAA versus Treat, Group
Analysis of Variance for VcpHIAA
Source DF SS MS F P
Treat 7 1 4 1 . 9 6 2 20.280 2 5 . 9 0 0.001
Group 1 1.283 1 . 2 8 3 1. 64 0 . 204
Interaction 7 6 . 9 8 2 0.997 1 . 27 0.274
Error 80 62 . 6 3 5 0.783
Total 95 2 1 2 . 862
Treat12
3
4
56 
7
Mean
3 . 3 8  
3 . 6 3
6,41 
7 . 03 
4.76 
5.29
5.39 
6.23
Individual 95% Cl
3.60 4.80 6.00 7.20
Group12
Mean
5.38
5.15
Individual 95% Cl --------H- *_
5. 00 5.20
 +'
5.40 5 . 6 0
One-way ANOVA: VcpHIAA versus Treatb
Analysis of Variance for VcpHIAA
Source DF SS MS
Treatb 15 147.644 9 . 8 4 3
Error 80 6 3 . 5 3 5 0.794
Total 95 211.179
Level N Mean StDev
11 6 3.5833 0.8796
12 6 3.1833 1.0610
21 6 3.5333 0.9070
22 6 3.7167 0.7360
31 6 6 . 7 3 3 3 0.7891
32 6 6 . 0 8 3 3 0 . 47 0 8
41 6 7.4167 0.8134
42 6 6.4667 0 . 7 3 9 4
51 6 4,5333 0 . 8 2 6 2
52 6 4.9833 0.7782
61 6 4.9667 0 . 8 1 1 6
62 6 5.6167 0.7223
71 6 5 . 6 3 3 3 0.8959
72 6 5.1500 0 . 61 8 9
81 6 6.6333 1.5227
82 6 5.8167 1.1907
Pooled StDev = 0.8912
F
12.39
P
< 0 . 0 0 1
Individual 95% CIs For 
Based on Pooled StDev
Mean
 +-
(-
—  )
3.2 4.8 6.4 8.0
1 1 8
5) Dorsal Raphe Nucleus. A two-way analysis of variance (ANOVA) showed an
extremely significant effect of group (AS v AS/AGU, F= 370.55, d f=1, p <0.001) and 
a very significant effect of treatment (F =71.35, df = 7, p < 0.001) (see p 119). 5-HIAA 
levels were significantly elevated in 5-HTP-treated animals compared with saline- 
treated ones at both 30 and 60 minutes after treatment (p < 0.05). Treating rats with L- 
DOPA (or L-DOPA and 5-HTP together as a combined treatment) resulted in 5-HIAA 
levels intermediate between saline and 5-HTP treatment (and significantly different 
from each for compaiable times after administration, p < 0.05). When the analysis was 
extended to compare AS and AS/AGU rats (p 119) AS/AGU mutants rats had higher 
levels of 5-HIAA than AS rats when treated with a) saline b) L-DOPA and c) L-DOPA 
+ 5-HTP combined.
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Two-way ANOVA: DrnHIAA versus Treat, Group
Analysis of Variance for DrnHIAA
Source DF SS MS F P
Treat 7 1971.33 2 8 1 . 6 2 71.35 0.001
Group 1 1462,50 1462.50 370.55 0 . 0 0 1
Interaction 7 591.13 84.45 2 1 . 4 0 0.001
Error 80 315.75 3 . 9 5
Total 95 4340.70
Treat12
3
4
56 
7
Individual 95% Cl
26.42 (-*--)
27.00 ( — *-)
38.00
39.75 (-*--)29.83 (-_*_)
31.12
33.17
34.67
28.00 32.00 36.00 40.00
Group12
Mean
2 8 . 5 9
36. 40
Individual 95% Cl
30.00 3 2 . 5 0
( - * - )  
35.00 37.50
One-way ANOVA: DrnHIAA versus Treatb
Analysis of Variance for DrnHIAA
Source DF SS MS F P
Treatb 15 4 0 2 4 . 9 6 2 6 8 . 3 3 67.99 < 0.001
Error
Total
80
95
315.75
4340.70
3 . 9 5
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev — 1------------1------------1------------j----
11 6 22 . 3 3 3 1.211 (-*-)
12 6 30.500 1.871 ( —  *-)
21 6 23.667 1 . 5 0 6 (-*-)
22 6 3 0 . 3 3 3 1.506 (-*-")
31 6 37.667 1.633 (-*-)
32 6 3 8 . 3 3 3 1 . 8 6 2 (__*_)
41 6 3 9 . 8 3 3 1.835 (-*-)
42 6 3 9 . 6 6 7 1 . 6 3 3
51 6 2 5 . 317 1.372 (-*-)
52 6 3 4 . 3 3 3 3 . 2 0 4 (- + -)
61 6 2 5 . 9 0 0 1 . 3 6 7 {“*-)
62 6 3 6 . 3 3 3 1.751 (-*-)
71 6 26.167 2 . 1 3 7 )
72 6 40.167 2.041 )
81 6 2 7 . 8 3 3 3.488 ( —  *- )
82 6 41.500 1.871 {-*-“ )
Pooled StDev = 1 . 9 8 7 2 1 . 0  28.0 35.0 42.0
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6) Median Raphe Nucleus. A two-way analysis of variance (ANOVA) showed a 
significant effect of group (AS v AS/AGU, F=10.32, d f=1, p <0.01) and a very 
significant effect of treatment (F = 15.77, df = 7, p < 0.001) (see p 121). 5-HIAA levels 
were significantly elevated in 5-HTP-treated animals compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). Treating rats with L-DOPA 
(or L-DOPA and 5-HTP together as a combined treatment) was not dissimilar to 
treatment with 5-HTP alone. When the analysis was extended to compare AS and 
AS/AGU rats (p 121) AS control rats had higher levels of 5-HIAA than AS/AGU rats 
when treated with L-DOPA + 5-HTP combined.
Two-way ANOVA: MrnHIAA versus Treat, Group
1 2 1
Analysis of Variance for MrnHIAA
Source DF SS MS F 0.
p
Treat 7 504 . 91 72,. 13 15..77 . 001
Group
Interaction
1
7
47
95
. 18 
.24
47 , 
13.
.18 
. 61
10.
2 .
. 32 
 97
0.
0.
. 002 
.008
Error 80 365 . 91 4 .57
Total 95 1013 .25
Individual 95 % Cl
Treat Mean
1 17. 83 ( — )
2 18 .67 { — -)
3 22.,81 ( — —  )
4 24 .58 ( *---- )
5 21,.58 (--- )
6 22 . 00 (- )
7 23 .25 (— — *---- )
8 24 . 17 ( _ ---)
17 .50 20. 00 22. 50 25. 00
Group12
Mean
22.56
21.16
Individual 95% Cl
( * )
( * )
--------------------- 4 - ----------------------------- + -----------------------------+  +  - ■
21.00 21.70 22.40 23.10
One-way ANOVA: MrnHIAA versus Treatb
Analysis of Variance for MrnHIAA
Source DF SS MS
Treatb 15 702.44 46.83
Error 80 298.08 3.73
Total 95 1000.51
Level N Mean StDev
11 6 18.333 1. 966
12 6 17.333 1.633
21 6 19.167 2 . 639
22 6 18.167 1.472
31 6 23.667 1.366
32 6 21.950 1.420
41 6 25.500 1.871
42 6 23.667 1.033
51 6 21.500 2.258
52 6 21.667 1. 751
61 6 20.833 2 . 317
62 6 23.167 1.835
71 6 25.500 1.049
72 6 21.000 2.449
81 6 27.000 1.414
82 6 2 1 . 5 0 0 3 . 0 8 2
Pooled StDev = 1.930
F
12 . 57
P
< 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev
---- +-
17 .5
- ) ( -
2 1 . 0 24.5
 1- .
2 8 . 0
1 2 2
53.2 .3  Dopamine
jji Anterior caudate-Dutamen. A two-way analysis of variance (ANOVA) showed no 
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 50.29, df = 7, p < 0.001) (see p 123). DA levels were significantly elevated in L- 
DOPA-treated animals (as well as in animals treated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). Unexpectedly, DA levels were also elevated in animals given 5- 
HTP alone (p < 0.05). When the analysis was extended to compare AS and AS/AGU 
rats (p 123) no differences were found between the two strains.
Two-way ANOVA: AcpDA versus group, treats
123
Analysis of Variance for AcpDA
Source DF SS MS F P
group 1 3.23 3 . 2 3 1.79 0.185
treata 7 633.98 90.57 50.29 0.001
Interaction 7 22.16 3.17 1.76 0.107
Error 80 144.08 1.80
Total 95 803.45
group12
Mean
26.19
2 6 . 5 6
Individual 95% Cl 
( *----------
2 6 . 1 0 26.40 26.70 27 . 00
treata12
3
4
56 
7
Mean
21.92
23 . 9 2  
25. 90
2 5 . 5 8  
26.81 
30.26 
27 . 04
29.59
Individual 95% Cl 
(--* — ) ( — * — ) ( — *--) ( —* — )
22.50 25.00
( — *— ) 
27.50
( — * — ) 
30. 00
One-way ANOVA: AcpDA versus treatb
Analysis of Variance for AcpDA
Source DF SS MS F P
treatb 15 659.37 4 3 . 9 6 24.41 < 0.001
Error
Total
80
95
144.08
803.45
1.80
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev — 1------------1------------1------------1—
11 6 2 2 . 1 6 7 1.169  ^ ^
12 6 2 1 . 6 6 7 1.633 ( —  *—  )
21 6 2 3 . 5 0 0 1.276 (--*— )
22 6 2 4 . 3 3 3 1 . 0 3 3 {---* —  )
31 6 25.133 0 . 6 0 2  ^ _ — J
32 6 2 6 . 6 6 7 1.211  ^ — 'A' — — ^
41 6 25.833 0 . 4 1 3 (--*--J
42 6 25.333 1.211
51 6 26.750 0.777
52 6 2 6 . 8 6 7 0 . 2 6 6 ( — * —  )
61 6 29.767 1.272 (“-* —  )
62 6 30 . 7 5 0 0 . 9 5 2
71 6 26.233 1.494  ^— — "Ar —. — ^
72 6 27.850 2 . 1 2 2 (---* —  )
81 6 30.167 2 . 6 3 9 ^--,— J
82 6 29.017 1.312 -^-J
Pooled StDev = 1 . 3 4 2 21.0 24.5 28.0 31.5
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^  Dorsal caudate-putamen. A two-way analysis of variance (ANOVA) showed a liighly 
significant effect of gi’oup (AS v AS/AGU F = 946, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 48.79, df = 7, p < 0.001) (see p 125). As with the 
anterior caudate-putamen (see above) DA levels were significantly elevated in L- 
DOPA-treated animals (as well as in animals treated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). Unlike the anterior caudate-putamen, no effect of 5-HTP alone 
could be found. When the analysis was extended to compare AS and AS/AGU rats 
(p 125) very large differences were found between the two strains under all treatments 
and times, with control AS rats having higher dopamine levels than AS/AGU mutants.
Two-way ANOVA: DcpDA versus group, treata
125
Analysis of Variance for DcpDA
Source DF SS MS
group 1 1130.25 1130.25
treata 7 407.90 58.27
Interaction 7 130.13 18 . 59
Error 80 95.54 1.19
Total 95 1763.82
F
946.41 
48.79 
15.57
P
0 . 0 0 1
0 . 0 0 1
0 . 0 0 1
Individual 95% Cl
group Mean
1 15.18 \ I
2 8.31 { - *)
10. 00 12.00 14.00 16.00
Individual 95% Cl
treata Mean ----- +----------
1 10.22  ^ ^
2 9.71  ^ — J
3 10.09 (--*---)
4 10.10  ^ -, .— ^5 11.20  ^ --')
6 15.37 { —  * —  )
7 12.79
8 14 .48  ^ — ‘k ---^
1 0 . 0 0 1 2 . 0 0 14.00 16.00
One-way ANOVA: DcpDA versus treatb
Analysis of Variance for 
Source DF SS 
treatb 15 1668.28 
Error 80 95.54 
Total 95 1763.82
DcpDA
MS 
1 1 1 .22 
1.19
F P 
93.13 < 0.001
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev
11 6 12.967 0.859 (-*-)
12 6 7.467 0.557 (-*“ )
21 6 12.217 0.749 (*-)
22 6 7.200 0.540 (*-)
31 6 13.683 0.646 (*-)
32 6 6.500 0.645 (-*-)
41 6 13.117 1.650 ("*-)
42 6 7 . 083 0.671 (-*-)
51 6 13.100 1.010 (-*-)
52 6 9.300 1.305 (-*)
61 6 19.750 1.507 { - *)
62 6 11.000 1.271 {-*-)
71 6 16.200 1.518 (*-)
72 6 9.383 0.496 (-*-)
81 6 2 0 . 3 8 3 1.933 (-*-)
82 6 8.583 0.549 (-*-)
Pooled StDev == 1.093 10.0 15.0 20.0
1 2 6
^  Lateral caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
highly significant effect of group (AS v AS/AGU F = 444, df = 1, p < 0.001) as well as 
a very significant effect of treatment (F = 30.58, df = 7, p < 0.001) (see p 127). As with 
other parts of the caudate-putamen (see above) DA levels were significantly elevated in 
L-DOPA-treated animals (as well as in animals tieated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). Like the anterior caudate-putamen, 5-HTP administration alone 
also led to raised DA levels (p < 0.05). Wlien the analysis was extended to compare AS 
and AS/AGU rats (p 127) very large differences were found between the two strains 
under all treatments and times, with contr ol AS rats having higher dopamine levels 
than AS/AGU mutants.
Two-way ANOVA: LcpDA versus group, treata
127
Analysis of Variance for LcpDA MSSource DF SS
group 1 761. 63 7 61.. 63
treata 7 367 .18 52 . 45Interaction 7 129. 37 18 . 48
Error 80 137 .21 1 .72
Total 95 1395. 39
group12
treata12
3
4
56 
7
F
444.08 
30. 58 
10.78
P
0 . 0 0 1
0 . 0 0 1
0 . 0 0 1
Mean
27.39
21.76
Mean
2 1 . 6 8
2 2 . 1 1
23.94
23.71 
25.36 
27 . 66
25.71 
26.46
Individual 95% Cl
(-*--)
22 . 40 24 .00 25.60 27 .20
Individual 95% Cl
(---* - - ] \ — )
(---
(---* —  ) ^™ .— k — —
( —  *---)
-)
22.00 24 . 00 26. 00 28.00
One-way ANOVA: LcpDA versus treatb
Analysis of Variance for LcpDA
Source DF SS MS
treatb 15 1258.18 83.88
Error 80 137.21 1.72
Total 95 1395.39
Level N Mean StDev
11 6 24.133 1.172
12 6 19.217 1.463
21 6 25.283 1.011
22 6 18.933 1.129
31 6 25.383 1.150
32 6 22.500 2.011
41 6 26.017 0.671
42 6 21.400 1.020
51 6 27.350 0.912
52 6 23.367 0.950
61 6 30.833 2.401
62 6 24.483 1.221
71 6 28.150 1.531
72 6 23.267 0.848
81 6 32.000 1.414
82 6 20.917 0.850
Pooled StDev = 1.310
F
48.91
P
< 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev-------+------------- 4---------------+ “■
(-*-)
( - V C - )
— +. 
2 0 . 0
---- + -
25.0
-------------+  .
30.0
-----+-
35 . 0
1 2 8
^  Ventral caudate-putamen. A two-way analysis of variance (ANOVA) showed a
significant effect of group (AS v AS/AGU F = 22.6, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 6.49, df = 7, p < 0.001) (see p 129). DA levels were 
significantly elevated in L-DOPA-treated animals both 30 and 60 minutes after 
treatment as well as in animals treated with both L-DOPA and 5-HTP simultaneously 
60 minutes after treatment (for all, p < 0.05). No effect of 5-HTP alone could be found. 
Wlien the analysis was extended to compare AS and AS/AGU rats (p 129) control AS 
rats had higher dopamine levels than AS/AGU mutants 60 minutes after a combined L- 
DOPA + 5-HTP administration; all other comparisons were non-significant.
Two-way ANOVA: VcpDA versus group, treata
129
Analysis of Variance for VcpDA
Source DF SS MS F P
group
treata
1
7
97 . 00 
194.96
97.00
27.85
2 2 . 6 0
6.49
0.001
0.001
Interaction 7 200.09 28.58 6.66 0. 001
Error 80 343.38 4 . 29
Total 95 835.42
Individual 95% Cl
group Mean
1 24.34 ( * „ )
2 22.33 (-------* — ------)
22.40 23.,20 24.00 24.80
Individual 95% Cl
treata Mean — _i---------
1 21.83 (-------* - ------ )
2 21.70 (--------* - ----- )
3 22.75 ( — ----- )
4 21.87 {-------- ------ )
5 24 .77 (---- ---*------- )
6 25.68 (--------^-------)
7 23.67 (---- ---)
8 24.42 (------ -------)— +--------
20.80 22 .40 24 . 00 25.60
One-way ANOVA: VcpDA versus treatb
Analysis
Source
treatb
Error
Total
of Variance for VcpDA
DF
15
80
95
SS
492.05
343.38
835.42
MS 
32.80 
4 .29
F
7 . 64 < 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev - -
11 6 21.500 2.665 (— "*---- )
12 6 22.167 1.941 ---- )
21 6 22.733 1.796 (---- *---- )
22 6 20.667 2.733 (---- *---- )
31 6 23.333 2.066
32 6 2 2 . 1 6 7 1.941
41 6 2 1 . 6 6 7 1.506 {---- *---- )
42 6 22.083 1 . 6 2 5 (---- *---- )
51 6 25.167 2.317 (---- *---- )
52 6 24.367 1.169
61 6 26.500 2.074 ( * )
62 6 24.867 1.451 (---- *-----)
71 6 24.833 1.472 (---- *---- )
72 6 22.500 1.378 (---- *---- )
81 6 29.000 3.950 ( *
82 6 19.833 1.169 (---- *___)
Pooled StDev = 2 . 072 21.0 2 4 . 5  28.0
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^  Dorsal raphe nucleus. A two-way analysis of variance (ANOVA) showed a
significant effect of group (AS v AS/AGU F = 6,66, df = 1, p < 0.05) as well as a very 
significant effect of treatment (F = 60.83, df = 7, p < 0.001) (see p 131). DA levels 
were non-detectable in the region of the dorsal raphe in control saline-treated rats of 
either strain. However, DA levels became detectable (and thus significantly elevated) 
in L-DOPA-treated animals - as well as in animals treated with both L-DOPA and 5- 
HTP simultaneously - compared with saline-treated ones at both 30 and 60 minutes 
after treatment (p < 0.05). Furthermore, administration of 5-HTP alone led to a rise in 
DA levels found (p < 0.05). When the analysis was extended to compare AS and 
AS/AGU rats (Fig. '*'*) differences were found between the two strains in animals 
treated with L-DOPA and L-DOPA combined with 5-HTP. However, since these 
differences included higher levels of dopamine in AS rats on some oceasions and in 
AS/AGU rats on others, it is unclear if they are of functional significance (see p 131). 
Levels of dopamine were always very low in the dorsal raphe.
Two-way ANOVA: DrnDA versus group, treata
131
Analysis of 
Source
Variance for DrnDA 
DF SS MS F P
group 1 2.870 2.870 6.66 0.012
treata 7 183.510 26,216 60.83 0,001
Interaction 7 36.073 5.153 11.96 0.001
Error 80 34.477 0.431
Total
group
95 256.930
Individual 95% Cl
1 1.704 {----- k
2 2.050 (--------- -
— — — —------j- —--- ----- --]-----------p —----
1.600 1.800 2.000 2 . 2 0 0
treata12
3
4
56 
7
Mean
- 0 . 0 0
- 0 . 0 0
1. 09 
1.26 
2.80 
3.64 
3.45
2. 77
Individual 95% Cl
 ^ -k J
^  k    J
( )
0 . 00 1 . 2 0
 ^  ^ J -^-
( — *-- ) ( — *— )
2.40 3.60
One-way ANOVA: DrnDA versus treatb
Analysis of Variance for DrnDA
Source DF SS MS F P
treatb 15 222.453 14.830 34.41 < 0.001
Error
Total
80
95
34.477 
256.930
0.431
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev
11 6 -0.0000 0.0000
12 6 -0.0000 0.0000
21 6 -0.0000 0,0000 (---------* --------- )
22 6 -0.0000 0.0000
31 6 1.0333 0.4719
32 6 1.1500 0.5683  ^—----- - ----- J
41 6 1.1333 0.7062 ( -------- k ------ J
42 6 1.3833 0 . 4 2 6 2 ( —  * --------)
51 6 1.4333 0.3830
52 6 4.1667 1.4720 (---------*  —  )
61 6 3.9667 0.6976 ( ----- k ----------J
62 6 3.3167 0.6369 ( - - * --------)
71 6 2 . 5 8 3 3 0.6274 ^ ----- k  — — J
72 6 4.3167 0.9948
81 6 3.4833 0.8704 ( —  ^ — — )
82 6 2.0667 0.5680 {-------- *  —  )
Pooled StDev = 0.65 65 0.0 1.5 3.0 4.5
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^  Median raphe nucleus. A two-way analysis of variance (ANOVA) showed no effect 
of group (AS V AS/AGU) but a very significant effect of treatment (F = 47.74, df = 7, p 
< 0.001) (see p 133). DA levels were non-detectable in the region of the median raphe 
in control saline-treated rats of either strain. However, DA levels became detectable 
(and thus significantly elevated) in L-DOPA-treated animals - as well as in animals 
treated with both L-DOPA and 5-HTP simultaneously - compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). Furthermore, administration 
of 5-HTP alone led to a rise in DA levels found (p < 0.05). Wlien the analysis was 
extended to compare AS and AS/AGU rats (p 133) a single difference was found 
between the two strains in animals treated with 5-HTP where mutants had higher DA 
levels than controls.
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Two-way ANOVA: MrnDA versus group, treata
Analysis of Variance for MrnDA
Source DF SS MS F P
group 1 0.220 0.220 1.41 0.239
treata 7 52.238 7 .463 47.74 0.001
Interaction 7 4 .475 0.639 4.09 0.001 i
Error 80 12.507 0.156 1Total 95 69.440
group12
Mean
1 . 0 0 2
1.098
Individual 95% Cl
0.960 1.040 1 . 1 2 0  1 . 2 0 0
treata12
3
4
56 
7
Mean 
0 . 00  
0 . 0 0  
0.85 
0. 94
23
25
34
78
Individual 95% Cl 
( — *—}
(--*—)-^-'A' ^
( k J
( — *— )^  ^— J
0.00 0.70 1.40 2.10
One-way ANOVA: MrnDA versus treatb
Analysis of Variance for MrnDA
Source DF SS MS F P
treatb
Error
Total
15
80
95
5 6 . 9 3 3
12.507
69.440
3 . 7 9 6
0.156
24.28 < 0.001
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev ------ 1------------1------------1---- ------- h —
11 6 0.0000 0.0000
12 6 0.0000 0.0000
21 6 0.0000 0.0000
22 6 0.0000 0.0000
31 6 0.8500 0.2168
32 6 0.8500 0.2258
41 6 0.4333 0.1211
42 6 1.4500 0.4037
51 6 0.9833 0.5345
52 6 1.4833 0.3061
61 6 2.2667 0.6055 (---*---
62 6 2 . 2 3 3 3 0.8548 (---*---
71 6 1.4667 0.4082 (--- -k — ,--J
72 6 1.2167 0.4535 (---*--- )
81 6 2.0167 0.2137 { — - *--- )
82 6 1.5500 0.5753 ____ _^_______ _^__ i ___ _____
Pooled StDev = 0.3954 0.00 0.80 1,60 2.40
1 3 4
S.3.2.4 Dihydroxyphenylacetic acid (DOPAC)
1) Anterior caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
highly significant effect of group (AS v AS/AGU F = 156, df = 1, p < 0.001) as well as 
a very significant effect of treatment (F = 61.54, df = 7, p < 0.001) (see p 135). DA 
levels were significantly elevated in L-DOPA-treated animals (as well as in animals 
treated with both L-DOPA and 5-HTP simultaneously) compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). The combined treatment was 
less effective than L-DOPA alone. 5-HTP alone also significantly raised DOPAC 
levels (p < 0.05). When the analysis was extended to compare AS and AS/AGU rats (p 
135) very large differences were foimd between the two strains both 30 and 60 minutes 
after L-DOPA administration; in each case, control AS rats had higher levels of 
DOPAC than AS/AGU mutants. A similar response was found in rats given L-DOPA + 
5-HTP 30 minutes after administration.
Two-way ANOVA: acpDOP versus group, treata
Analysis of Variance for acpDOP 
Source 
group 
treata 
Interaction 
Error
1 3 5
Total
group
1
2
treata
1
2
3
4
5
6 
7
DF SS MS F P
1 144.305 144.305 156.04 0.001
7 398.357 56.908 61.54 0.001
7 210.136 30.019 32.46 0. 001
80 73.982 0.925
95 826.780
Mean 
6.98 
4 . 52
Mean 
3,43 
3 .11 
4.56
Individual 95% Cl
( —  *  !
!  *  —  )
 + -
4.80
----- + -
5. 60
 +--------------- +.
6.40 7.20
44
95
53
18
79
Individual 95% Cl
( —  * - -  )
( —  )
( - - * — )
( - - *  —  )
 ^—  * —  
( — *  —  ) + —
6 . 00
-----------+ -
4 .00
-----
8 . 00
 + .
1 0 . 0 0
One-way ANOVA: acpDOP versus treatb
Analysis of Variance for acpDOP
Source DF SS MS F P
treatb 15 752.798 50.187 54.27 < 0.001
Error 80 73.982 0.925
Total 95 826.780 Individual 95% CIs For Mean
StDev
Based on Pooled StDev
Level N Mean
11 6 3.200 1.147 (-*-)
12 6 3.667 0,819 (_*__)
21 6 4 .150 0. 929 (-*-)
22 6 2.067 0.234 (-*-)
31 6 4 . 900 1.318 (-*-)
32 6 4.217 0 . 313 (-*-)
41 6 5.783 0.804 ( —  *- )
42 6 5.100 1.257 { - * - )
51 6 11.300 1.230 (-* —  )
52 6 4 . 600 0.522 (-*“ ) {-*-61 6 13.300 1.691
62 6 5.767 1.015 (-*-“ )
71 6 7.783 0.850 (-*-)
72 6 4 .567 0.427 {-*-)
81 6 5 . 3 8 3 0 .595 („*__)
82 6 6.200 0.949 ( — *-)
Pooled StDev = 0 . 9 6 2 3.5 7.0 10.5
1 3 6
2) Dorsal caudate-putamen. A two-way analysis of variance (ANOVA) showed a highly 
significant effect of group (AS v AS/AGU F = 26.8, df = 1, p < 0.001) as well as a very 
significant effect of treatment (F = 62.57, df = 7, p < 0.001) (see p 137). As with the 
anterior caudate-putamen (see above) DA levels were significantly elevated in L- 
DOPA-treated animals (as well as in animals treated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). 5-HTP alone also significantly raised DOPAC levels (p < 0.05). 
When the analysis was extended to compare AS and AS/AGU rats (p 137) many 
significant differences were found between the two strains. When the treatment was 
saline alone, DOPAC levels were higher in mutants than controls. However, when the 
treatment was a pharmacological inteiwention of any kind, the reverse was observed, 
with control AS rats having higher dopamine levels than AS/AGU mutants.
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Two-way ANOVA: dcpDOP versus group, treats
Analysis of Variance for dcpDOP
Source DF SS MS F P
group 1 10.402 10.402 26.80 0.001
treata 7 169.990 24.284 62.57 0.001
Interaction 7 37.742 5.392 13.89 0. 001
Error 80 31.047 0.388
Total 95 249.180
Individual 95% Cl
group Mean ---- +- --------- +--------- — +-------- !
1 5 .504 (----- -------) !
treata12
3
4
56 
7
4 . 846
Mean
 +-
4 . 750
 +  -
5 . 0 0 0
 +-
5.250
 +-
5. 500
09
32
53
78
31
7.1968
50
Individual 95% Cl
 ^ . "A* —. — ^
 ^  ^ ^
(--* — )
 ^ _ "A* _ _ ^
 ^ "A"   J
)
3.60 4.80 6.00 7.20
One-way ANOVA: dcpDOP versus treatb
Analysis of Variance for dcpDOP
Source DF SS MS F P
treatb
Error
Total
15
80
95
218.133 
31.047 
249.180
14.542
0.388
37.47 < 0.001
Individual 95% CIs For Mean 
Based on Pooled StDev
Level N Mean StDev — H------------!------------1------- ----1---
11 6 2 . 48 3 3 0.4491
12 6 3.7000 0.3098 (-"*-)
21 6 2 . 8 0 0 0 0.5099 {--*—  )
22 6 3.8333 0.4082 (-*“-)
31 6 6.1500 0.6473 (-"*-)
32 6 4.9167 0.3764  ^ __ J
41 6 4.9667 0 . 6 8 6 1 ("-*-)
42 6 4.6000 0.4382 ( —  )
51 6 6.2167 0.6969 (-*““ )
52 6 4.4000 0.4561 ( ——* —  )
61 6 7.9333 0 . 9374 ( —  *- )
62 6 6.4500 0.8408
71 6 6.9333 0.6186 ( —  *- }
72 6 4.4167 0.4262 (-*_-)
81 6 6.5500 0.6285 ( — + -)
82 6 6.4500 1.0114 (-*--)
Pooled StDev = 0.6230 2.0 4.0 6.0 8 . 0
1 3 8
3) Lateral caudate-putamen. A two-way analysis of variance (ANOVA) showed a 
highly significant effect of group (AS v AS/AGU F = 209, d f -  1, p < 0.001) as well as 
a very significant effect of treatment (F = 87.25, df = 7, p < 0.001) (see p 139). As 
with the anterior caudate-piitamen (see above) DA levels were significantly elevated in 
L-DOPA-treated animals (as well as in animals treated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). 5-HTP alone also significantly raised DOPAC levels (p < 0.05). 
When the analysis was extended to compare AS and AS/AGU rats (p 139) many 
significant differences were found between the two strains. When the treatment was 
saline alone, DOPAC levels were higher in mutants than controls. However, when the 
treatment was a phai*macological intervention of any kind, the reverse was observed, 
with control AS rats having higher dopamine levels than AS/AGU mutants.
Two-way ANOVA; IcpDOP versus group, treata
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Analysis of Variance for IcpDOP
Source DF SS MB
group 1 90.229 90.229
treata 7 263.077 37.582Interaction 7 109.390 15.627
Error 80 34 . 459 0. 431
Total 95 497.156
group
1
2
treata
1
2
3
4
5
6 
7
F
209.47
87.25
36.28
Mean
6.106
4.167
Mean
50 
71 
83 
08 
.08 
. 90 
.55 
.45
Individual 95% Cl
P
0 . 0 0 1
0 . 0 0 1
0 . 0 0 1
( - - *  ) +----------------+-
4.200 4.800
 +  -
5.400
 +  -
6 . 0 0 0
Individual 95% Cl + +-----
( — * - )
( - * _ _ )
( - * -
00
— +. 
4.50
_ *  —  )
 + -
6 . 00
--------------+  .
7.50
One-way ANOVA: IcpDOP versus treatb
Analysis of Variance for IcpDOP
Source DF SS MS
treatb 15 462.697 30.846
Error 80 34.459 0.431
Total 95 497.156
Level N Mean StDev
11 6 2.033 0.216
12 6 2.967 0.320
21 6 2 . 5 2 8 0.101
22 6 2.883 0 . 3 0 6
31 6 4 . 683 0.591
32 6 4 . 967 0.476
41 6 6.183 0 . 5 7 8
42 5 3.983 0.538
51 6 9.917 0.930
52 6 4.233 0.750
61 6 8 . 567 0 . 5 1 6
62 6 5.233 0.734
71 6 8.033 0.532
72 6 5.067 0 . 2 5 8
81 6 6.900 0 .810
82 6 4.000 1.483
Pooled StDev = 0 . 6 5 6
F
71.61
P
< 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev
---------- _i-------------------------+ ------------------------ + —
(-*-)
— + .
2.5
- * - )  
 + .
5.0
--- +-
7.5
 +  .
1 0 . 0
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4) Ventral caudate-putamen. A two-way analysis of variance (ANOVA) showed no 
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 26.29, df = 7, p < 0.001) (see p 141). As with the anterior caudate-putamen (see 
above) DA levels were significantly elevated in L-DOPA-treated animals (as well as in 
animals treated with both L-DOPA and 5-HTP simultaneously) compared with saline- 
treated ones at both 30 and 60 minutes after treatment (p < 0.05). 5-HTP alone also 
significantly raised DOPAC levels (p < 0.05). When the analysis was extended to 
compare AS and AS/AGU rats (p 141) many significant differences were found 
between the two strains. When the treatment was saline alone, DOPAC levels were 
higher in mutants than controls. However, when the treatment was a pharmacological 
intervention of any kind, the reverse was observed, with control AS rats having higher 
dopamine levels than AS/AGU mutants (significantly so with 5-HTP and L-DOPA 
treatments).
Two-way ANOVA: vcpDOP versus group, treata
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Analysis of Variance for^ycpDOP 
Source 
group 
treata 
Interaction 
Error 
Total
group
1
2
DF SS MS F P
1 0.215 0.215 0.27 0 . 6 0 2
7 144.115 20.588 2 6 . 2 9 0.001
7 42.584 6.083 7.77 0.001
80 62.660 0.783
95 249.574
Mean
5.12
5.02
Individual 95% Cl 1 1-----
(--------------(■---- +-
4 . 80
----- +-
4 . 95
----- +-
5.10
----- +-
5.25
treata
1
2
3
4
5
6 
7
Mean 
3.08 
3.13 
6. 08 
4 . 53 
5.83 
5. 96 
6.05 
5.89
Individual 95% Cl  + 1--
( ------------* --------- )(------ *----- )
---- +-
3.00 00
---- +-
5.00
 + .
6 . 0 0
One-way ANOVA: vcpDOP versus treatb
Analysis of Variance for vcpDOP
Source DF SS MS
treatb 15 186.914 12.461
Error 80 6 2 . 6 6 0 0.783
Total 95 249.574
Level N Mean StDev
11 6 2.1500 0 . 2 6 6 5
12 6 4.0167 1.2875
21 6 2.2733 0.1796
22 6 3 . 9 8 3 3 1.2497
31 6 6.9000 1.0640
32 6 5.2500 0.5683
41 6 4.0500 0.7314
42 6 5.0167 0.7705
51 6 6 . 6 3 3 3 1.0857
52 6 5 . 0 1 6 7 0.5565
61 6 6 . 2 1 6 7 0.8424
62 6 5.7000 1.1349
71 6 6.2833 1.0304
72 6 5.8167 0.7859
81 6 6.4167 1.0944
82 6 5 . 3 6 6 7 0.5125
Pooled StDev = 0.8850
F
15. 91 < 0 . 0 0 1
Individual 95% CIs For Mean 
Based on Pooled StDev ^  + +------------
 ^—I.— — “A" — — J
( * )(--*  )
( *--)
"Ar — J
 ^ ---
( - -*  ) ^ J
( * ) ^ — — ’A'. j— ^  — ^ ^   'A' — ^
 ^^  "A — — ^
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2 . 0 4 . 0 6 . 0
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5) Dorsal raphe nucleus. A two-way analysis of variance (ANOVA) showed no
significant effect of group (AS v AS/AGU) but a very significant effect of treatment (F 
= 29.11, df = 7, p < 0.001) (see p 143). DOPAC was not detectable within the raphe 
region of saline-treated control rats of either strain. However, levels became detectable 
(i.e. were significantly elevated) in L-DOPA-treated animals (as well as in animals 
treated with both L-DOPA and 5-HTP simultaneously) compared with saline-treated 
ones at both 30 and 60 minutes after treatment (p < 0.05). 5-HTP alone also 
significantly raised DOPAC levels (p < 0.05). Wlien the analysis was extended to 
compare AS and AS/AGU rats (p 143) no significant differences between the two 
strains could be found.
Two-way ANOVA: DrnDOP versus group, treata
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Analysis of Variance for DrnDOP
Source
group
treata
Interaction
Error
Total
group
1
DF
1
7
7
80
95
SS 
0.023 
162.512 
9.937 
63.795 
2 3 6 . 2 6 7
MS 
0.023 
23.216 
1.420 
0.797
F
0.03
29.11
1.78
P
0.864
0 . 0 0 1
0.103
Mean
2.05
Individual 95% Cl 
-+  +
1.80 1.95 2.10 2.25 2.40 
Individual 95% Cl ____________________ 1--------treata Mean
1 -0.00 {---*--- )
2 -0.00 (---*--- )
3 3.82 ( * )
4 2.57 ( )
5 1.83
6 2.42
7 2.88 (_ ^
8 2 . 9 8
0.00 1.20 2.40 3.60
One-way ANOVA: DrnDOP versus treatb
Analysis of Variance for DrnDOP
Source DF SS MS F P
treatb 15 172.472 11.498 14.42 < 0.001
Error 80 63.795 0.797
Total 95 236.267 Individual 95% CIs For Mean
Based on Pooled StDev
Level N Mean StDev
11 6 -0.0000 0.0000 (---- *---- )
12 6 -0.0000 0.0000 (---- *---- )
21 6 -0.0000 0.0000 (---- *---- )
22 6 -0.0000 0.0000
31 6 3 . 4 3 3 3 1.0783 { * )
32 6 4.2000 1.7855 ( * )
41 6 2 . 68 3 3 0.8998 ( * )
42 6 2.4500 0 . 9 4 8 2
51 6 1.4333 0.3830 ( * )
52 6 2.2167 1.0666 ( * )
61 6 2.5667 0 . 9 3 5 2 ( * )
62 6 2 . 2667 0.6743 ( * )
71 6 2.6167 0.5879 ( * )
72 6 3.1500 1.3795 ( * - )
81 6 3.6333 1.2972 ( * )
82 6 2.3333 0.3933 (---- * —  ")
Pooled StDev : 0.8930 0 . 0  1 . 6  2L2 4 . 8
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6) Median ranhe nucleus. A two-way analysis of variance (ANOVA) showed a 
significant effect of group (AS v AS/AGU, F = 1 3 .1 1 , d f ^ l , p <  0.001) and a very 
significant effect of treatment (F =42.94, df = 7, p < 0.001) (see p 145). DOPAC was 
not detectable in samples from the median raphe of saline-treated control rats. 
However, levels became detectable (i.e. were significantly elevated) in L-DOPA- 
treated animals (as well as in animals treated with both L-DOPA and 5-HTP 
simultaneously) compared with saline-treated ones at both 30 and 60 minutes after 
treatment (p < 0.05). 5-HTP alone also significantly raised DOPAC levels (p < 0.05). 
When the analysis was extended to compare AS and AS/AGU rats (p 145) some 
significant differences were found between the two strains with mutants having hifher 
levels of DOPAC than the parent strain.
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Two-way ANOVA: MrnDOP versus group, treata
Analysis of Variance for MrnDOP
Source DF S3 MS F P
group 1 7 . 370 7 .370 13.11 0.001
treata 7 168.942 24.135 42.94 0.001
Interaction 7 33.143 4.735 8.42 0.001
Error 80 44.963 0.562
Total 95 254.418
group
1
2
Mean
1 - 8 8
2.43
Individual 95% Cl
1.75 2 . 0 0 2.25 2.50
treata
1
2
3
4
5
6 
7
Mean
0 . 0 0
0 . 0 0
00
86
47
39
38
14
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 )
0 . 0 0
 +  -
1 . 2 0
(  * —  )
2.40 3.60
One-way ANOVA: MrnDOP versus treatb
Analysis of Variance for MrnDOP
Source DF SS MS F
treatb 15 209.455 13.964 24.84
Error
Total
80
95
44.963 
254.418
0.562
Individu; 
Based on
Level N Mean StDev ------ 1---
11 6 0.0000 0.0000 (---* —
12 6 0.0000 0.0000 (---* —
21 6 0.0000 0.0000 {---* —
22 6 0.0000 0.0000 (---* —
31 6 2.4000 0.6481
32 6 3.6000 1.1883
41 5 4.0500 1.0710
42 6 3.6667 0.7528
51 6 0.9833 0.5345 ('
52 6 3.9500 0.8142
61 6 2.7000 0.7239
62 6 2.0833 0.6735
71 6 1.5667 0.6022
72 6 3.1833 1.4219
81 6 3.3167 0.8329
82 6 2.9667 0.6653 _____
Pooled StDev = 0.7497 0,0
P
< 0 . 0 0 1
CIs For Mean
■ + ----------------------------- - + ------------------  j--
(-
( •
•)
( — ■■
1.5 3.0
 +-
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5.4 DISCUSSION
Over 100 animals were used in this part of the study, yielding some 400 individual pieces 
of data. In the analysis of such a large body of material (pp 93-144 ), it is recognised that 
complex and conflicting results may emerge and that some random differences will appear 
statistically significant by chance. For that reason, I wish to concentrate in the Discussion 
on the strongest themes which emerge from my results. These are ;-
1. That mutants have reduced 5-HT in the dorsal raphe nucleus where the cell bodies of 
serotonergic neurons are concentrated. They also have reduced 5-HT in some parts of 
the striatum (where the terminals of these cells aie located) but not in all. Interestingly, 
serotonin is not reduced in the median raphe which does not project to the striatum.
2. That, in general, mutants have elevated 5-HIAA in those parts of the brain where 5-HT 
is reduced. This is especially tme of the dorsal raphe nucleus and the dorsal caudate- 
putamen.
3. That 5-HT and 5-HIAA levels are elevated by the administration of the precursor 5- 
HTP.
4. That 5-HT levels are markedly reduced by the administration of the dopamine 
precursor L-DOPA, a reduction which the simultaneous administration of 5-HTP is 
generally unable to compensate for.
5. That mutants have reduced DA levels compared with the parent AS strain in the dorsal 
and lateral caudate-putamen, but not in the anterior or ventral parts. This replicates 
almost precisely date reported some years ago (Campbell et al, 1997).
6. That DA levels are elevated by the administration of L-DOPA (alone or in combination 
with 5-HTP) in all areas of the caudate-putamen in both strains. Fmthermore, L-DOPA 
administration led to detectable DA within the dorsal and median raphe nuclei; in 
saline-treated controls, DA was non-detectable. In general, increases in DA were more 
pronounced in control AS than in mutant AS/AGU rats.
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7. That DA levels were also elevated by the administration of the 5-HT precursor 5-HTP, 
both within the striatum and within the raphe nuclei.
8- That DOPAC levels were higher in mutants than controls in several striatal regions, 
including the dorsal and ventral caudate-putamen.
9. That DOPAC levels are elevated by the administration of L-DOPA (alone or in 
combination with 5-HTP) in all areas of the caudate-putamen in both strains. 
Furthermore, L-DOPA administration led to detectable DOPAC within the dorsal and 
median raphe nuclei; in saline-treated controls, DOPAC was non-detectable. In 
general, increases in DOPAC were more pronounced in control AS than in mutant 
AS/AGU rats.
Different parts of the caudate-putamen 1) show intiinsic differences in levels of catechol- 
or indoleamines and their metabolites 2) show differences in response to simple 
pharmacological interventions. In particular, the dorsal and lateral caudate-putamen are 
more likely to show differences than the ventral and anterior regions.
Similarly, the dorsal raphe nucleus is much more likely to show differences in basal levels 
and resposes to intervention than the median raphe nucleus. This is not unexpected given 
that it is the dorsal raphe (rather than the median) which shows cell losses - see Chapter 3. 
Elevation of 5-HIAA in those brain regions where 5-HT is reduced supports the notion 
that there are changes in 5-HT release mechanisms rather than cell death. If so, this may be 
because vesicles are not forming propely (or are leaking) as has already been proposed for 
DA (Payne et ah, 2000).
5-HTP administration increased both 5-HT and its major metabolite 5-HIAA. This 
indicates that the synthetic pathway is functioning propely. Administration of 5-HTP leads 
to increase synthesis of 5-HT (Moir and Eccleston, 1968) and an increase in levels of 5-HT 
(Moir and Eccleston, 1968; Okada et ah, 1972) and its metabolite 5-HIAA in the brain 
(Moir and Eccleston, 1968; Okada et ah, 1972; Cespuglio et ah, 1981).
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L-dopa administration decreased 5-HT levels. Although this may appear paradoxical, it 
agrees with previous findings (Bartholini et ah, 1968; Everett and Borcherding, 1970).
Also it has been reported that administration of L-dopa increases the release of 5-HT (Ng 
et ah, 1970) and its metabolites from the striatum (Bjorklund and Dunnett, 1992), 
suggesting that a portion of administered L-dopa may enter serotonergic nerve terminals 
and undergo decarboxylation to DA with resultant displacement of endogenous 5-HT (Aral 
et ah, 1994). At least one in vitro study has shown that L-dopa interferes with tryptophan 
hydroxylase activity and reduces 5-HT synthesis, while 5-HTP inliibits tyrosine 
hydroxylase activity and lowers DA synthesis (Manuyama et ah, 1992).
It has been reported that tissue content of 5-HT and 5-HT innervation were significantly 
decreased in the striatum of 6-OHDA-lesioned rat (Dunnett et ah, 1988; Takeuchi et ah, 
1991), and some animals with mesencephalic DA-rich grafts showed increases in 5-HT 
level and serotonergic hyperinnervation in the striatum (Dunnett et ah, 1988; Takeuchi et 
ah, 1991).
Reduction of DA levels in mutant animals compaied with the parent AS strain confirms 
previous reports (Campbell et ah, 1997). The reduction was noticed in two areas in mutant 
rats namely DCPU and LCPU while other areas were unaffected. This is similar to the 
regional pattern of striatal DA loss observed in patients with Parkinson’s disease 
(Hornykiewicz, 1995).
Elevation of DA in the striatum after L-dopa administration agrees with preivous reports 
(Langelier et ah, 1973; Watanabe, 1983). Moreover L-dopa was able to increase DA to 
detectable levels in DRN and MRN. It is possible that L-dopa may be using 5-HT cells to 
produce or facilitate DA production in the raphe nuclei. For example, when L-dopa and a 
peripheral AADC inhibitor were administrated, DA-ir cells were found in serotonergic 
nuclei (Barrett and Batch, 1971; Butcher et ah, 1970; Lidbrink et ah, 1974; Tison et ah, 
1991). More recently. Aria and colleagues (1994) examined rats which had received L-
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dopa plus AADC; by using double-labeling they showed that serotonin-stained neurons of 
the dorsal raphe nucleus of rat were also immunoreactive to dopamine.
A final interesting result of the present study is that the mutant rats have more DOPAC 
than normal animals, and the levels of DOPAC can be increased with L-dopa in both 
strains. Again, this suggest that the dopaminergic system is capable of synthesis and 
metabolise and the increase was similar in both strains in all areas investigated. DOPAC 
levels were also elevated by administrating L-dopa and that has been reported before 
(Wesemann et ah, 1993). Furthermore, DOPAC levels became detectable in DRN and 
MRN after L-dopa injection, as did DA levels when 5-HTP was administreted.
The present experiment clearly demonstrates that midbrain 5-HT and DA systems 
projecting to the basal ganglia are physically intact in mutants at this age (though they may 
show cell loss later-chapter 4). Moreover, they can respond to precursor administration 
with synthesis and elevate release. There does appear to be dysfunction of normal 
physiological release mechanisms (as repated previously for the nigrostriatal system and -  
now- for the raphestriatal system).
This does confirm my predictions
a) That a mutation in a basic enzyme such as PKC should affect multiple transmitter 
system.
b) That the AS/AGU rat continues to be a model, which can often insight into human 
conditions where several transmitters systems are affected.
The lack of deficit in 5-HT levels in the MRN leaves open the question of whether striatal 
afferent systems are especially vulnerable and, if so, why?
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6 Experiment 5. Extracellular levels of 5-HT, 5-HIAA, 
DA and DOPAC in the dorsal striatum of AS and
AS/AGU rats.
1 5 2
6.1 Introduction
Campbell and colleages recently documented reduced dopamine levels in the dorsal and 
lateral caudate-putamen of the AS/AGU rat compared to Albino Swiss (AS) controls 
between six and 12 months of age using high performance liquid cluomatography with 
electrochemical detection of micropunch samples (Campbell et ah, 1996; 1998). Similarly, 
Roffler-Tarlov and Graybiel, (1984) revealed that dopamine levels were severely depleted 
in the dorsal striatum of the weaver mouse. One difficulty with interpreting concentrations 
of substances in micropunch samples is that the technique cannot distinguish between 
intra- and extracellular levels of tr ansmitters, so it was necessary to assess the extracellular 
levels of dopamine using microdialysis. In the AS/AGU rats, this technique demonstrated a 
massive (80-90%) reduction in extracellular DA (Campbell et ah, 1998; 2000). The present 
experiment was undertaken to confirm these findings and to extend them to serotonin 
release.
The analysis of chemical events which occur between cells has been difficult. The 
chemical analysis of tissue samples represents a static reflection of synaptic events, mixing 
cells, organelles and extracellular fluid. To obtain a more dynamic picture of the chemical 
interplay between cells in living tissue, microdialysis has been introduced. Microdialysis 
involves perfusing a thin dialysis tube inserted in the tissue. The concentration of 
compounds such as neurotransmitters and metabolites in the emerging perfusate reflects 
their concentration in the extracellular fluid as a result of their diffusion across the dialysis 
membrane.
Micro dialysis has advantages over older techniques such as the push-pull cannula and 
cortical cup techniques. The dialysis membrane over the tip of the probe is the main feature 
of difference between microdialysis and push-pull cannula. Tins difference means that in 
microdialysis there is no need to balance the push of the flow of liquid with the pull of the 
flow. In push-pull cannulae, liquid has to be infused through the tissue and be pulled out 
through the cannula. As a result, there may be damage to tissue which is minimised in
1 5 3
microdialysis. The dialysis membrane also acts as a barrier which improves the sterility of 
the fluid diffusing into the brain and excludes proteins and other macromolecules from 
coming out of the brain which would have to be removed before HPLC analysis. These are 
major advantages over earlier techniques and microdialysis can be performed on most 
organs of the body. An additional feature of microdialysis is the ability to stimulate the 
tissue locally by including substances such as pharmacological agents in the perfusion 
mixture. Neurotransmission and release processes may be examined at the same time as the 
stimulation of receptors by the local administration of a drug via the microdialysis probe 
(Westerink et ah, 1987).
Ultrastructural studies of 5-HT have revealed both synaptic and nonsynaptic terminals. The 
paradigm of nonsynaptic 5-HT neuiotransmission is the supraependymal axon located 
inside the cerebral ventricles (Chan-Palay, 1977). Similary, synaptic 5-HT terminals at'e 
rarely found in the median eminence and cerebral cortex (Calas et al., 1974; Descarries et 
al., 1975). On the other hand, electron microscopic studies reveal that >90% of 5-HT 
terminals in the substantia nigra pars reticulata (SNr) exhibit synaptic complexes 
(Moukhles et al., 1997). The ultrastructure of other serotonergic brain regions exhibits both 
synaptic and nonsynaptic 5-HT terminals (Beaudet and Descarries, 1981; Descarries et al., 
1990; Maley et al., 1990).
A particularly complex situation occui’s in the dorsal raphe nucleus (DRN), the primary site 
of 5-HT cell bodies in the CNS. In this region, 5-HT cell bodies and dendrites accumulate 
5-HT and package it in vesicles, apparently in a releasable form (Hery and Ternaux, 1981; 
Iravani and Kruk, 1997; Bunin et ah, 1998). Early studies suggested that 5-HT 
accumulation was restricted to cell bodies and dendrites (Fuxe, 1965; Loizou, 1972; 
Descarries et ah, 1979, 1982; Baraban and Aghajanian, 1981), but 5-HT axon collaterals 
and terminals appear to exist as well (Mosko et ah, 1977; Liposits et ah, 1985; Chazal and 
Ralston, 1987). Ultrastructural studies suggest that release sites in the DRN are both 
synaptic and nonsynaptic.
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5-HT is similar to dopamine in the nucleus accumbens in which ultrastructuial studies have 
identified abundant synaptic specializations (Garris et ah, 1994). These systems stand in 
dramatic contrast to the glutamate and G ABA systems, in which the most evidence 
suggests classical synaptic transmission (Isaacson et ah, 1993a; Clements et ah, 1996). 
Much of our knowledge on the mechanisms by which central serotonergic neurons release 
5-HT is derived from brain tissue preparations in vitro. From such studies there is 
considerable evidence that 5-HT, like other neui'otransmitters in the brain, can be released 
fr’om the nerve terminal via an excitation-secretion coupled event (for review see Sanders- 
Bush and Martin, 1982). For instance, electrical stimuli or depolarizing agents such as 
potassium ions, evoke the release of preloaded [^H]5-HT or endogenous 5-HT fr om 
perfused or incubated rat brain slices and synaptosomes (Chase et ah, 1969; Elks et ah, 
1979; Farnebo, 1971; Gothert and Weinheimer, 1979; Lane and Aprison, 1977; Mulder et 
ah, 1975).
The brain perfusion method, microdialysis, coupled to higli performance liquid 
cliromatography (HPLC) with electrochemical detection, offers a direct way to study 
release of 5-HT in the brain of the rat in vivo (Sharp et ah, 1989a; Di Chiara, 1990; Sharp 
and Hijoith, 1990). Of great value is the fact that, using this approach, effects of drugs on 
release of 5-HT in the brain can be studied under conditions when exocytosis is limited by 
the omission of calcium from the perfusion medium (Carboni and Di Chiara, 1989; Sharp 
et ah, 1990) and when serotonergic neuronal activity is selectively inhibited by 
administration of the 5-HT i a receptor agonist, 8- hydroxyl-2-(di-n-propylamine) tetralin 
(8-OHDPAT) (Sprouse and Aghajanian, 1986; Sharp et ah, 1989b; Sharp and Hjorth,
1990; Hjorth and Sharp, 1991). Here this methodology has been used to measuie the basal 
levels of 5-HT and its major metabolite 5-HIAA in dialysates of the dorsal striatum of the 
AS and AS/AGU rats.
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6.2 Material and Methods
All animal procedures were in accordance with the Home Office Guidelines and were 
specifically licensed under the Animal (Scientific Procedures) Act 1986, The Home Office 
project licence was 60/2167.
Nine AS and nine AS/AGU animals aged three months were used to determine 
extracellular levels of serotonin and if  s metabolite 5-HIAA in the striatum in freely 
moving rats, dopamine and DOPAC were also measured.
Microdialysis followed by HPLC was used according to the method adopted by Campbell 
et al. (1998). This teclinique allows the monitoring of normal basal neurotransmitter levels 
in conscious animals, and also has the benefit of being able to show the effects of drugs 
administered either before or during the microdialysis process. Samples can be collected at 
a chosen flow rate thus determining sample volume, and neurotransmitters can be detected 
at very low concentrations (picomoles) in protein-ffee samples.
There are three main stages to the extracellular sampling:
1- The surgical procedure,
2- Microdialysis procedure.
3- Transmitter and metabolite analysis.
6.2.1 The surgical procedure
AS and AS/AGU male rats were anaesthetised using Vetalar (Ketamine hydrochloride; 
lOOmg/ml) and Rompun (Xylazine hydrochloride 2%) in a ratio of 2:1.1.P injection was 
given at 1.1 ml/kg of body weight.
When the animal was deeply anaesthetised (usually after 5-10 minutes verfied by toe 
pinching) it was placed into ear bars on a Kopf stereotaxic fr ame (fig 6.1), and the head 
held in place using tooth and nose bars. This stabilised the head to allow a midline incision
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to be made in a pre-shaved area o f the scalp using a scalpel blade, the skin being held back 
from the skull using retractors.
Figure 6.1 A Kopf stereotaxic frame.
The intersection point o f coronal and sagittal cranial sutures (bregma) was identified by 
scraping o f the skull using a scalpel blade, then marked with pencil.
An atlas o f the rat brain (Paxinos and Watson, 1982) was used to locate the dorsal caudate- 
putamen. These coordinates were; 1mm (anterior/posterior), 3.5mm (lateral) and 4.5mm 
(ventral) (fig.6.2). All these coordinates were based on the bregma as starting point.
£
Figure 6-2 Diagram of a coronal brain section at the level of the striatum where 
microdialysis samples were taken. The gray circle indicate the DCPU. From  ^The rat 
brain in stereotaxic coordinates' (Paxinos and Watson, 1982).
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Anterior/posterior and lateral coordinates were used to locate the point on the skull where 
the hole should be drilled by a 1mm drill and marked again by a pencil. The hole was 
drilled very carefully avoiding damaging any tissue beneath the skull. Then the cannula 
was lowered very slowly into the hole until the appropriate ventral coordinate was reached. 
The cannula was secured in place until the end of the experiment by Rediofast dental 
cement. A further two holes were drilled into the skull in an area close to the probe, two 
screws were placed into these holes before the cement was poured over the whole area 
which was contained within a plastic “hat” made by cutting a 5 ml plastic syringe to obtain 
a 1cm deep cylinder. The function of the screws was to secur e the cannula in place. At the 
end of the operation the camiula was kept patent by inseiling a guide cannula into the 
cannula.
Then the rat was removed from the stereotaxic frame and received subcutaneously 0.1ml of 
Antisedan (atipamezole hydrochloride, 5mg/ml) to reverse the effect of the anaesthetic. It 
was important to observe the animal in an incubator until recovery was complete, when it 
was moved back to its cage.
The whole procedure must not exceed 40 minutes to make sure that the animal did not 
recover before the operation finished.
6.2.2 Microdialysis procedure
Microdialysis was started two days after surgery, to allow the rat to fully recover. The rat is 
linked to the microdialysis system. This consisted of a CM A automatic microinjector, a 
series of lengths of narrow bore tubing, a microdialysis probe and a perspex box 
(42x23x41cm). In the box, the rat was fr ee to walk normally on box bedding material with 
easy access to water and food. Also in the top of the Perspex box a metal lever (reflex 
arm) was attached which allowed the rat to move freely while ensuring the safety of the 
probe and tubes.
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Figure 6-3 An image of CMA automatic microinjector and Perspex box with reflex 
arm attached.
The probe was inserted carefully into the cannula while the animal’s head was held 
securely and immobilised. The mirosyringe was attached to the probe’s inflow tubing via a 
connection at the collection port that was situated at the end o f the reflex arm. The outflow 
probe tubing was connected to a plastic collecting vial at this port.
Figure 6-4 Diagram of the same brain section as fig 6.2 with probe attached.
The microdialysis probe is a single cannula type and is a variation on that used by Carswell 
and colleagues (1997). It consists o f a series o f tubing types o f different diameters ranging
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from a 1mm diameter plastic tube down to a silica glass tubing which is situated innermost 
in a concentric arrangement, and has an outer diameter of 25 pm.
The tip of the probe is the active area which consists of a 200 pm ID semi-permeable 
tubular dialysis membrane with a 40, 000 molecular weight cut-off. The pore size is 60Â. 
Microdialysis occurs over the exposed sur face of this membrane, and its length can be 
adjusted to suit the size of the brain area under investigation. Artificial cerebrospinal fluid 
(ACSF) flows into the region where the microdialysis takes place and the dialysed liquid 
then flows back out of the probe via the silica glass tubing that is situated inside the 
microdialysis tubing, the tip of which is plugged with RS epoxy resin.
The dialysis membrane allows the two-way passage of fluid with exclusion of any high 
molecular weight protein matter that would contaminate the sample. Neurotransmitters are 
thus passed through a concentration gradient into the transmitter-free ACSF. This allows 
us to monitor basal extracellular concentrations under standardised conditions as well as 
following pharmacological interventions. ACSF is passed through the probe at a flow rate 
of 2pl per minute via a length of narrow bore perspex tubing (0.28mm internal diameter) 
and is collected after microdialysis in the plastic collecting vial. Samples are collected 
every 20 minutes giving a sample volume of 40pl. No pre-HPLC treatment is required for 
these pure samples, hence they can be either injected onto the HPLC system immediately 
or frozen in liquid nitrogen for injection at a later time.
The animals were allowed to move around freely in the perspex box for a period of 2 hours 
after implantation of the probe before samples were collected (Hjorth and Sharp, 1991; 
Gartside etal., 1992). After that basal samples were collected for period of 4 hours.
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6.2.3 Transmitter and metabolite analysis
5-HT, 5-HIAA, DA and DOPAC analysis was achieved by using HPLC, which consisted 
of a Gilson 305 pump with 805 manometric module, a 71251 Rheodyne sample injector, a 
microbore column and an ANTEC intro electrochemical detector. The column (stationary 
phase) was a Hichrom microbore reverse phase column with a Cl 8 0D S2 5pm packing 
gel. This allowed effective and consistent separation o f indole- and catecholamines when 
used with a buffered mobile phase consisting of: Citric acid (83 mM), EDTA (ImM), 
Disodium Hydrogen Phosphate (43mM), Octane Sulphonic Acid (0.2mM) and Methanol 
(10%). PH was 3.5.
Figure 6-5 An image of HPLC-ECD showing (from left to right) a Gilson pump, 
sample injector, intro electrochemical detector and data collection (computer).
A lOOpl sample loop was used on the injector to ensure that the whole sample (45pl) was 
injected onto the column. This maximised the amount o f detectable neurotransmitter. 
Before injecting the samples, a composite standard which contained all o f the detectable 
amines and metabolites (5-HT, 5-HIAA, DA and DOPAC) was injected at a concentration 
o f 10 nanograms per ml for each. An internal standard (DHBA) was added to the 
composite mixture at the same concentration.
There are two main functions o f  using the composite mixture, 1 - it was used to determine 
the time that it takes each substance to be eluted from the column, and detected by the
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BCD (retention time). 2- the peak areas from the resulting composite chromatogram are 
used to calculate the response factor (RF) for each substance,
A typical 45 pi microdialysis sample contains 40 pi of dialysate and 5 pi of DHBA at the 
same concentration as in the composite standard. With some experiments, a sample volume 
of slightly less than 45 pi was injected due to a smaller return per 20 minutes via the 
microdialysis probe. The 5 pi of DHBA (internal standard) was added in order to obtain a 
peak from each sample that represented a known concentration. This internal standard was 
chosen because it is stable, is not found in the brain, and it is not known to react with any 
of the indole- or catecholamines present in the sample. The DHBA peak area was used to 
calculate the unknown concentration of amines within the sample.
From the chromatograms, the order of the elution of the internal standard and 
nem'ochemicals under investigation can be seen. The peaks of 5-HT, 5-HIAA, DA and 
DOPAC are identifiable by their retention times, a line drawn underneath the peaks, and 
the areas calculated by computer software.
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Results were analysed and quantified using the following equations:
1“ Response factor (RF) = Area of internal standai'd in composite standard
Area of Amine in composite standard
2- RF used to calculate the final figures for each 5-HT and 5-HIAA as follow:
Peak Concentration = Area of Amine_______   x RF
Area of internal standard in sample
The final concentrations are expressed as picogiams per 45 pL
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6.3 Results
The dorsal caudate-putamen is an important projection area for serotonergic cells of the 
dorsal raphe nucleus (Azmitia and Segal, 1978; Bobillier et al., 1976; Dray et al., 1978; 
Parent et a l, 1981; Steinbusch, 1981; Steinbusch and Nieuwenhuys, 1983) as well as for 
dopaminergic cells of the substantia nigra pai s compacta. AS/AGU mutants have 
significantly reduced extracellular levels of serotonin and dopamine which are less than 
30% and 20% respectively of levels found in the parent AS strain. By contrast, levels of 
their metabolites in the extracellular fluid of the dorsal caudate-putamen ai e substantially 
elevated in the AS/AGU mutant; thus, 5-HIAA levels are some three times higher in the 
mutant than in the parent strain, while DO?AC levels are approximately quadrupled.
AS AS/AGU t
5-HT 291 ±34 82.9 ±21 5.20 p < 0.001
5-HIAA 81+6.1 280 ± 36 5.42 p <  0.001
DA 126 + 11 20.2 ± 1.9 9.82 p <  0.001
DOPAC 15.67 ±1.1 57.9 ±3.7 11.06 p <  0.001
Table 6.1. Extracellular levels of serotonin (5-HT) and its metabolite 5- 
hydroxyindoleacetic acid (5-HIAA), together with dopamine (DA) and its metabolite 
dihydroxyphenylacetic acid (DOPAC) in the dorsal caudate-putamen of Albino Swiss 
(control) and AS/AGU (mutant) rats. All figures are mean pg/20 mins ± SEM (n = 9 
per group). Significance levels are based on a two-tailed distribution.
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Figure 6.6 Extracellular levels of 5-HT in the dorsal caudate-putamen measured with 
HPLC-ECD.
Two Sample T-Test and Confidence Interval
Two sample T for C13(AS) vs Cl4 (AS/AGU)
AS
AS/AGU
Mean
291
82.9
St Dev 
102 
63. 3
SE Mean 
34
21
95% Cl for mu C13 - mu C14: ( 121, 294)
T-Test mu C13 = mu C14 (vs not =): T = 5.20 P < 0.002 DF = 13
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Figure 6.7 Extracellular levels of 5-HIAA in the dorsal caudate-putamen measured 
with HPLC-ECD.
Two Sample T-Test and Confidence Interval
Two sample T for Cl6 (AS) vs Cl7 (AS/AGU)
AS
AS/AGU
Mean
81.0
280
StDev
18.4
109
SE Mean 
6 . 1  
36
95% Cl for mu C16 - mu C17: ( -283.5, -114)
T-Test mu C16 = mu C17 (vs not =): T = -5.42 P < 0.006 DF =
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Figure 6.8 Extracellular levels of DA in the dorsal caudate-putamen measured with 
HPLC-ECD.
Two Sample T-Test and Confidence Interval
Two sample T for C6(AS) vs C7(AS/AGU)
N Mean StDev SE Mean
AS 9 126.0 31.8 11
AS/AGU 9 20.17 5.67 1.9
95% Cl for mu AS - mu AS/AGU: (81, 130.7)
T-Test mu AS = mu AS/AGU (vs not =): T = 9.82 P < 0.001 DF
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Figure 6.9 Extracellular levels of DOPAC in the dorsal caudate-putamen measured 
with HPLC-ECD.
Two Sample T-Test and Confidence Interval
Two sample T for CIO (AS) vs Cll (AS/AGU)
AS
AS/AGU
Mean 15. 67 
57.9
StDev
3.32
1 1 . 0
SE Mean 
1.1 
3.7
95% Cl for mu CIO - mu Cll: ( -50.9, -33.6)
T-Test mu CIO = mu Cll (vs not =): T = -11.06 P < 0.001 DF = 9
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6.4 Discussion
The dorsal raphe nucleus (DRN) is the origin of most ascending serotonergic neurons and 
is almost exclusively the source of the raphe-striatal pathway (Azmitia and Segal, 1978, 
Bobillier et al., 1976; Dray et al., 1978; Parent et al, 1981; Steinbusch, 1981; Steinbusch 
and Nieuwenhuys, 1983). Serotonin (5-HT) released in the caudate nucleus can be 
controlled by presynaptic mechanisms (Hamon et al, 1974) involving axoaxonic contacts. 
However, striatal amine release is also controlled by nerve activity generated at the cell 
body level, i.e. in the DRN (Hery et a l, 1979). Thus, stimulation of DRN 5-HT cell bodies 
which modifies the activity of these neurons enhances 5-HT release at the nerve endings 
(Ashkenazi et a l, 1972; Fujjiwara et a l, 1981; Hery et a l, 1979). Several neurotransmitters 
such as GAB A (Aghajanian and Wang, 1978) or L-glutamic acid (Aghajanian, 1972, 
Baramwell and Gonye, 1976) control the activity of DRN 5-HT neurons. Among them, 5- 
HT alone plays an important role. Perfusion of 5-HT or 5-HT agonists into the DRN causes 
a rapid inhibition of the activity of serotonergic neurons (Aghajanian et a l, 1968) and 
prevents 5-HT release at the nerve ending ( Sharp et a l, 1989).
The fact that injection of 5-HT into the DRN is able to modify the electrical activity of the 
5-HT ascending pathway is particularly interesting as has been demonstrated that 5-HT can 
be synthesised and released in the DRN (Hery et a l, 1982).
The basal levels of 5-HT and its metabolite 5-HIAA in control AS rats were comparable 
with those reported by other groups (Price and Lucki, 2001; Balcioglu et a l, 2003) and in 
the case of DA and its metabolite DOPAC in AS animals were also similar to those 
reported previously in the same lab some years ago (Campbell et al, 2000; Payne et al, 
2000). AS/AGU mutants rats showed a reduction in both 5-HT and DA together with an 
increase in their metabolites 5-HIAA and DOPAC respectively.
One possible cause of the extracellular reduction in both amines in the mutant rats is the 
reduction in the cell numbers. However, in the case of 5-HT there were only a 23% 
reduction in serotonergic cells in DRN in the mutants while the drop in extracellular 5-HT
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levels was about 70%. Moreover, the dopaminergic cells loss was about 40% in the mutant 
at one year old, while the drop in extracellular DA levels reached 90% in the mutant rats 
compare to the paient AS rats.
Furthermore, although transmitter levels declined, metabolite levels (5-HIAA and 
DOPAC) substantially increased. This again is not an obvious result of cell loss. It could, 
however, be the result of a failure of mechanisms associated with synaptic vesicle 
formation, in which case a) reduced amounts of transmitter would be available for release 
with b) transmitters located free within the cytoplasm of the synaptic terminal and 
available for metabolism via mitochondrial enzymes. Such a possibility has already been 
proposed for DA in the AS/AGU rat (Campbell et al, 2000; Payne et a l, 2000). A similar 
disruption to normal vesicular sequestering could underlie the results obtained here for 5-
HT and 5-HIAA.
What is clear from this present study is that 5-HT/5-HIAA levels in the striatum mirror 
those already found for DA/DOPAC and therefore, this suggests a shared mechanism of 
dysfunction.
170
7 Experiment 6. Spontaneous locomotion of the AS and 
AS/AGU rats: Strain differences and response to 
serotonin manipulation
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7.1 Introduction
AS/AGU rats have serious movement impairments which particularly affect the hind limbs 
causing rigidity, a staggering gait and falling over every few steps (Clarke and Payne,
1994; Payne et al., 1998). A variety of simple tests have been useful tools to show the 
disruption of motor performance in adult AS/AGU rats compared to the parent AS strain 
(Payne et al, 1998). One such test is Mid-Air Righting where animals are held upside down 
50 cm above a soft substrate and dropped. Rats are usually able to turn around within a 
vertical drop of 20 cm to land on all fours and thus the success rate of control AS animals 
is virtually 100% until one year old when success declines. In contrast, AS/AGU mutant 
rats have an initial success rate of only 60% and this shows a steep decline over the period 
of a year after birth. Another test is the inclined ramp test where rats attempt to walk down 
a series of inclined wooden ramps 85 cm long and of varying widths, into a large container 
filled with wood chips. This is best illustrated with a ramp of 70mm width angled 
downwards at 14  ^where AS rats show no decrease in performance over a year while 
AS/AGU rats were increasingly unable to negotiate the plank without falling off (Payne et
al., 2000).
The role of 5-HT has been investigated in many behavioural activities. Thus, studies using 
raphe lesions showed that 5-HT is involved in sleep (Jouvet, 1972), general activity levels 
(Kostowski et al, 1968; Lorens et al, 1971; Neill et al, 1972; Vergues et al, 1973; Veignes 
et al, 1974), habituation (Davis and Sheard, 1974), aggression (Vergnes et al, 1973; 
Vergnes et al, 1974), pain sensitivity and morphine analgesia (Harvey et al, 1974; Hole and 
Lorens, 1975; Lorens and Yunger, 1974), avoidance behaviour (Hole and Lorens, 1975; 
Lorens, 1973; Lorens et al, 1971; Lorens and Yunger, 1974), self- stimulation (Lorens, 
1971) and water consumption (Lorens et al, 1971; Lorens and Yunger, 1974).
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Many methods have been used to reduce brain 5-HT levels, among them electrolytic 
lesioning of the 5-HT-containing cells of the midbrain raphe nuclei (Dahlstrom and Fuxe, 
1964), systemic injection of p-chlorophenylalanine (PCPA), an inhibitor of tryptophan 
hydroxylase (Koe and Weissman, 1966) or the halogenated phenethylamine, p- 
chloroamphetamine (PCA), which is toxic to 5-HT neurons (Harvey et al, 1975; Kohler et 
al, 1978; Sander-Bush and Steranka, 1978; Massari et al, 1978), as well as intracerebral 
administration of the neurotoxic 5-HT analogs 5-6 and 5-7- dihydroxytryptamine (DHTs) 
which selectively destroy 5-HT nerve terminals in the CNS under specific conditions 
(Baumgarten et al, 1976; 1978; Rotman, 1977; Bjorklund et al, 1975).
On other hand, 5-HT can be increased by systemic administration of the 5-HT precursor 5- 
hydroxytryptophan (5-HTP), which enters the brain and is decarboxylated by L-aromatic 
amino acid decarboxylase to form 5-HT. In normal physiological conditions, this enzyme 
is not saturated with its substrate, so that administration of 5-HTP leads to increased 
synthesis of 5-HT (Moir and Eccleston, 1968) and an increase in levels of 5-HT and its 
metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in the brain (Moir and Eccleston, 1968; 
Okadaet al, 1972;).
The purpose of this experiment is to observe the role of 5-HT on spontaneous locomotion 
within the cage environment. This was done by measuring the basal activity in a group of 
animals and then administering either a) the 5-HT precursor, 5-HTP or b) the 5-HT 
synthesis inhibitor p-chlorophenylalanine (PCPA) or c) Saline. In each case the activity 
level was measured by means of a computerised infrared sensor system in both AS 
(control) and the mutant rats AS/AGU.
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7.2 Material and Methods
In this chapter two sets o f experiments have been carried out. Initially, a comparison o f the 
spontaneous locomotion o f AS and AS/AGU rats was made using Infrared movement 
analysis. Experiment two was then undertaken to see the effect on locomotion o f 5-HT 
depletion (using PCPA) and 5-HT increase by administration o f 5-HTP.
7.2.1 Experiment 1. Comparison of spontaneous locomotion of AS and 
AS/AGU rats
Twenty-seven AS and twenty-seven AS/AGU male rats aged six months were used in this 
experiment where spontaneous locomotion activity within the cage environment was 
studied using the computerised infrared sensor system, which is illustrated in fig.7.1.
Figure 7.1 An image of infra-red apparatus showing cages with infra-red sensors 
which are attached to the computer (data collection).
With a Coulbum Instruments infrared motion activity system, the measurement of  
movements within the cages was detected in three dimensions, and recorded information 
included the number and duration o f movements based on pre-programmed criteria.
The infrared sensor was fixed firmly at the top o f a cage whose dimensions were 50x32x18 
cm. The sensor was facing into the cage at an angle o f 45° to make sure that activity in all 
areas o f the cage was detectable. The sensors were connected to a computer with a 
software package where the data could be collected and then analysed. The activity was 
measured over a six hour time period, with data being reported every five minutes. The
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data collected include small movements (1-3 seconds duration), and large movements 
(more than 3 seconds. One advantage of not recording movement lasting less than one 
second is to eliminate natural phenomena such as breathing, or tremor in the case of 
mutants.
7.2.2 Experiment 2. The effects of serotonergic manipulation on 
locomotion
Twenty seven AS control and twenty seven AS/AGU male rats aged six months were 
assessed. Activity was measured over a six hour time period, with data being reported 
every five minutes. The data collected include small movements (1-3 seconds duration), 
and large movements (more than 3 seconds) as described above.
When spontaneous movement had been quantified the animals were split into 3 groups 
which were tested on a subsequent occasion after receiving either
i) p-chlorophenylalanine
Ten AS and ten AS/AGU rats were given DL-p-chlorophenylalanine methyl ester 
hydrochloride (PCPA) (Sigma Aldrich Co Ltd., Poole, Dorset) intraperitoneally (i.p.) (100 
mg/kg) dissolved in 0.9% NaCl or 0.9% NaCl vehicle alone. All doses were injected at 
10:00 in the morning and the testing for six hours began at once,
ii) 5-hydroxytryptophan
Ten AS and ten AS/AGU rats were given 5-hydroxy-L-tryptophan, Hydrochloride (5-HTP) 
(Calbiochem., La Jolla, CA) 50 mg/kg dissolved in (i.p) 0.9% NaCl or 0.9% NaCl vehicle 
alone. All doses were injected at 10:00 in the morning and the testing for six horns started 
at once. Each injection was preceded by an injection of the peripheral decarboxylase 
inhibitor Carbidopa (Sigma Aldrich Co Ltd., Poole, Dorset) intraperitoneally (i.p.)
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(Darwish and Furman, 1977; Koshikawa et al., 1990; Datla and Curzon, 1997)(25 mg/kg) 
dissolved in 0.9% NaCl, 30 minutes prior to 5-HTP treatment (Eble and Goodrich, 1987). 
This ensured that the administrated 5-HTP was being metabolised in the brain only.
iii) Saline
Fourteen AS and fourteen AS/AGU rats were given a saline (i.p) injection. All doses were 
injected at 10:00 in the morning and the testing for six hours started at once
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7.3 Results
7.3.1 A comparison of spontaneous locomotion levels in AS and AS/AGU 
rats
Twenty-seven AS and 27 AS/AGU male rats were put in cages with infra-red monitors for 
6 hours
AS/AGU mutants exhibit far more small movements ( < 3 seconds) and large movements 
(> 3 seconds) than AS controls. See Table 7.1. The differences are highly significant (p <
0 .001).
Small movements Large Movements
AS 97.6 + 12 15.9 ±2.0
AS/AGU 193.5 ±16 43.7 ±6.6
t
4.81,df=52, p< 0.001 4.03, df = 52, p < 0.001
Table 7.1 The number of small (< 3 secs) and large (> 3 secs) movements made per six 
hours by AS and AS/AGU male rats aged six months.
7,3.2 Second experiment. What are the effects of treating AS and 
AS/AGU rats with saline (control), pCPA or 5-HTP ?
Because of the differences in movement between the two groups found above, it was 
decided to analyse movement in response to pharmacological treatments in terms of 
percentage (%) change over basal levels. Animals were tested a) before treatment b) after 
treatment
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a) small movements A general linear model analysis shows no significant vaiiance foi 
group (AS V AS/AGU) but a highly significant variance for treatment (F = 166.23, d f= 
2, p < 0.001). Saline treatment produced no significant change over basal levels, but 
pCPA treatment reduced movement (significantly so in the case of AS rats), while 5- 
HTP treatment significantly raised movement in both groups (p < 0.05). 
t)) large movements. A general linear model showed significant variance due to both 
group (AS V AS/AGU, F = 16.57, df = 1, p < 0.001) and treatment (F = 134.14, df= 2, 
p < 0.001). Saline treatment produced no significant change over basal levels, but 
pCPA treatment reduced movement significantly in both groups of rats, while 5-HTP 
treatment significantly raised movement in both both groups (p < 0.05). However, the 
percentage increase in response to 5-HTP was substantially greater in AS/AGU 
mutants than in controls, and this appears to be the contributing factor to the significant 
variance due to gioup.
178
% change AS AS/AGU
i) Small 
movements
Saline 2.5 ±1.2 - 5.86 ±2 ns
PCPA -55.0 ±8 - 32.7 ± 7 ns
5-HTP 99.8 ± 4 101.5 ±3 ns
ii) large 
movements
Saline 3.63 ± 1 1.14 ±0.8 ns
PCPA -51.7 ±9 - 43.8 ± 6 ns
5-HTP 64.4 ±5 150.0 ±6.8 P < 0.05
Table 7.2 The percentage change in the number of small (< 3 secs) and large (> 3 secs) 
movements made over a six-hour period by AS and AS/AGU rats treated with saline, 
PCPA or 5-HTP.
General Linear Model: Small versus group, treat
Analysis of Variance for Small, using Adjusted SS for Tests
Source DF Seq SS Adj SS Adj MS F P
group 1 722 574 574 0.87 0. 354
treat 2 218342 218342 109171 166.23 0. 001Error 51 33495 33495 657
Total 54 252559
One-way ANOVA: Small versus treatb
Analysis of Variance for Small
Source DF SS MS F Ptreatb
Error
Total
5
49
54
221252
31307
252559
44250
639 69.26 0.001
Individual 95% CIs For Mean 
Based on Pooled StDevLevel N Mean StDev11 8 2.50 14 .76 Ç —, —1 ^  M ^12 7 -5.86 10.79 ( —  *--)21 10 -55.00 6. 82 ( — *— )22 10 -32.70 9. 15 (-“•*")31 10 99. 80 36.75 (-32 10 101.50 41.84 (-— +---------- +---------- +-------- —  'j
Pooled StDev = 25.28 
Tukey's pairwise comparisons
-60 0 60 120
General Linear Model: Large versus group, treat
Analysis of Variance for Large, using Adjusted SS for Tests
Source DF Seq SS Adj SS Adj MS F Pgroup 1 15944 15290 15290 16.57 0.001treat 2 247546 247546 123773 134.14 0.001ErrorTotal 5154
47057
310547
47057 923
One-way ANOVA: Large versus treatb
Analysis of Variance for Large
Source DF SS MStreatb 5 285173 57035Error 49 25375 518Total 54 310547
Level N Mean StDev11 8 3. 63 18.8812 7 1. 14 17 . 9221 10 -51.70 8.5022 10 -43.80 11.4431 10 64 .40 21.7732 10 150.00 40.64
Pooled StDev = 22.76
F
110.14
P
0 . 0 0 0
Individual 95% CIs For Mean Based on Pooled StDev
 1--------------------------- 1--------------------1—
{ - * - )
(“ *-)
(-*-)
( _ * _ )
( - * - ) +---------------- +--------------+-----
0 70 140
Tukey's pairwise comparisons
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7.4 Discussion
As described previously (Payne et al., 2000) the AS/AGU mutant rat is characterized by 
many locomotor defects ranging from rigidity to falling every few steps. Simple tests like 
the inclined ramp test and mid-air righting show marked differences between the 
performance of AS/AGU and the parent AS rats. Administration of L-Dopa plus the 
peripheral Dopa decarboxylase inhibitor benserazide have improved the success in 
locomotor tests (Campbell et al, 1997; Russell et al, 1998).
A wide variety of locomotor tests have been used to examine animals which have received 
toxic substances (Jolicoeur et al., 1979; Ivens, 1990) or animals with mutations which lead 
to locomotor dysfunction such as the shaker rat (Wolf et al., 1996) or weaver mouse 
(Eisenman et al., 1998). Locomotor testing has been used intensively in models of 
Parkinson’s disease such as the rat 6-OH-DA model (Sakia and Gash, 1994; Borlogan et 
ai., 1996; Mukhida et al., 2001) and in non-human primates and mice with MPTP lesions 
(Herrero et al., 1993; Gnalalingham et al., 1995; Moratalla et al., 1992; Rosas et al., 1998; 
Fredriksson et al., 1990; Nishi et al., 1991). In most of these studies, spontaneous general 
locomotor activity has been observed and considered as a valuable tool for assessing 
ti'eatment with drugs or toxins (Borbgan et al., 1996; Doan et al., 1999; Med et al., 1994). 
However, more specific tests have proved useful in some circumstances. For example, the 
handgrip test has been studied in monkeys (Rouiller et al., 1998; Lemon et al., 1996) and 
rodents (Ivens, 1990; Gad, 1982) to observe motor control of fingers. Gait analysis has 
been found to be a useful tool in measuring locomotors deficits, with paiameters such as 
stride length, gait width, and gait symmetry used to observe the abnormal gait patterns 
(Wolf et al., 1996). Similar tests Include placement of forelimb and hind limb (Wolf et al., 
1996), the ability to walk along a rod, and to right in mid-air and on a surface (Wolf et al., 
1996; Gad, 1982).
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One interesting use of locomotor tests was to examine the improvement of spontaneous 
motor activity after introducing L-dopa treatment to MPTP-treated mice where the 
spontaneous motor activity had decreased (Fredriksson et al, 1990).
5-HT has been found to increase locomotor activity after administration of L- tryptophan 
or 5-HTP in combination with a monoamine oxidise inhibitor or peripheral decarboxylase 
inhibitor (Modigh, 1973; Magyar et al., 1978; Clarke et al., 1984). More recent work on 
lesioned cats found that serotonin, its precursor 5-hydroxytryptophan (5-HTP) and the 
agonist quipazine improved locomotion (Brustein and Rossignol, 1999). Furthermore, 
decreasing 5-HT levels by PCPA was found to reduce locomotion (Marsden and Curzon, 
1977; Matte and Tornow, 1978) and exploration (Dringenberg et al, 1995).
Spontaneous locomotion measurement can be affected by external factors such as fear, 
frustration, sudden noise, light and dark and exploration to the novel environment. It is 
necessary to keep the environment and experimental conditions under strict control so that 
spontaneous movement is a reflection of treatment as much as possible.
The motivation for spontaneous locomotion may include feeding, exercise, or curiosity.
In this study the mutant rat is far more active than the control; this could be because its 
clumsier movement causes more activition of the sensor but it could also be less able or 
willing to settle in the cages.
Adminstration of 5-HTP to both strains increased both small and large movements, which 
agrees with many previous studies (Grahame-Smith, 1971; Magyar et al, 1978; Modigh, 
1972; Modigh and Svensson, 1972; Schlosberg and Harvey, 1979; Stewart et a l, 1976).
By eontrast, administration of PCPA (5-HT synthesis inhibitor) has led to decreased 
locomotor activity in both strains in large and small movement to a smiliar degree with 
slightly greater effect in large movement in mutant rats.
Decreased movement with PCPA has been previously reported by Marsden and Curzon, 
(1976) Matte and Tomow, (1978) Steigrad et a l, (1978). Moreover, lesioning midbrain
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raphe nuclei leads to suppressed open-field activity (Bouhuys and Van den Hoofdakker, 
1977; Dray et al, 1978; Jacobs et al., 1975; Kohler and Lorens, 1978; Lorens et al., 1976). 
The above drugs have opposing effects on 5-HT content of brain, with 5-HTP increasing 
the amine while PCPA decreasing it. In the case of 5-HTP the micropunch data (chapter 4) 
in this study confirm this.
It is wholly unclear what determines the amount of spontaneous locomotion carried out by 
an animal in a given time. When an animal is put into a new cage, as in my present 
experiment, the amount of locomtion could reflect any (or all) of :
2) Exploration of a novel environment
3) The establishment of territorial ownership
4) Assertiveness versus fear within a novel situation
5) Relative dexterity of (or ability to initiate) movement
Similiaiy, when any pharmacological treatment is administered, it is unclear whether the 
treatment affects locomotion directly or whether it is altering motivation and, hence, 
movement by indirect means. In this context, it is of interest to note that 5-HT has been 
reported to influence emotionality, territoriality and exploration.
A relationship between the 5-HT system and emotionality has been found in that hyper­
emotionality is reportedly linked to the hyper-activity of serotonergic neurons (Li et al., 
1995), Moreover, both 5-HT receptors and serotonin transporters also have influence on 
modulation of emotionality (Tsuji et al., 2000; Murphy et al., 2001)
The steady basal serotonergic activity recorded in the dorsal raphe neurons in cats has been 
shown to be decreased during sleep and increased with arousal (Jacobs and Fornal, 1999). 
Supporting data were obtained fi'om microdialysis studies, which showed that various 
stressful and nonstressful conditions caused a similar increase in extracellular' 5-HT in 
several forebrain sites (Rueter and Jacobs, 1996; Wilkinson et al., 1996). In addition, the 
relation between 5-HT and territoriality have been reported (Lasley and Thurmond, 1985).
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Serotonin depletion causes iong-tenn reduction of exploration in the rat (Lipska et al, 
1992). Moreover, 5-HTia agonists are found to enhance exploratory process in hamsters 
(Buhot et al., 1989) and the involvement of 5-HT in exploration has been reported by 
Meert et al., (1992; 1997) and reviewed by Insel and Winslow, (1998).
Furthermore, 5-HT has been reported to have an effect on anxiety, which may influnce 
movement (Graeff et al., 1996; Artaiz et al., 1998; Malleret et al., 1999).
Open field testing (roughly similar to our appar atus) is one of the most traditional and 
widely used methods for the assessment of emotionality (Tobach, 1969; for review; see 
Archer, 1973) exploratory behaviour (Cuomo et al., 1996) and anxiety (Henderson and 
Flint, 2001).
Although I canot say what the underlying motivation for the spontaneous locomotion seen 
here is,
a) Tests of spontaneous locomotion ar e amongst the most widely used simple 
neuropsychological studies.
b) Both strains respond similarly to 5-HT manipulation despite the massive 
differences in normal 5-HT content and release noted in experiments (4,5).
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This study was undertaken primarily to see if the raphe-striatal serotonergic system was 
affected in the AS/AGU rat (which carries a mutation in the gene for protein kinase C-y 
(Craig et aL, 2001)) similar to the dysfunction already reported in the nigrostriatal 
dopaminergic system (Campbell et al., 1998; Payne et al., 2000). The programme of work 
consisted of several complimentar y studies, each of which has been reported separately 
with its own Discussion. The purpose of this short overall Discussion is therefore to review 
these and to put the work in a broad context by posing a series of questions.
Has the mutation been correctlv identified?
This was confirmed to be the case by finding positive immunostaining for PKC-y in AS 
rats in several brain regions (cerebellum, hippocampus, cerebral coidex, striatum, 
substantia nigra and dorsal and median raphe nuclei) but negative staining in the AS/AGU 
mutant. The areas chosen for examination were those which were found positive for PKC-y 
in previous studies (Huang et al., 1988; Saito et al., 1994; Tsujino et al., 1990; Yoshihara 
et al., 1991)
Is PKC-y restricted to the nervous system and what other PKC isoforms occur there?
It used to be thought that PKC-y was restricted to the nervous system (Saito et al., 1988) 
but Goodnight and colleagues (1995) have found it expressed in fibroblasts. More recent 
work has shown it to be expressed in kidney epithelial cells also (Nowicki et al., 2000).
The function of PKC-y is poorly understood in the nervous system (see Introduction) and 
wholly unknown in non-neuronal tissues.
Several studies have shown that other isoforms (a,p,y,s,0,ô,r|,A.) of PKC are also expressed 
in the brain (Saito et al., 1994; Tsujino et al., 1990; Yoshihara et al., 1991) and at least a  
and P have been shown to have role in transmitter on packaging and release (Ben-Shlomo 
et al., 1991). We have no information on whether other PKC isoforms are up-regulated as a 
result of the loss of PKC-y.
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Does the dorsal raphe nucleus provide afferents to the dorsal caudate-putamen?
The use of retrograde tracers (CTb) confirmed the rostral projection from the DRN to the 
striatum while the MRN projects elsewhere. This agrees with previous studies (Azmitia 
and Segal, 1978; Bobiller et al., 1979; Imai et al., 1986). Azmitia and Segal (1978), and 
Imai and colleagues (1986) found that axons from the DRN project mainly to the caudate- 
putamen, amygdala and substantia nigra pars compacta. By contrast, the MRN projects 
mainly to the hippocampus, hypothalamus and mammillary body (Azmitia and Segal,
1978; Van der Kar and Lorens, 1979; Bobiller et al., 1979).
The DRN cells which project to the DCPU are distributed throughout the length of the 
DRN. Even if the number of cells projecting to the DCPU seem to be small, their influence 
on their target sites can be substantial since it is estimated that there are up to 6x 10 
serotonergic varicosities/mm^ in parts of the rat brain (Audet et al., 1989).
Does the mutation lead to decreased cell numbers in the midbrain, raphe nuclei?
My first step to investigate the effect of the mutation on the serotonergic system was to 
compare the cell numbers of DRN and MRN in the mutant rat and the parent AS strain.
Cell counts using both conventional and unbiased stereology methods showed that 5-HT 
cell numbers in the DRN of mutant rats were reduced by 23% compared to the parent AS 
strain. The change looks to be restiicted to the DRN, since no change in cell numbers was 
found to occur in the MRN of the mutant rats.
As is well established, the DRN is the sole source of the serotonergic projections to the 
striatum. The reduction in cell numbers could affect the availability of 5-HT in the striatum 
and this will be discussed below.
It is not clear why one nucleus (DRN) is affected and the other (MRN) is not. However, 
recent paper by Kovacs and colleagues (2003) reported selective loss of cells in different 5- 
HT groups according to paificulai' human disorders. It does appeal’, therefore, that we 
should not expect all 5-HT cell groups to react similarly to a single circumstance or 
condition.
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It does not seem that serotonergic cell numbers have been counted in lab models designed 
to replicate PD (e.g. 6-OH-DA or MPTP models), but the loss of serotonergic cells in the 
DRN of human PD patients has been reported by Jellinger (1992) as 44% in post mortem 
brains. In this present study the loss of DRN cells was 23% in one-year-old animals which 
might subsequently become comparable with what Jellinger (1992) found with PD 
patients. We are restricted by HO licence in the age to which we can keep the mutant rats. 
On the other hand, we do not know when cell loss occurs. Animal may be bom with 
reduced cell numbers or acquire loss subsequently. Nor do we know how cell numbers 
change in the AS rat with age. But serotonin neuron loss in normal human ageing has been 
linked to neuropsychiatrie disorders (Meltzer et al., 1998). It is known that old rats show 
lower levels of serotonin and dopamine (Goicoechea et al., 1997).
Is there a decrease in available 5-HT in the striatum- a confirmed target of DRN cells?
The whole-tissue study conducted here found that 5-HT levels were reduced in the striatum 
and in the DRN, but no affect was noticed in the MRN. This is to be expected given the 
observations on differential cell loss.
The microdialysis study showed that the extracellular levels of 5-HT in the mutant rats are 
reduced by 70% compared with normal animals. Since 5-HIAA levels in the dialysate were 
greatly elevated, this does not suggest a simple relationship to cell loss or dysfunction. 
Most of these results found with 5-HT systems in the AS/AGU rats are very similar to 
those found previously for the nigrostriatal dopaminergie system (Campbell et al., 2000; 
Payne et al., 2000). This indicates that the mutation of PKC y may affect both 
dopaminergic and serotonergic systems in a similar fashion. It is not clear if the effect is a 
direct one on the two cell groups or if the effects on one cell group subsequently effects the 
other also.
To shed light on that we have to understand potential links between 5-HT and DA.
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The interaction between DA and 5-HT systems are well known (Benloucif and Galloway, 
1991; Parsons and Justice, 1993; Iyer and Bradberry, 1996) for review see Broderick and 
Phelin, (1997). These include: -
i) Anatomical connections between the two aminergic systems
There are projections fi'om the DRN to DA cell bodies in the ventral tegmental area,
substantia nigra and striatum (Steinbush et ah, 1980; Van der Kooy and Hattori, 1980,
Herve et ah, 1987). More detailed studies have shown that serotonergic neurons make
direct synaptic contact with DA cell bodies and dendrites in the SN and VTA (Corvaja et
ah, 1993; Herve et ah, 1987; Needergaard et ah, 1988). Other studies have demonstrated
that 5-HT neurons projecting to the SN appear to be collaterals of 5-HT neurons projecting
from the dorsal raphe to the striatum (Imai et ah, 1986; Van der Kooy and Hattori, 1980).
In addition, Ferre and Arigas (1993) have indicated that DA from projections from the
substantia nigra or the ventral tegmental area may increase 5-HT release in the DRN
ill Neuronhvsiological connections between the aminergic svstem
When the DRN is stimulated (or 5-HT agonists and antagonists are administered directly to 
the SN or the ventral tegmental area) modulation of the electrophysiological activity of 
dopaminergic neurons has been reported (Brodie and Bunney, 1996, Cameron et ah, 1997, 
Kelland et ah, 1990; Minabe et ah, 1996; Pessia et ah, 1994; Prisco et ah, 1994; Trent and
Tepper, 1991).
For example, experiments using microdialysis have shown that dopamine release is 
facilitated by serotonin agonists (Benloucif and Galloway, 1991) as is dopamine release in 
the cerebral cortex (Iyer and Bradberry, 1996). Similarly, Parsons and Justice (1993) have 
shown that serotonin perfusion leads to increased extracellular dopamine in the nucleus 
accumbens.
A reciprocal relationsliip has also been demonstrated. Thus dopaminergic regulation of 5- 
HT release has been reported in vitro within the SN (Benkirane et ah, 1987; Hery et ah, 
1980; Iravani and Kiukl997; Kelly et ah, 1985). In vivo studies (Chen et ah, 1992) have 
also confirmed a link, showing that apomorphine can elevate tryptophan, serotonin and 5-
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HIAA concentrations in the DRN and its corresponding projection site, the striatum, but 
not in the MRN and its terminal area, the hippocampus. These effects are mediated tlrrough 
DA in the SN. In addition, Ferre and Aiigas (1993) have indicated that DA from 
projections from the substantia nigia or the ventral tegmental area may increase 5-FIT 
release in the DRN. Ferre et al. (1994) have shown DA D2-like receptor-mediated 
regulation of serotonin in the DRN.
All these studies indicate that reciprocal interactions between serotonergic and 
dopaminergic systems occur in different brain areas including the midbiain nuclei and the
striatum.
It is not possible, therefore, to decide between
a) The mutation having a direct affect on two cell groups independently or
b) The mutation affecting one cell group which, in turn, leads to a dysfunction of the
other.
The fact that the mutation is in the gene for a protein kinase that may be involved in 
transmitter packaging and release might tend towards the first explanation, but this cannot
be proposed with certainty at this stage.
Should we expect dysftinction of more than one transmitter system in conditions
involving the basal ganglia and/or locomotor disorders?
Involvement of 5-HT in many neui'odegenerative disorders has been reported. Jellinger 
(1992) has indicated that raphe cell numbers are reduced in Parkinson’s disease. In 
addition, reductions in serotonin concentration have been reported in the substantia nigra, 
hippocampus and other known serotonin-rich regions of Parkinsonian brains (Agid, 1987; 
Rinne et al., 1974; Scatton et al., 1983). Moreover, reduced 5-HIAA levels have been 
reported in the cerebrospinal fluid of PD patients (Tohgi et ah, 1993). Many other studies 
have reported the significant losses of serotonin and its major metabolite 5-HIAA in 
Parkinson’s disease in several brain regions including the striatum, globus pallidus, 
thalamus and substantia nigra (Curzon, 1972; 1977; 1978; F aim et al., 1971; Guldberg et 
al., 1967; Lloyd and Hornykiewicz, 1974; Lloyd, 1977). Other neui'odegenerative disorders
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related to Parkinson’s disease, such as supranuclear palsy and multiple system atrophy, are 
also characterised by cell loss in a number of amine systems including 5-HT (Hedera and 
Whitehouse, 1994).
What is the effect of serotonin on locomotion in control and mutant rats?
The role of serotonin in locomotion can be studied by increasing and decreasing the 
availability of the 5-HT in the brain. In the present study, increasing 5-HT (by injection of 
5-HTP) was found to cause more movement while depletion of 5-HT (by injection of 
PCP A) led to less movement as detected with infra-red apparatus. Open field studies have 
frequently been used to examine the role of 5-HT in locomotion. The results are similar to 
mine. Thus, administration of 5-HTP increased locomotion (Grahame-Smith, 1971,
Magyar et al, 1978; Modigh, 1972; Modigh and Svensson, 1972; Schlosberg and Harvey, 
1979; Stewart et ah, 1976) whereas decreased movement followed PCPA administration 
(Marsden and Curzon, 1976; Matte and Tornow, 1978; Steigrad et ah, 1978). Moreover, 
lesioning midbrain raphe nuclei leads to suppressed open-field activity (Bouhuys and Van 
den Hoofdakker, 1977; Dray et ah, 1978; Jacobs et ah, 1975; Kohler and Lorens, 1978; 
Lorens et ah, 1976).
Both gi-oups of rats (AS and AS/AGU) respond to 5-HT manipulation with similar changes 
in locomotor activity. This means that the remaining DRN cells in the AS/AGU are 
capable of mediating this change unless another 5-HT system is involved, for which there
is no evidence.
How can a mutation in PKC-y cause dvsfunction and death of serotonei gic neurons?
I am going to try answering this in three stages. Firstly, is there any role of the PKC family 
in general which may explain the dysfunction? Secondly, and specifically, is there any 
function of PKC- y which could be linked to the dysfunction and, finally, is there any 
relation between PKC and 5-HT or PKC- y and 5-HT.
The PKC family, as mentioned eaiJier in this thesis (chapter 2), has a wide variety of 
functions including modulation of ion channels (for review see Sheaiman et al., 1989) and
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the desensitisation of receptors (Huganir and Greenyard, 1990). These may have indirect 
effects on the release of neurotransmitters where protein phosophorylation regulates the 
efficacy of synaptic transmission by modulating the release of neurotransmitter from the 
presynaptic neiwe terminal and by modulating the sensitivity of receptors in the 
postsynaptic membrane. Perhaps the most interesting function of PKC in the context of the 
present study is the enhancement of neurotransmitter release (Malenka et ah, 1986,1987).
Although there is a substantial literature on the PKC family, it is relatively rare to make 
distinctions between the different isoforms. The work on PKC- y has shown involvement 
of this isoform in many disparate functions such as alcohol preference and tolerance 
(Bowers and Wehner, 2001) processing in the dorsal horn (Narita et ah, 2001) postnatal 
reduction of cerebellar afferents (Ebralidze et ah, 1996) and involvement in spinocerebellar 
ataxia (Chan, 2003; Chen et ah, 2003). The work of our laboratory, showing locomotor 
abnormality plus a dysfunction of dopaminergic and, now, serotonergic inputs to the 
striatum, is quite different again. The recent demonstration of a role for PKC- y in 5-HT 
secretion (Liu et ah, 2003) supports our findings.
With dopamine there is a coherent hypothesis (unproved but reasonable) “DA must be free 
in the cytoplasm to allow such large amount of DOPAC/ HVA to be produced: Free DA is 
toxic to its own cells (forming free radicals, dopaquinones) therefore the cells become 
nonviable and die” (Payne et ah, 2000).
Can a similar hypothesis be formulated for 5-HT? On the face of it the situation is the same 
(low 5-HT but high 5-HIAA), so
a) is free 5-HT auto-toxic? or
b) does the one mutation kill off 2 sets of cells by different means? or
c) is the DA death hypothesis wrong?
Indoleamines are often associated with the role of free radical scavengers. This is so not 
only for melatonin but also others including 5-HT (Poeggeler et ah, 2002). However, it
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also clear that 5-HT can be metabolised to toxic dimers and serotonin quinone-imines and 
that serotonin metabolism may lead to free radical formation (Perez-Reyes and Mason, 
1981). This means that there is a possibility of serotonin acting as an auto-toxic agent to its 
own cells as has been proposed for DA (Payne et ah, 2000).
My results show that the raphe-striatal serotonergic system is affected in AS/AGU rats. 
These findings together with previous studies on the mutant AS/AGU showing dysfunction 
of the nigro striatal dopaminergic system, continue to demonstrate the potential importance 
of this model along side other neui'odegenerative models in giving insight into human 
neurodegenerative conditions which involve abnormalities of aminergic systems, the basal 
ganglia and locomotion.
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Appendix 1
I - Cut and mount sections on slides coated with APES.
2- Deparaffinise sections and rehydrate to distilled water.
3- Place sections in 0.5% hydrogen peroxide/ H2O for 10 minutes.
4- Wash sections in tap water.
5- Heat 1500ml of the recommended unmasking solution (0.0 IM citrate buffer, pH 6.0 
until boiling in stainless pressure cooker.
6" Position slides into metal staining racks and lower into pressure cooker ensuring 
slides are completely immersed in unmasking solution.
7- When the pressure cooker reaches operating temperature and pressure (after about 5 
minutes) start a timer for 1 minute.
8- When the timer rings, remove pressure cooker from heat source and run under cold 
water with lid on.
9- Remove the slides and place immediately into a bath of tap water.
10-Place the sections in PBS.
II - Process for ICC.
Solution
1“ 0.01 M citrate buffer (pH6)
Add 3.84 grams of citric acid (anhydrous) to 1.8 litres of distilled water. Adjust to pH6 
using concentrated NaOH. Make up to 2 litres with distilled water.
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Appendix 2
Solution required for the HPLC procedure
Internal standard:
- 25mg DHBA/25ml 0.1 M HCL(stock)
- 1 ml stock / 99ml 0.1M HCL
- 1 ml above / 99ml 0.1MHCL 
This gave a final concentration of Ing / 20pl
Composite standard:
- DOPAMINE (DA),
- DHBA,
- 5-hydroxyindoleacetic acid (5-HIAA),
- Serotonin (5-HT)
1 ng / 20pl injection of each of the above.
Mobile Phase:
- 6.74g citric acid
- 4.81 g sodium citrate
- 47mg ethylenediaminetetra acetic acid (EDTA)
- 200mg heptane sulphoric acid (HAS)
- 1.15ml glacial acetic acid
- 3ml tetrahydrofuran(THF)
- 25ml/L 2.5% methanol
The mobile phase was buffered to pH 4.9 with 10M NaOH and made up to 1 litre 
with HPLC de-ionized water. It was degassed for lOmins, every morning, with 
helium.
